<PAGE>
FORM 10-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (FEE REQUIRED)
For the fiscal year ended May 31, 1996
------------------------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (NO FEE REQUIRED)
For the transition period from __________ to ___________
Commission File Number 0-19820
-------
VITALINK PHARMACY SERVICES, INC.
------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 37-0903482
- ------------------------------- ------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1250 East Diehl Road, Naperville, Illinois 60563
- --------------------------------------------- ----------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (630) 245-4800
---------------
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, Par Value $0.01 per share
------------------------------------------------------------------
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- -----
<PAGE>
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K ((S)229.405 of this chapter) is not contained herein, and
will not be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. [X]
The aggregate market value of the voting stock held by non-affiliates was
$60,001,775 as of August 5, 1996 based upon a closing price of $24.25 per share.
The number of shares of Vitalink's Common Stock outstanding at May 31, 1996
was 13,979,700.
DOCUMENTS INCORPORATED BY REFERENCE:
PART II 1996 Annual Report to Stockholders
PART III Proxy Statement dated August 29, 1996
PART I
------
ITEM 1. Business.
- ------ --------
General
- -------
Vitalink Pharmacy Services, Inc. (the "Company" or "Vitalink") provides
institutional pharmacy services to nursing facilities and other institutions.
Vitalink presently operates 23 institutional pharmacies and 4 regional infusion
pharmacies, which specialize in pharmaceutical dispensing of individual
medications, pharmacy consulting (drug regimen review of potential medication
interaction as well as regulatory compliance with medication and administration
guidelines) and infusion therapy products. The Company, through its subsidiary
Vitalink Infusion Services, Inc., provides parenteral and enteral nutrition
products to patients who qualify under Medicare Part B and bills Medicare
directly for these products.
In 1981 Vitalink was acquired by a subsidiary of Manor Care, Inc. (Manor
Care, Inc. or its subsidiary are referred to as "Manor Care"), one of the
nation's largest publicly owned providers of long-term care services. Vitalink
was included in the acquisition of Americana Healthcare Corporation, which had
incorporated the predecessor of Vitalink in 1967. The Company changed its name
from TotalCare Pharmacy Services, Inc. in January 1992.
Vitalink sold 2,475,000 shares of its common stock in an initial public
offering in 1992. As of May 31, 1996, Manor Care owned approximately 82.3% of
Vitalink's common stock.
On November 3, 1995, the Company acquired the institutional pharmacy
business of Brentview Clinical Pharmacy, located in Los Angeles, California for
$3,206,000 in cash plus the
2
<PAGE>
assumption of $45,000 in liabilities and future contingent payments based on the
achievement of certain future profitability objectives.
On July 6, 1995, the Company acquired the infusion therapy business of Home
Intravenous Care, Inc., located in Loveland, Colorado for $2,325,000 in cash
plus the assumption of $105,000 in liabilities and future contingent payments
based on the achievement of certain future profitability objectives.
Institutional Pharmacy Industry
- -------------------------------
Institutional pharmacies purchase and distribute prescription and non-
prescription medications for residents in institutional settings, including
nursing facilities, correctional facilities and retirement centers.
Institutional pharmacies also provide consultant services, including evaluation
of individual patient drug therapy and monitoring of nursing facility drug
administration, storage and control practices to help ensure a sound
pharmaceutical delivery system and compliance with state and federal
regulations.
A number of factors are expected to contribute to the continuing expansion
of the nursing facility segment, including the growth in, and the greater
affluence of, the U.S. elderly population, the trend toward delivery of cost-
efficient health care in non-hospital settings and the increasing practice of
early patient discharge from hospitals due to cost-containment measures.
Pharmacy Operations
- -------------------
The Company provided institutional pharmacy services to approximately
49,900 beds from 22 institutional pharmacies as of May 31, 1996. A twenty-third
pharmacy was acquired in July 1996. The Company services each market in which
it operates through a hub pharmacy or, in cases where markets are geographically
close, a satellite pharmacy. A market consists of nursing facilities within a
radius of up to 150 miles, depending on demographics and travel times.
Vitalink has expanded from 3 pharmacies in 1981 to 23 institutional
pharmacies and 4 regional infusion pharmacies as of July 1996. The pharmacies
are located in 14 states: California, Colorado, Florida, Illinois, Indiana,
Iowa, Maryland, New Jersey, Pennsylvania, Ohio, Oklahoma, Oregon, Texas and
Wisconsin.
Management has developed a focused growth strategy that includes (i)
continued penetration of existing markets through selling more products to
existing customers and marketing directed to non-Manor Care nursing facilities;
(ii) expansion into additional markets in which there is a sufficient base of
Manor Care beds to support a Company pharmacy; (iii) infusion therapy revenue
generation created by targeting specific nursing facilities and home health care
agencies; and (iv) acquisitions of pharmacies that can be consolidated with
existing Company pharmacies or serve as a more rapid entry into new markets.
3
<PAGE>
The table below sets forth the number of beds serviced by the Company
during the past three fiscal years:
<TABLE>
<CAPTION>
Year Ended May 31
----------------------
1994 1995 1996
------ ------ ------
<S> <C> <C> <C>
Manor Care Affiliated Beds...... 14,300 16,000 19,300
Non-Manor Care Affiliated Beds.. 25,100 26,400 30,600
------ ------ ------
Total beds serviced........ 39,400 42,400 49,900
====== ====== ======
</TABLE>
In the past five fiscal years, the Company has acquired seven institutional
pharmacies and one regional infusion pharmacy with contracts to service
approximately 23,000 non-Manor Care facility beds.
Services Offered by the Company
- -------------------------------
Pharmacy Services - The basic service provided by the Company is the
-----------------
customized filling of prescription and non-prescription medications for
individual patients pursuant to physician orders delivered to nursing
facilities. The Company maintains a 24-hour on-call availability for clinical
consultation and emergency delivery of medications as well as maintaining a
provision of emergency and contingency doses of medications at each nursing
facility. The Company uses a computerized medical records system that generates
monthly nursing facility medical records including preprinted physician order
forms, medication administration records and treatment records. As an
additional service to its nursing facility customers, the Company maintains and
documents ancillary orders such as diet orders, therapy orders and activity
orders. The Company has nurse consultants on staff to observe medication
administration procedures, consult on medical records and conduct in-service
training programs as well as intravenous certification programs.
Consultant Pharmacist Services - The Company provides to its nursing
------------------------------
facility customers trained consultant pharmacists whose primary responsibility
is to monitor and report on prescription drug therapy to help ensure quality
patient care. For a nursing facility to participate in the Medicare and
Medicaid reimbursement programs, it is required to have the services of a
consultant pharmacist.
The Company, in response to regulatory demands on nursing facilities, has
defined the primary responsibilities of its consultant pharmacists to include:
(i) monthly drug regimen reviews of each patient; (ii) participation on key
nursing facility committees; (iii) monthly inspection of medication carts and
storage rooms; (iv) monthly written review of facility medication administration
systems and practices; (v) development and maintenance of a pharmaceutical
policy and procedures manual; (vi) on-site educational seminars; and (vii)
assistance to the nursing facility in complying with state and federal
regulations on patient care. The Company bills nursing facilities for
consultant pharmacist services.
4
<PAGE>
Infusion Therapy Products and Services - Infusion therapy basically
--------------------------------------
consists of a product (nutrient, antibiotic, chemotherapy or other drugs or
fluids) and the administration of the product (tube, catheter or intravenous).
Patients can receive these therapies at home or in a nursing facility at a cost
that is substantially less than hospital-based care. The trend toward delivery
of health care in the lowest cost setting and the increasing ability to treat
certain illnesses outside of hospitals represents an opportunity for nursing
facilities to attract infusion therapy patients.
The Company prepares the product to be administered, delivers the product
and trains others in administering infusion therapy. The Company does not
itself administer the therapy.
Purchasing
- ----------
The Company purchases the drugs and supplies used in its pharmacies
directly from national wholesale distributors, through membership in purchasing
groups and from pharmaceutical manufacturers. Direct purchases from drug
manufacturers allow greater price discounts than purchase through wholesale
distributors but require a significant lead time between order and actual
delivery. The advantage of buying through wholesale distributors is daily
delivery and the ability to more efficiently manage the Company's inventory of
drugs and supplies.
Reimbursement and Billing
- -------------------------
The Company's computerized billing system enables it to bill for products
and services in a variety of ways. The pharmacy generally bills the responsible
party directly.
Charges for pharmacy services provided to patients who are eligible for
Medicare Part A are billed by the nursing facility directly to Medicare. Under
Part A, Medicare categorizes most of the expenses related to pharmacy products
as ancillary services, which are not subject to the cost reimbursement ceilings
under Medicare regulations. However, the Company and Manor Care are subject to
related party regulations that could result in reimbursements for pharmacy
services provided to Medicare Part A patients in Manor Care nursing facilities
equal to Vitalink's permitted fully allocated costs of the services.
For patients who are eligible for Blue Cross/Blue Shield or other
insurance, the insurer is billed directly by the nursing facility or by
Vitalink. Patients not covered by insurance, Medicare or Medicaid are generally
billed directly by Vitalink.
For patients qualifying for Medicaid reimbursement in all states in which
the Company has a pharmacy, the pharmacy bills Medicaid directly, as the nursing
facility cannot obtain reimbursement from Medicaid for pharmacy services.
Medicaid is a cooperative state-federal program for medical assistance to the
medically and categorically needy.
For patients who qualify under Medicare Part B and receive PEN (parenteral
and enteral) therapies, Vitalink's specialized PEN billing subsidiary bills
Medicare Part B directly.
5
<PAGE>
The federal Medicare program provides for reimbursement under two separate
programs, Part A and Part B. Part A provides benefits covering inpatient
hospital, nursing facility and home health services. Reimbursement for nursing
facility services under Part A is restricted to those eligible for Part A
coverage who have been discharged within thirty days from an acute care hospital
after a stay of at least three days and are in need of daily skilled nursing or
rehabilitation services.
Part B provides coverage for physician services and general outpatient
services, including therapies, as well as durable medical equipment. Certain
Vitalink infusion therapy products are eligible for Part B reimbursement based
on Medicare-approved payment amounts. Part B coverage is generally subject to
an annual deductible of $100 and a statutorily mandated co-payment thereafter.
For its fiscal year 1996, the Company received approximately 65% of its net
revenues from private pay sources, including commercial insurance, managed care
and Medicare Part A patients; 6% of net revenues from Medicare Part B direct
bill; and 29% of net revenues from Medicaid direct bill.
Dependence on Key Customer
- --------------------------
Net revenue from Manor Care and its patients (including revenues pursuant
to government reimbursement programs) accounted for approximately 48%, 49% and
47% of total net revenues in fiscal 1996, 1995 and 1994, respectively. Under
various master agreements with Manor Care discussed below, the Company may at
its option provide pharmaceutical, consulting and infusion therapy products and
services to any and all nursing facilities owned or operated by Manor Care
through May 2001 according to the terms of the agreements and subject to each
patient's right to designate his or her own pharmacy or infusion therapy
provider. Each master agreement, however, may be limited or terminated under
certain circumstances including with respect to any nursing facilities disposed
of by Manor Care. Additionally, while the Company hopes to extend the duration
of the master agreements, there can be no assurance that the Company will be
able to do so, or that, if it is able, the extended or new agreements will be on
terms no less favorable to the Company. Any material loss of business from
Manor Care would have a material adverse effect on the Company.
Pursuant to four agreements with Manor Care entered into on June 1, 1991,
the Company provides pharmaceutical products and services, enteral and
parenteral therapy supplies and services, urological and ostomy products,
intravenous products and services and pharmacy consulting services to nursing
facilities operated by Manor Care. The Company is not restricted from providing
similar services to non-Manor Care facilities. The agreements have an initial
term of ten years.
Pursuant to the master agreement for pharmacy services and the master
agreement for infusion therapy services, the Company has the option to provide
pharmaceutical and infusion therapy products and services to nursing facilities
owned or licensed by Manor Care. Through
6
<PAGE>
fiscal year 1995, the Company paid each Manor Care nursing facility an
administrative fee equal to 3% of the private pay revenues derived from that
facility for the facility's agreement to bill and collect for services and for
assuming the risk of bad debt. Effective June 1, 1995, the Company no longer
pays Manor Care the 3% administrative fee as the Company assumed the billing and
collecting of private pay revenues derived from Manor Care facilities. The
change did not have a material effect on the Company's results of operations.
Pursuant to the master pharmacy consulting agreement, the Company provides
consultant pharmacy services to nursing facilities owned or licensed by Manor
Care that the Company is able to service. Each nursing facility is billed
monthly by the Company based on the number of beds serviced.
Pursuant to the pharmacy services consultant agreement, the Company assists
Manor Care at the corporate level in establishing uniform pharmacy delivery
standards for all of its nursing facilities including those not serviced by the
Company. Manor Care pays the Company an annual fee based on the number of
nursing facility beds operated by Manor Care.
The Company does not believe that its present contractual arrangements with
Manor Care with respect to the length of term are comparable to those obtainable
from third parties. Contracts with nursing facilities not affiliated with Manor
Care are generally for a period of one to two years and are terminable by
either party for any reason upon thirty days notice.
Competition
- -----------
The Company competes with numerous local and regional institutional
pharmacies, as well as the pharmacy operations owned by long-term care providers
other than Manor Care. These competitors provide product and service offerings
similar to those provided by the Company. A number of competitors are larger or
have greater financial resources than the Company.
Quality Assurance
- -----------------
The Company maintains high standards of pharmaceutical dispensing and
record keeping. The Company conducts monthly quality assurance audits at each
nursing facility it services to assess the quality and accuracy of pharmacy
services to nursing facilities.
The consultant pharmacist visits the nursing facility routinely and makes
recommendations to the nursing staff concerning various phases of the
pharmaceutical services and patient care programs. The consultant pharmacist
reviews each patient's drug regimen monthly on-site to ensure the patient drug
therapy is appropriate and the facility is complying with state and federal
regulations. The consultant pharmacist reports irregularities to the patient's
attending physician and the nursing facility's director of nursing and
administrator.
7
<PAGE>
Government Regulation
- ---------------------
Institutional pharmacies and nursing facilities are subject to various
federal and state regulations covering qualifications and day-to-day operations,
including documentation of activities. The Company's pharmacies are each
licensed by the states in which they operate and are registered with the federal
government pursuant to regulations covering controlled substances. The nursing
facilities served by the Company are separately required to be licensed by the
states in which they operate, and if they serve Medicare or Medicaid patients,
are required to be certified by the Federal government.
Given that a substantial number of nursing facility patients are covered by
the Medicare and Medicaid programs, the Company is subject to extensive
regulation under the programs, including regulation relating to persons covered,
amount of coverage, reimbursement and pricing. As a result of Manor Care's
ownership of a substantial portion of the Company's outstanding common stock,
the Company and Manor Care are subject to related party regulations that could
result in reimbursement for pharmacy services provided to Medicare Part A
patients in Manor Care nursing facilities equal to Vitalink's permitted fully
allocated costs of the services.
Changes in Medicare and Medicaid programs, regulations, reimbursements or
interpretations of existing programs, regulations or reimbursements, including
changes intended to limit or decrease the growth of Medicare and Medicaid
expenditures, or changes in the state and federal laws regulating institutional
pharmacies could adversely affect the Company's business.
Various federal and state laws provide nursing facility patients with the
freedom to choose their own pharmacy provider. The Company markets its services
primarily to nursing facilities and acts as the pharmacy provider to the
patients in such facilities that do not otherwise choose their own provider.
Increases in the percentage of patients choosing their own provider or changes
in freedom-of-choice laws may adversely affect the Company's business.
Employees
- ---------
At May 31, 1996, the Company had approximately 945 employees. The Company
believes it enjoys a good relationship with its employees. None of the
Company's employees are covered by a collective bargaining agreement.
Insurance
- ---------
Insurance coverage is principally maintained through Manor Care. The cost
of the coverage is allocated entirely to the Company when the coverage is
specific to the Company and otherwise allocated between Manor Care and the
Company. In the opinion of the Company, its current coverage is adequate given
the risks associated with the operation of an institutional pharmacy business of
the Company's size.
8
<PAGE>
ITEM 2. Properties.
- ------ ----------
The Company's corporate offices are located in Naperville, Illinois. As of
May 31, 1996, Vitalink had 23 leased pharmacies (including the four regional
infusion pharmacies) located in Appleton, Wisconsin; Monticello, Elgin and
Hickory Hills, Illinois; Indianapolis, Indiana; Bettendorf, Iowa; Baltimore,
Maryland; Allentown, Bridgeville, York and Williamsport, Pennsylvania; Copley,
Ohio; Deerfield Beach and St. Petersburg, Florida; Ocean, New Jersey; Portland
and Eugene, Oregon; Santa Rosa and Los Angeles, California; Northglenn and
Loveland, Colorado; Oklahoma City, Oklahoma; and San Antonio, Texas. The
Company also leases administrative office space in Calumet City, Illinois.
ITEM 3. Legal Proceedings.
- ------ -----------------
Vitalink is subject to regulatory and legal investigations, actions or
claims for damages that arise from time to time in the ordinary course of
business. Vitalink is defending any such investigations, actions and claims
against it and believes that these proceedings will not have a material adverse
effect on its financial condition.
ITEM 4. Submission of Matters to a Vote of Security Holders.
- ------ ---------------------------------------------------
No matter was submitted to a vote of security holders during the fourth
quarter of the fiscal year ended May 31, 1996.
EXECUTIVE OFFICERS OF VITALINK PHARMACY SERVICES, INC.
The name, age, title, present principal occupation, business address, and
other material occupations, positions, offices and employment of each of the
executive officers of the Company are set forth below. The business address of
Ms. DeNardo, Mr. DiTrapano, Mr. Macomber and Mr. Thompson is 1250 East Diehl
Road, Suite 208 Naperville, Illinois 60563. The business address of the
remaining officers is 11555 Darnestown Road, Gaithersburg, Maryland 20878.
Donald C. Tomasso (51) was appointed Chairman of the Board and Chief
Executive Officer in December 1994 and was Vice Chairman from September 1991 to
December 1994. He has been President of Manor Healthcare Corp. ("Healthcare")
since February 1995 and was President and Chief Operating Officer of Healthcare
from May 1991 to February 1995. He has been a Director of Healthcare since May
1991, of the Company since September 1991 and of In Home Health, Inc. since
October 1995. Prior to joining Healthcare, Mr. Tomasso was employed by Marriott
Corporation for more than five years, last serving as Executive Vice
President/General Manager of its Roy Rogers Division.
9
<PAGE>
Stewart Bainum, Jr. (50) was appointed Vice Chairman of the Company in
February 1995. He was Chairman and Chief Executive Officer from September 1991
to February 1995 and was President and Chief Executive Officer from March 1987
to September 1991. Mr. Bainum has been Chairman of the Board and Chief
Executive Officer of Manor Care since March 1987 and President since June 1989.
He has been Chairman of the Board of Healthcare since March 1987 and Chief
Executive Officer since June 1989. He has served as a Director of the Company
since 1991, of Manor Care since 1981 and of Healthcare since 1976.
Donna L. DeNardo (44) has been President and Chief Operating Officer and a
Director of the Company since September 1991. Ms. DeNardo has served as a Vice
President of Healthcare and a Vice President and General Manager of the Company.
In those positions, she was responsible for managing the Company since December
1989. Ms. DeNardo has held various management positions with Healthcare since
1977, including Senior Regional Director of nursing facility operations and
nursing facility administrator in the Chicago metropolitan area.
Vincent C. DiTrapano (50) was appointed Senior Vice President, Operations
in January 1994. He served as Regional Vice President, Operations-Eastern
Region from June 1993 to January 1994. He previously was employed by Geriatric
Pharmacy Services, Inc. for seven years, including as President and Chief
Executive Officer.
Scott T. Macomber (41) was appointed Vice President, Finance and Chief
Financial Officer of the Company in September 1991. He was Vice President,
Corporate Finance for Manor Care from June 1990 to March 1992 and previously
held various acquisition and development positions within Manor Care for more
than 10 years.
Stephen A. Thompson (41) has been Vice President, Human Resources and
Administration, since August 1995. He was Senior Director, Professional
Relations, of the Company from March 1992 to August 1995, and held human
resources positions with Manor Care and Healthcare from 1986 to 1992.
James H. Rempe (66) has served as Secretary of the Company since January
1983 and a Director since September 1994. He was Senior Vice President and a
Director of the Company from January 1983 to September 1991. He has served as
Senior Vice President, General Counsel and Secretary of Manor Care since August
1981 and of Healthcare since December 1980. He has served as a Director of In
Home Health, Inc. since October 1995.
James A. MacCutcheon (44) has served as Treasurer of the Company since
September 1992 and a Director since September 1994. He was Senior Vice
President-Finance and Treasurer and a Director of the Company from October 1987
to September 1991. He has served as Senior Vice President, Chief Financial
Officer and Treasurer of Manor Care and Healthcare since September 1993 and was
Senior Vice President-Finance and Treasurer from October 1987 to September 1993.
10
<PAGE>
PART II
-------
ITEM 5. Market for Registrant's Common Equity and Related
- ------ -------------------------------------------------
Stockholder Matters.
-------------------
The shares of Vitalink's Common Stock are traded through the National
Association of Securities Dealers' Automated Quotation System (NASDAQ).
Information on the high and low sales prices of Vitalink's Common Stock during
the past two years is included on page 25 of the 1996 Annual Report and is
incorporated herein by reference.
As of August 5, 1996, there were 84 record holders and approximately 1,500
beneficial holders of Vitalink Common Stock.
The Company has not paid, and does not anticipate paying for the
foreseeable future, any dividends to holders of its Common Stock.
<TABLE>
<CAPTION>
Pages
-----
<S> <C> <C>
ITEM 6. Selected Financial Data.
- ------ -----------------------
The required information is included in the
specified pages of the 1996 Annual Report
and is incorporated herein by reference Preceeding 1
ITEM 7. Management's Discussion and Analysis of
- ------ ---------------------------------------
Financial Condition and Results of Operations.
----------------------------------------------
The required information is included in the
specified pages of the 1996 Annual Report
and is incorporated herein by reference 26-28
ITEM 8. Financial Statements and Supplementary Data.
- ------ -------------------------------------------
The required information is included in the
specified pages of the 1996 Annual Report
and is incorporated herein by reference.
See Item 14 for index to financial statements
and schedules 14-25
ITEM 9. Changes in and Disagreements with Accountants
- ------ ---------------------------------------------
on Accounting and Financial Disclosure.
--------------------------------------
Not applicable
</TABLE>
11
<PAGE>
PART III
--------
<TABLE>
<S> <C> <C>
ITEM 10. Directors and Executive Officers of the
- ------- ---------------------------------------
Registrant.
----------
The required information on directors is
included in the specified pages of the
Proxy Statement dated August 28, 1996
and is incorporated herein by reference. 2-3, 5-6
The required information on executive
officers is set forth in Part I of this
Form 10-K under an unnumbered item captioned
"Executive Officers of Vitalink Pharmacy
Services, Inc."
ITEM 11. Executive Compensation.
- ------- ----------------------
The required information is included in
the specified pages of the Proxy Statement
dated August 28, 1996 and is incorporated
herein by reference. 7-11
ITEM 12. Security Ownership of Certain Beneficial
- ------- ----------------------------------------
Owners and Management.
---------------------
The required information is included in
the specified pages of the Proxy Statement
dated August 28, 1996 and is incorporated
herein by reference. 2-4
ITEM 13. Certain Relationships and Related
- ------- ---------------------------------
Transactions.
------------
The required information is included in
the specified pages of the Proxy Statement
dated August 28, 1996 and is incorporated
herein by reference. 17-18
</TABLE>
12
<PAGE>
PART IV
-------
<TABLE>
<S> <C> <C>
ITEM 14. Exhibits, Financial Statement Schedules, and
- -------- --------------------------------------------
Reports on Form 8-K.
--------------------
(a) 1. Financial Statements
Included on the following pages of the 1996
Annual Report:
Report of Independent Public Accountants......... 13
Consolidated Statements of Income................ 14
Consolidated Balance Sheets...................... 15
Consolidated Statements of Stockholders' Equity.. 16
Consolidated Statements of Cash Flows............ 17
Notes to Consolidated Financial Statements....... 18-25
2. Financial Statement Schedule
The following Report and Schedule are filed
herewith on the pages indicated:
Report of Independent Public Accountants
on Schedule...................................... 17
Schedule II - Valuation and Qualifying
Accounts......................................... 18
3. Exhibits
3.1 Restated Articles of Incorporation. Exhibit 3.1
to Registration Statement No. 33-43261 is
incorporated herein by reference.
3.2 By-Laws. Exhibit 3.2 to Registration Statement
No. 33-43261 is incorporated herein by reference.
10.1 Administrative Services Agreement, dated as of June 1,
1991, by and between the Company and Manor Care, Inc. Exhibit 10.1 to
Registration Statement No. 33-43261 is incorporated herein by reference.
</TABLE>
13
<PAGE>
10.2 Tax Agreement, dated as of June 1, 1991, by and between the
Company and Manor Care, Inc. Exhibit 10.2 to Registration
Statement No. 33-43261 is incorporated herein by reference.
10.3 Intercompany Debt and Credit Agreement, dated as of June 1,
1991, by and between the Company and Manor Care, Inc.
Exhibit 10.3 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.4 Lease Agreement, dated as of June 1, 1991 by and between
the Company and Manor Healthcare Corp. Exhibit 10.5 to
Registration Statement No. 33-43261 is incorporated herein
by reference.
10.5 Master Agreement for Pharmacy Services, dated as of June 1,
1991, by and between the Company and Manor Healthcare Corp.
Exhibit 10.6 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.6 Master Pharmacy Consulting Agreement, dated as of June 1,
1991, by and between the Company and Manor Healthcare Corp.
Exhibit 10.7 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.7 Pharmacy Services Consultant Agreement, dated as of June 1,
1991, by and between the Company and Manor Healthcare Corp.
Exhibit 10.8 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.8 Master Agreement for Infusion Therapy Products and
Services, dated as of June 1, 1991, by and between Vitalink
Billing Services, Inc. and Manor Healthcare Corp. Exhibit
10.9 to Registration Statement No. 33-43261 is incorporated
herein by reference.
10.9 Key Executive Stock Option and Appreciation Rights Plan.
Exhibit 10.10 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.10 Amendment to Key Executive Stock Option and Appreciation
Rights Plan. Annex A to the Proxy Statement dated August
20, 1993 is incorporated herein by reference.
10.11 Form of Executive Cash Incentive Plan. Exhibit 10.11 to
Form 10-K for the year ended May 31, 1995 is incorporated
herein by reference.
10.12 Employment Agreement dated June 5, 1995, between Vitalink
Pharmacy Services, Inc. and Donna L. DeNardo. Exhibit 10.12
to Form 10-K for the year ended May 31, 1995 is
incorporated herein by reference.
14
<PAGE>
10.13 Employment Agreement dated June 5, 1995, between Vitalink
Pharmacy Services, Inc. and Vincent C. DiTrapano. Exhibit
10.13 to Form 10-K for the year ended May 31, 1995 is
incorporated herein by reference.
10.14 Operations Stock Grant Plan for Key Management Employees.
10.15 Employment Agreement dated November 30, 1995, between
Vitalink Pharmacy Services, Inc. and Harold Blumenkrantz.
10.16 Guarantee Agreement dated December 15, 1995, between
Vitalink Pharmacy Services, Inc. and Harold Blumenkrantz.
13 1996 Annual Report to Stockholders.
21 Subsidiaries of the Registrant.
23 Consent of Independent Public Accountants.
99 Proxy Statement dated August 28, 1996.
(b) No report on Form 8-K was filed during the last quarter of the fiscal
year ended May 31, 1996.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: August 28, 1996 VITALINK PHARMACY SERVICES, INC.
--
By: /s/ Scott T. Macomber
---------------------------
Scott T. Macomber
Vice President, Finance
and Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
15
<PAGE>
<TABLE>
<CAPTION>
Signature Title Date
- --------------------------- ------------------- ---------------
<S> <C> <C>
/s/ Donald C. Tomasso Chairman, Director August 28, 1996
- --------------------------- and Chief Executive
Donald C. Tomasso Officer
/s/ Stewart Bainum, Jr. Vice Chairman August 28, 1996
- --------------------------- and Director
Stewart Bainum, Jr.
/s/ Donna L. DeNardo Director, President August 28, 1996
- --------------------------- and Chief Operating
Donna L. DeNardo Officer
/s/ James A. MacCutcheon Director and August 28, 1996
- --------------------------- Treasurer
James A. MacCutcheon
/s/ James H. Rempe Director and August 28, 1996
- --------------------------- Secretary
James H. Rempe
/s/ Harold Blumenkrantz Director August 28, 1996
- ---------------------------
Harold Blumenkrantz
/s/ Anil K. Gupta Director August 28, 1996
- ---------------------------
Anil K. Gupta
/s/ Marvin Wilensky Director August 28, 1996
- ---------------------------
Marvin Wilensky
/s/ Joseph R. Buckley Director August 28, 1996
- ---------------------------
Joseph R. Buckley
</TABLE>
16
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
TO THE SHAREHOLDERS OF VITALINK PHARMACY SERVICES, INC.:
We have audited in accordance with generally accepted auditing standards,
the consolidated financial statements included in Vitalink Pharmacy Services,
Inc.'s annual report to shareholders incorporated by reference in this Form 10-
K, and have issued our report thereon dated June 25, 1996. Our audits were made
for the purpose of forming an opinion on those statements taken as a whole. The
schedule listed in the index in Item 14(a)2 is the responsibility of the
Company's management and is presented for purposes of complying with the
Securities and Exchange Commission's rules and is not part of the basic
consolidated financial statements. The schedule has been subjected to the
auditing procedures applied in the audits of the basic consolidated financial
statements and, in our opinion, fairly states in all material respects the
financial data required to be set forth therein in relation to the basic
consolidated financial statements taken as a whole.
ARTHUR ANDERSEN LLP
Washington, D.C.,
June 25, 1996
17
<PAGE>
VITALINK PHARMACY SERVICES, INC. AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
(IN THOUSANDS OF DOLLARS)
SCHEDULE II
<TABLE>
<CAPTION>
ADDITIONS
----------------------
BALANCE AT CHARGED BALANCE AT
BEGINNING TO PROFIT WRITE- END OF
DESCRIPTION OF PERIOD AND LOSS OTHER/1/ OFFS PERIOD
- ----------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Allowance for doubtful accounts
Year ended May 31, 1996 $1,378 $2,412 -- $(1,627) $2,163
Year ended May 31, 1995 2,113 1,772 (1,019) (1,488) 1,378
Year ended May 31, 1994 1,310 1,612 135 (944) 2,113
</TABLE>
- ----------------
/1/ In fiscal year 1995, represents reclassification as discussed in
Registrant's consolidated financial statements included in its 1995 Annual
Report. In fiscal year 1994, represents reserve of acquired company.
18
<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________
EXHIBITS
to
FORM 10-K
Annual Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
________
VITALINK PHARMACY SERVICES, INC.
================================================================================
<PAGE>
EXHIBIT INDEX
-------------
3.1 Restated Articles of Incorporation. Exhibit 3.1 to Registration Statement
No. 33-43261 is incorporated herein by reference.
3.2 By-Laws. Exhibit 3.2 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.1 Administrative Services Agreement, dated as of June 1, 1991, by and
between the Company and Manor Care, Inc. Exhibit 10.1 to Registration
Statement No. 33-43261 is incorporated herein by reference.
10.2 Tax Agreement, dated as of June 1, 1991, by and between the Company and
Manor Care, Inc. Exhibit 10.2 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.3 Intercompany Debt and Credit Agreement, dated as of June 1, 1991, by and
between the Company and Manor Care, Inc. Exhibit 10.3 to Registration
Statement No. 33-43261 is incorporated herein by reference.
10.4 Lease Agreement, dated as of June 1, 1991 by and between the Company and
Manor Healthcare Corp. Exhibit 10.5 to Registration Statement No. 33-43261
is incorporated herein by reference.
10.5 Master Agreement for Pharmacy Services, dated as of June 1, 1991, by and
between the Company and Manor Healthcare Corp. Exhibit 10.6 to
Registration Statement No. 33-43261 is incorporated herein by reference.
10.6 Master Pharmacy Consulting Agreement, dated as of June 1, 1991, by and
between the Company and Manor Healthcare Corp. Exhibit 10.7 to
Registration Statement No. 33-43261 is incorporated herein by reference.
10.7 Pharmacy Services Consultant Agreement, dated as of June 1, 1991, by and
between the Company and Manor Healthcare Corp. Exhibit 10.8 to
Registration Statement No. 33-43261 is incorporated herein by reference.
10.8 Master Agreement for Infusion Therapy Products and Services, dated as of
June 1, 1991, by and between Vitalink Billing Services, Inc. and Manor
Healthcare Corp. Exhibit 10.9 to Registration Statement No. 33-43261 is
incorporated herein by reference.
10.9 Key Executive Stock Option and Appreciation Rights Plan. Exhibit 10.10 to
Registration Statement No. 33-43261 is incorporated herein by reference.
10.10 Amendment to Key Executive Stock Option and Appreciation Rights Plan.
Annex A to the Proxy Statement dated August 20, 1993 is incorporated
herein by reference.
<PAGE>
10.11 Form of Executive Cash Incentive Plan. Exhibit 10.11 to Form 10-K for
the year ended May 31, 1995 is incorporated herein by reference.
10.12 Employment Agreement dated June 5, 1995, between Vitalink Pharmacy
Services, Inc. and Donna L. DeNardo. Exhibit 10.12 to Form 10-K for the
year ended May 31, 1995 is incorporated herein by reference.
10.13 Employment Agreement dated June 5, 1995, between Vitalink Pharmacy
Services, Inc. and Vincent C. DiTrapano. Exhibit 10.13 to Form 10-K for
the year ended May 31, 1995 is incorporated herein by reference.
10.14 Operations Stock Grant Plan for Key Management Employees.
10.15 Employment Agreement dated November 30, 1995, between Vitalink Pharmacy
Services, Inc. and Harold Blumenkrantz.
10.16 Guarantee Agreement dated December 15, 1995, between Vitalink Pharmacy
Services, Inc. and Harold Blumenkrantz.
13 1996 Annual Report to Stockholders.
21 Subsidiaries of the Registrant.
23 Consent of Independent Public Accountants.
99 Proxy Statement dated August 28, 1996.
<PAGE>
EXHIBIT 10.14
VITALINK PHARMACY SERVICES, INC.
OPERATIONS STOCK GRANT PLAN
FOR KEY MANAGEMENT EMPLOYEES
Regional Vice Presidents, Pharmacy Managers, Satellite Managers, and
Reimbursement Managers are eligible to become participants in the Vitalink
Pharmacy Services, Inc. Operations Stock Grant Plan for key Management
Employees. Participants are eligible to receive grants of a minimum of 500
shares, and a maximum of 3,000 shares. Awards shall be recommended by Management
and approved by the Compensation Committee of the Board of Directors.
Shares will be held by the Company in custodial accounts in the names of
the participants until such time as the shares have vested. Vesting shall occur
upon completion of five years of continuous employment after the award and the
payment of any and all withholding taxes.
There will be no partial vesting during the five year period.
If a participant's employment is terminated for any reason during the
five-year period, the shares of stock in his account will be forfeited and
returned to the fund of shares allocated under the Plan.
Absent an election under Section 83(b) of the Internal Revenue
Code, the granting of shares will not result in taxable income to the
participants. (The Internal Revenue Service does not impose a tax now
because there is a "substantial risk of forfeiture" of these shares.
However, once the shares are no longer subject to a "substantial risk
of forfeiture," they will be taxable to the participants.) In other
words, when vesting occurs, the shares awarded to a participant would
be taxable to him at that time based upon their then-current value.
Until vesting has occurred, participants shall not be entitled to
dividends (other than stock dividends) declared on the shares and the Company
shall vote the shares held by it.
Upon vesting, the shares received by participants will be freely
transferable.
As consideration for grants of shares hereunder, each participant shall
be subject to such non-compete provisions as the Compensation Committee shall
determine.
1
<PAGE>
As a condition to the vesting of the shares granted at the expiration of
five years, a participant shall deposit with the Company any and all withholding
taxes, state or federal, required to be collected by the Company. A participant
may elect to satisfy his tax withholding obligation in the form of shares. In
that event, the number of shares equivalent to the withholding obligation will
be retained by the Company as Treasury shares and the Company will pay cash to
the taxing authorities. The value of the shares will be the mean between the
high and low prices at which the Company Common Stock was sold in the over-the-
counter market as reported by NASDAQ, as published in The Wall Street Journal on
-----------------------
the date of vesting or, if the date of vesting is not a trading date on such
market, on the first trading date subsequent to the date of vesting.
In the event that additional shares of Company Common Stock are issued
pursuant to a stock split or a stock dividend, the number of shares reserved for
the purposes of the Plan shall be increased by the same proportion. In the event
that the issued and outstanding shares of the Company Common Stock are reduced
by a combination of shares, the number of shares of Company Common Stock
reserved for the purposes of the Plan shall be reduced by the same proportion.
All such adjustments shall be made by the Compensation Committee, whose
determination shall be final and binding upon the participants. No adjustment
shall be made for cash or property distributions or the issuance to stockholders
of rights to subscribe for additional Company Common Stock or other securities.
2
<PAGE>
VITALINK PHARMACY SERVICES. INC.
--------------------------------
STOCK AGREEMENT
---------------
This Stock Agreement ("Agreement") is made and entered into this 15th
day of December, 1995 by and between (i) Vitalink Pharmacy Services, Inc.
(hereinafter referred to as the "Company"), and (ii) FIELD(1), FIELD(2), an
employee of the Company (hereinafter referred to as the "Participant").
RECITALS
--------
A. The Company has adopted the Vitalink Pharmacy Services, Inc.
Operations Stock Grant Plan for Key Management Employees (the "Plan"), which is
hereby incorporated into this Agreement by this reference.
B. The Company, through its Compensation Committee (the "Committee") has
determined that, under and pursuant to the terms and conditions of the Plan, the
Participant is eligible for a grant of shares of the Company's $ .01 par value
Common Stock (the "Shares").
C. The Participant is desirous of participating in the Plan and
receiving the Shares.
NOW, THEREFORE, in consideration of the mutual covenants hereinafter set
forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and Participant hereby agree as
follows:
1. Grant of Shares. The Company hereby grants to the Participant, as
---------------
separate inducement in connection with his employment, and not in lieu of any
salary or other compensation for his services, a total of FIELD(3) Shares.
2. Restrictions on Shares.
----------------------
(a) The Shares shall be held by the Company in a Custodial Account in
the name of the Participant until such time as the Shares have vested pursuant
to the terms of paragraph 2(b) of this Agreement.
(b) The Shares held by the Company shall remain in the Custodial Account
until vesting which shall occur upon completion by the Participant of five (5)
years of continuous employment from the date hereof and the deposit by the
Participant with the Company of any and all withholding taxes, federal or state,
required to be collected by the Company.
Upon vesting, the Shares shall be distributed to the Participant
within a reasonable period of time not to exceed ninety (90) days from the date
of vesting and the Custodial Account shall be terminated.
<PAGE>
-2-
(c) If the Participant's employment with the Company is terminated for
any reason prior to vesting, the Participant shall forfeit the Shares, and the
Custodial Account shall be terminated. Ownership of the forfeited Shares shall
revert back to the Company.
(d) The Shares shall not be deemed to be salary or any other
compensation to the Participant for the purpose of computing benefits to which
the Participant may be entitled under any pension plan, profit-sharing plan, or
other arrangement of the Company for the benefit of its employees.
(e) The Shares granted under the Plan, while held by the Company
pursuant to the Custodial Account, shall not be transferred, assigned, pledged,
or hypothecated in any way (whether by operation of law or otherwise), and shall
not be subject to execution, attachment, or similar process. Upon any attempt so
to transfer, assign, pledge, hypothecate, or otherwise dispose of the Shares, or
of any right or privilege conferred thereby, contrary to the provisions hereof,
or upon the levy of any attachment or similar process upon such rights and
privileges, the Participant shall forfeit the Shares and ownership of the
forfeited Shares shall revert back to the Company.
3. Dilution or Other Adjustment. In the event that additional
----------------------------
shares of Company Common Stock are issued pursuant to a stock split or a stock
dividend, the Shares shall be increased by the same proportion. In the event
that the issued and outstanding shares of Company Common Stock are reduced by a
combination of shares, the Shares shall be reduced by the same proportion. All
such adjustments shall be made by the Committee, whose determination shall be
final and binding upon the Participant. No adjustment shall be made for cash or
property distributions or the issuance to stockholders of rights to subscribe
for additional Company Common Stock or other securities.
4. Rights as a Stockholder. The Participant hereby agrees
-----------------------
that the Company shall vote the Shares held by it. In consideration of the grant
of the Shares, the participant hereby waives all rights to dividends (other than
stock dividends) until vesting upon the occurrence of the events set forth in
paragraph 2(b) hereof.
5. Title. The Shares held by the Company shall be held in the
-----
name of the Participant. Such Shares shall at all times remain in the Company
Custodial Account until they have been (i) forfeited by the Participant, or
(ii) distributed to the Participant.
6. Risk of Loss. The Participant agrees to assume all risks in
------------
connection with any decrease in the value of the Shares granted to the
Participant placed into the Custodial Account for the benefit of the
Participant.
<PAGE>
-3-
7. Notice to Company. The Participant shall notify the Company
-----------------
immediately if he elects to make an election under Section 83(b) of the Internal
Revenue Code or upon the occurrence of any other event resulting in the value of
the Shares being included in the Participant's gross income prior to vesting.
8. Covenant Not to Compete. As consideration for the grant
-----------------------
hereunder, Participant agrees as follows:
a) During his employment with the Company and for a period of
eighteen (18) months after Participant leaves the employ of the Company
for any reason, whether voluntarily or involuntarily, Participant shall
not, without the express prior written authorization of an officer of
the Company, directly or indirectly, engage or hold an interest in any
business competing with the business of the Company as conducted by the
Company, or its subsidiaries, or their respective successors, nor
directly or indirectly, have any interest in, own, manage, operate, be
connected with as a shareholder of more than five percent (5%) of the
issued and outstanding stock of a publicly held corporation, as joint
venturer, officer, director, partner, employee or consultant, or
otherwise engage or invest or participate in any business which shall
compete with the Company's business as conducted by the Company, or its
subsidiaries, or their respective successors, within a 150 mile radius
of the office of the Company where Participant was employed.
b) During his employment with the Company and for a period of
eighteen (18) months after Participant leaves the employ of the Company
for any reason, whether voluntarily or involuntarily, Participant shall
not, without the express prior written authorization of an officer of
the Company, directly or indirectly, interfere with the employment
relationship between the Company and its other employees. Participant
agrees that during his employment with the Company and for a period of
eighteen (18) months after Participant leaves the employ of the Company
for any reason, whether voluntarily or involuntarily, Participant shall
not, without the express prior written authorization of an officer of
the Company, directly or indirectly solicit, directly or indirectly,
business from any client or prospective client of the Company up to the
termination date of the Participant's employment with the Company, for
himself or for any entity in which the Participant has an ownership
interest or by which Participant is employed or has a contractual
relationship with, which entity is engaged in and competitive with the
business conducted by the Company, its subsidiary or parent companies,
or their respective successors.
c) Participant recognizes and acknowledges that the Company's and
its affiliates' present and prospective clients, contracts, development
plans, operating data, policies and personnel, as they may exist from
time to time, are confidential,
<PAGE>
-4-
valuable, special and unique assets of the Company's business.
Throughout the term of the Participant's employment and for a period of
eighteen months (18) months after its termination or expiration for
whatever cause or reason, Participant shall not directly or indirectly,
or cause others to: make use of or disclose to others any proprietary,
confidential information relating to the business of the Company that
has not otherwise been made public. Such proprietary and confidential
information shall include without limitation, the Company's and its
affiliates' present or prospective clients, contracts, development
plans, operating data and policies, sales methods, prospecting methods,
customer lists, computer technology of any kind or nature used in
managing, marketing or furthering the Company's business. Upon
termination of the employment relationship, Participant will return to
the Company all documents, records, notebooks, manuals, computer disks
and similar repositories of or containing the Company's proprietary,
confidential information, including all copies thereof, then in
Participant's possession or control, whether prepared by Participant or
otherwise. Participant shall take all reasonably necessary and
appropriate steps to insure that the confidentiality of such proprietary
and confidential information shall be maintained.
Covenants herein contained are cumulative to the rights of the
Company under the laws of the United States and any state as applicable
respecting the right of the Company to protect itself from the competition of
Participant.
In the event of an actual or threatened breach by Participant of the
provisions of this paragraph, the Company shall be entitled to injunctive relief
restraining Participant from committing such breach or threatened breach.
Nothing herein stated shall be construed as preventing the Company from pursuing
any other remedies available to the Company for such breach or threatened
breach, including the recovery of damages from Participant.
9. Severability of Provisions. Any provision of this Agreement
--------------------------
which is deemed invalid, illegal, or unenforceable in any jurisdiction shall, as
to that jurisdiction and subject to this paragraph, be ineffective to the extent
of such invalidity, illegality or unenforceability, without affecting in any way
the remaining provisions hereof in such jurisdiction or rendering that or any
other provisions of this Agreement invalid, illegal or unenforceable in any
other jurisdiction. If any covenant should be deemed invalid, illegal or
unenforceable, because its scope or time is considered excessive, such covenant
shall be modified so that the scope of the covenant is reduced only to the
minimum extent necessary to render the modified covenant valid, legal and
enforceable.
10. Entire Agreement; Amendment of Agreement. This instrument
----------------------------------------
contains the entire agreement of the parties. No modification or amendment of
this Agreement shall, without the consent of the Participant, affect his rights
under this Agreement.
<PAGE>
-5-
11. Employment. This Agreement does not impose any obligation upon the
----------
Company to retain the Participant in its employ for any period and the
Participant's continued employment by the Company shall be within the Company's
sole discretion.
12. Governing Law. The validity, construction, and administration of
-------------
this Plan shall be determined under the laws of the State of Delaware, without
reference to its conflict of laws principles.
13. Gender. Where applicable, words in the masculine shall
------
include the feminine, words in the neuter shall include the masculine and
feminine, and words in the singular shall include the plural, and vice versa.
IN WITNESS WHEREOF, the Company has caused this Agreement to be
duly executed by its authorized officers and its corporate seal hereunto
affixed, and the Participant has hereunto set his hand and seal, all on the day
and year first above written.
ATTEST: VITALINK PHARMACY SERVICES, INC.
_____________________________ By: _____________________________
Its:
[Corporate Seal]
WITNESS: PARTICIPANT
_____________________________ _____________________________
_____________________________
Participant Soc. Security No.
<PAGE>
EXHIBIT 10.15
EMPLOYMENT AGREEMENT
--------------------
THIS EMPLOYMENT AGREEMENT is made by and between Harold
Blumenkrantz ("Employee") and Vitalink Pharmacy Services, Inc., a Delaware
corporation (" Employer").
IN CONSIDERATION of the premises, the covenants set forth herein
and other consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:
1. Term.
-----
1.1 Employer hereby employs Employee and Employee
accepts employment by Employer, as Executive Director, under the terms and
conditions herein set forth.
1.2 The term of this Agreement shall commence on December 1,
1995 and shall continue for three (3) years through November 30, 1998.
2. Compensation. For all services rendered by Employee during the
-----------
term of this Agreement, Employee shall receive compensation as follows:
2.1 Salary. A base salary of Forty-Five Thousand Dollars
------
($45,000) per annum for the term of this Agreement payable in accordance with
Employer's standard payroll practices from time to time in effect.
2.2 Fringe Benefits. Employee will be entitled to participate in
---------------
such medical and accident and health plans, and other fringe benefit plans, in
accordance with their terms, as shall be made available by Employer generally to
its management employees, and Employer shall pay such premiums arising with
respect to coverage as it pays generally for its management employees.
2.3 Automobile. Employer shall provide Employee with the
----------
use of an automobile of Employee's choice during the term of the Agreement. In
addition, Employer shall reimburse Employee for automobile maintenance expenses
incurred by Employee upon presentation by Employee of an itemized account of
such expenditures in a manner prescribed by Employer. Notwithstanding the above,
the total annual cost to Employer for the provision of the automobile including
lease payments, insurance and maintenance expenses will not exceed Ten Thousand
Dollars ($10,000.00) per year. Any costs in excess of Ten Thousand Dollars
($10,000.00) per year will be the responsibility of the Employee.
<PAGE>
2.4 Stock Options. Subject to the approval of Employer's Board of
--------------
Directors, effective December 15, 1995 Employee shall be granted options to
purchase Fifteen Thousand (15,000) shares under Employer's Key Executive Stock
Option and Appreciation Rights Plan at the price in effect or applicable as of
the close of business December 15, 1995, substantially in accordance with
Exhibit 2.4.
2.5 401 (k) Savings and Retirement Plans. Employee shall
------------------------------------
be entitled to participate in Employer's 401(k) Plan, Cash Accumulation
Retirement Plan and/or Employer's Non-Qualified Retirement Savings and
Investment Plans as provided for in said plans and Employer will make all such
contributions as may be required by, and in accordance with, such plans.
2.6 Business Expenses. Employer authorizes Employee to
-----------------
incur reasonable business expenses in connection with Employer's business, as
provided for and pursuant to Employer's policies and procedures, including
membership fees for professional and business societies, fees for professional
licenses, dues and subscriptions, entertainment, and other reasonable expenses
necessary to retain the goodwill of all nursing homes, convalescent homes and
other institutions which are customers of Employer.
2.7 Travel Expenses. Employee's responsibilities will
---------------
require travel to both existing and potential new markets for Employer as well
as attendance at various professional meetings, seminars and industry
conventions. Employer will reimburse Employee for all travel related expenses up
to a maximum expenditure of Ten Thousand Dollars ($10,000.00) per year.
Expenditures over Ten Thousand Dollars ($10,000.00) per year will be the
responsibility of Employee.
3. Leave. Employee shall be entitled to vacations, personal
-----
leave, holiday leave and sick leave in accordance with the general practices of
the Employer, in effect from time to time with respect to its management
employees.
4. Duties.
------
4.1 Service. It is understood and agreed that Employee
-------
will faithfully and diligently serve Employer to the best of his ability in his
position, and Employee further agrees to perform such duties and to assume such
responsibilities, commensurate with his title and experience, as may be assigned
to him by Employer.
4.2 Other Business Activities. Except as allowed by
-------------------------
Section 6.1 of this Agreement, Employee shall not engage in any business
activity, including having passive investments, in any entity, partnership or
individual proprietorship, that is a competitor or potential competitor of
Employer except Employee shall be allowed to invest his assets in the securities
of public
2
<PAGE>
or private companies if such holdings are passive investments which do not
involve Employee's holding positions of officer, director, employee, general
partner, or a direct, indirect or beneficial owner of ten percent (10%) of the
stock, whether voting or not, of any entity, or which do not involve Employee
becoming a secured or unsecured creditor. Notwithstanding the above, Employee
may engage in business activities outside of the institutional pharmacy and
medical supply businesses as well as those business activities listed on Exhibit
4.2. Employee warrants and represents that he is not a party to any contracts,
and has no obligations to any other person or entity, which would conflict with,
violate the terms of, cause a default under or materially inhibit the
performance of his services under this Agreement, except as listed on Exhibit
4.2 hereof.
5. Confidential Information. Employee recognizes an acknowledges
-------------------------
that Employer's and its affiliates' present and prospective clients, contracts,
acquisitions and personnel, as they may exist from time to time, are valuable,
special and unique assets of Employer's business. Employee shall not, at any
time during or for a period of two (2) years subsequent to the term of this
Agreement make use of or disclose to others any written or oral information
relating to the business of Employer that has not otherwise been made public, or
is not otherwise available to the public, (as long as such information has not
been made public by Employee), including but not limited to Employer's present
or prospective clients, contracts or acquisitions, financial information or
personnel information. Employee, at the termination of this Agreement, by
expiration of its term or otherwise, shall return to Employer all documents that
contain any such confidential or proprietary information and Employee shall
retain no copies of such documents. Throughout the term of this Agreement and
for a period of two (2) years after its termination or expiration for whatever
cause or reason, Employee shall not, directly or indirectly, or cause others to:
(1) without Employer's prior written consent, offer employment or employ on
behalf of Employee or any other person, any person who at any time is or has
been within the preceding one (1) year an employee of Employer or any affiliate
of Employer, or induce such person, directly or indirectly, to leave his or her
employment; or (2) without Employer's prior written consent, solicit the
business of any of Employer's present institutional pharmacy or medical supply
clients, which for purposes of this subsection (2) shall mean clients that have
been actually serviced by Employer within the two (2) years prior to the time
Employee's employment terminates. Notwithstanding the above, Employee may
solicit any of Employer's employees who are listed on Exhibit 5 or their
designated successors.
3
<PAGE>
6. Restrictions.
------------
6.1 Employee acknowledges that his services are unique and
extraordinary. Employee agrees that for any reason other than termination by
Employer without cause, Employee shall not directly or indirectly engage in the
institutional pharmacy or medical supply business anywhere in Employer's service
area, which service area shall be defined as being within the state of New
Jersey and within the area encompassed by a line from Easton, Pennsylvania to
Harrisburg, Pennsylvania to the North, south from Harrisburg, Pennsylvania to
the Pennsylvania - Maryland state line and east from such line to the
Pennsylvania - Delaware state line, during the term of this Agreement. For
purposes of this paragraph "directly or indirectly engaging in the business of
Employer or in any business competitive with Employer" shall mean engaging in
business, with or without compensation, as an owner, general or limited partner,
stockholder of more than one percent (1%) of the outstanding shares, director,
officer, manager, employee, agent, consultant, or otherwise, of any entity
(other than Employer) regardless of size, that provides institutional pharmacy
services, medical supply services, or institutional consultant pharmacy
services. During the term of this Agreement Employee may consult with West End
Family Pharmacy, Inc. which respect to its retail pharmacy business and may
remain an officer, director or shareholder thereof, but only if West End Family
Pharmacy, Inc. does not engage in the business of providing goods or services to
institutions, including but not limited to nursing homes, hospitals, retirement
homes and assisted living facilities and only to the extent Employer reasonably
determines such consultation does not interfere with Employee's duties
hereunder.
6.2 Employee recognizes and acknowledges that the
services to be rendered by him hereunder are of a special and unique character
and that the restrictions on activities as contained in this Agreement are
required for Employer's reasonable protection. Employee agrees that in the event
of breach of this Agreement, Employer will be entitled, if it so elects, to
institute and prosecute proceedings at law and in equity to obtain damages
(including attorney's fees) with respect to such breach and to enforce the
specific performance of this Agreement by Employee and to enjoining Employee
from engaging in any activity in violation hereof.
6.3 Sections 5, 6.1, 6.2 and 6.3 are intended by the
parties hereto as separate and divisible provisions, and if for any reason any
one or more is held to be invalid or unenforceable, neither the validity nor the
enforceability of the others shall thereby be affected. If any court holds that
the whole or any part of Sections 5, 6.1, 6.2 and 6.3 is unenforceable by reason
to the extent, duration or geographic scope thereof, or otherwise, then the
court making such determination shall have the right to reduce such extent,
duration, geographic scope, or other provisions
4
<PAGE>
hereof, and in its reduced form such Section shall be enforceable in the manner
contemplated hereby.
7. Indemnity. Employer shall indemnify Employee and hold him
---------
harmless for any lawful acts or decisions reasonably made by him in good faith
while performing services for Employer. Employer shall pay all expenses actually
or necessarily incurred by Employee in connection with defense of any action,
suit, or proceeding arising from any lawful acts or decisions made by Employee
in good faith while performing services for Employer.
8. Termination. The employment of Employee under this Agreement shall
-----------
terminate at the end of the term described in Section 1 or on such earlier date
as is set forth below:
8.1 Death. The death of Employee.
-----
8.2 Discharge for Cause. Employer shall have the absolute
-------------------
right at any time to discharge Employee for cause, which shall be defined for
this purpose as any of the following: willful or intentional inflicting of
substantial injury upon Employer; or material waste or gross or intentional
misuse of assets of Employer; or embezzlement, dishonest, fraud or other acts of
criminal nature involving Employee's employment; or alcohol, drug or other
substance abuse; or failure to substantially perform his duties to the best of
his abilities; or the commission of any conduct that may, from time to time be
determined by Employer as requiring immediate termination without notice by
Employer's Policies and Procedures Manual, as applicable to its management
personnel generally; or breach of any negative covenant contained in this
Agreement.
8.3 Mutual Termination. If Employer and Employee mutually
------------------
agree to terminate this Agreement anytime between December 1, 1996 and November
30, 1997 Employer will pay Employee Twenty-Five Thousand Dollars ($25,000) and
the stock options granted pursuant to Section 2.4 and the Stock Option and
Appreciation Rights Agreement dated December 15, 1995 ("Stock Options") will
immediately terminate. If the Employer and Employee mutually agree to terminate
this Agreement anytime between December 1, 1997 and November 30, 1998 Employer
will pay Employee Fifty Thousand Dollars ($50,000) and the Stock Options will
immediately terminate.
8.4 Employee Option. Notwithstanding Section 4.2 above,
---------------
Employee may request approval from Employer to engage in business activities in
the institutional pharmacy and medical supply businesses which compete or
potentially could compete with Employer outside of Employer's service area as
defined in Section 6.1. If Employer determines not to grant such approval then
Employee has the right to terminate this Agreement.
5
<PAGE>
9. Miscellaneous.
-------------
9.1 Waiver of Breach. The waiver by either party hereto of
----------------
a breach of any provision of this Agreement shall not operate or be construed as
a waiver of any subsequent breach by either party.
9.2 Notices. Any notice required or permitted to be given
-------
under this Agreement shall be sufficient if in writing, sent by certified mail
to Employee's residence as it appears on the records of the Employer in the case
of Employee or to the principal office of Employer, to the attention of the
President, in the case of Employer, or to such other address as each party may
hereafter specify in writing to the other.
9.3 Binding Effect. This Agreement shall be binding upon and shall
--------------
inure to the benefit of the parties hereto and their respective heirs, legatees,
personal representatives and other legal representatives, successors and
assigns.
9.4 Assignment. Employee shall not transfer or assign any or all of
----------
its rights or interest hereunder without the prior written consent of Employer.
9.5 Employee Status. Employee shall be deemed to be an employee
---------------
under this Agreement and not an independent contractor. As such, Employer
retains the right to direct and instruct Employee regarding his duties
hereunder.
9.6 Amendments. This Agreement may be amended only in writing
----------
executed by the parties hereto affected by such amendments.
9.7 Enumeration and Headings. The enumeration and headings
------------------------
contained in this Agreement are for convenience of reference only and are not
intended to have any substantive significance in interpreting this Agreement.
9.8 Gender and Number. Unless the context otherwise requires,
-----------------
whenever used in this Agreement, the singular shall include the plural, the
plural shall include the singular, and the masculine gender shall include neuter
or feminine gender and vice versa.
10. Survival. The provisions of Sections 5 and 6 shall survive
--------
any termination of this Agreement, whether by reason of Section 1, Section 8, or
otherwise, except that the restrictions contained in Section 6.1 shall not
survive termination of this Agreement if Employee is terminated by Employer
without cause and will only survive until November 30, 1997 in the event
Employee exercises his right to terminate this Agreement as per Section 8.4 on
or before November 30, 1997.
6
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed under seal this 30th day of November, 1995.
----
WITNESS: EMPLOYEE:
/s/ Natalie L. Schwartz /s/ Harold Blumenkrantz
- ------------------------- -------------------------------- (SEAL)
Harold Blumenkrantz
ATTEST: EMPLOYER:
VITALINK PHARMACY SERVICES, INC.
/s/ /s/ Donna DeNardo
- ------------------------- -------------------------------- (SEAL)
Donna DeNardo, President
7
<PAGE>
EXHIBIT 4.2
-----------
OTHER BUSINESS ACTIVITIES
1. Med-Care
2. West End Family Pharmacy - Retail
3. Baron Drug in Westfield - Retail
4. Towne Pharmacy - Retail
5. Terry Drug - Retail
6. Woodlane Pharmacy - Retail
7. Homestead Pharmacy - Retail
8. Drug Guild - Executive Board
9. Sampson Enterprises - Board of Directors
10. Elderlife Management - Board of Directors
8
<PAGE>
EXHIBIT 5.0
-----------
MED-CARE EMPLOYEE LIST
Lisa Calcaterra
Donna Santaniello
Susan Demillio
Michael Nutt
Catherine Digiorgio
9
<PAGE>
EXHIBIT 10.16
GUARANTEE AGREEMENT
-------------------
This Guarantee Agreement is made this 15th day of December, 1995,
by and between Harold Blumenkrantz ("Participant") and Vitalink Pharmacy
Services, Inc. ("Company").
WHEREAS, Company has granted Participant the option to purchase
15,000 shares of the stock of Company (the "Option" or "Options"), pursuant to,
and subject to the terms and conditions of, that certain Stock Option and
Appreciation Rights Agreement (the "Stock Option Agreement") between the Company
and Participant of even date herewith, which is incorporated herein by this
reference; and
WHEREAS, such Option shall vest as to 15,000 shares on December 1,
1998; and
WHEREAS, such Option shall expire on December 1, 1999; and
WHEREAS, as part of Participant's compensation for his employment by
Company, Company has agreed to guarantee that, subject to certain terms and
conditions contained herein, such Option will have a certain minimum value to
Participant.
NOW THEREFORE, in consideration of the mutual covenants hereinafter set
forth and for other good and valuable consideration, Company and Participant
agree as follows:
1. Definitions. For purposes of this Guarantee Agreement, the terms "Stock",
-----------
"Plan" and "Appreciation Right" shall have the meanings set forth in the Stock
Option Agreement. The term "fair market value" shall have the meaning set forth
in the Plan.
2. Guarantee of Minimum Value of Stock Option. Company agrees that the
------------------------------------------
Options granted pursuant to the Stock Option Agreement shall have a guaranteed
value to Participant of Five Dollars ($5.00) per share in excess of the purchase
price set forth in Section 3 of the Stock Option Agreement (the "Purchase
Price"), in accordance with, and subject to, the terms and conditions set forth
below.
a) Company's guarantee of the value of Participant's stock option shall
become effective on December 1, 1998 (the "100% Vesting Date") but only
if Participant has been employed by the Company from December 1, 1995
through November 30, 1998.
b) Subject to Participant's employment as per subsection a) above, Company
will pay to Participant on or before thirty (30) days after the 100%
Vesting Date an amount equal to the Purchase Price of 15,000 shares of
Stock plus $75,000 minus the fair market value of 15,000 shares of
Stock on the 100% Vesting Date (the "Guaranteed Value Payment"),
subject to subsection c) below.
<PAGE>
c) In no event shall the Guaranteed Value Payment exceed $75,000.
d) If Participant voluntarily leaves his employment with Company prior to
the 100% Vesting Date, or if his employment is terminated by Company
for cause (as that term is defined in Section 8 of that certain
Employment Agreement between Participant and Company on even date
herewith) prior to the 100% Vesting Date, Company shall not be
obligated to make the Guaranteed Value Payment (as hereinafter defined)
to Participant. However, if Employee's employment is terminated by
Company for reasons other than cause, Company shall pay Participant
within thirty (30) days after the 100% Vesting Date, the sum of Seventy
Five Thousand Dollars ($75,000.00).
3. No Effect on Existing Rights. Nothing in this Guarantee Agreement shall
----------------------------
effect the rights or obligations of either party under the Stock Option
Agreement.
4. Governing Law. This Guarantee Agreement shall be governed and construed
-------------
according to the laws of the State of Maryland, United States of America.
5. Headings. The headings in this Guarantee Agreement are for ease of
--------
reference only and are not a part of this Agreement.
6. Conflict of Terms. To the extent that any of the terms of this Guarantee
-----------------
Agreement and the terms of the Stock Option Agreement conflict in any manner,
the terms of the Stock Option Agreement shall control.
IN WITNESS WHERE OF, Participant and the Company have executed
this Agreement as of the date first above written.
HAROLD BLUMENKRANTZ VITALINK PHARMACY SERVICES, INC.
/s/ Harold Blumenkrantz /s/ Donna DeNardo
- ------------------------ ------------------------
Participant Donna DeNardo, President
2
<PAGE>
Financial Highlights
$141.1
$112.3
$88.8
$86.7
$40.2
92 93 94 95 96
Net Revenues
(in millions)
[BAR GRAPH APPEARS HERE]
$22.3
$18.7
$15.0
$11.3
$8.6
92 93 94 95 96
Income from Operations
(in millions)
[BAR GRAPH APPEARS HERE]
$13.8
$11.7
$8.2
$7.3
$5.5
92 93 94 95 96
Net Income
(in millions)
[BAR GRAPH APPEARS HERE]
Selected Financial Data
(in thousands, except per share data)
<TABLE>
<CAPTION>
Year Ended May 31: 1996 1995 1994 1993 1992
<S> <C> <C> <C> <C> <C>
Net Revenues $141,115 $112,257 $98,569 $65,714 $40,164
Income From Operations 22,301 18,726 14,995 11,305 8,643
Net Income 13,870 11,680 9,204 7,341 5,497
Earnings Per Share .99 .84 .66 .53 .46
Total Assets 95,923 80,713 69,587 57,425 47,027
Working Capital 22,830 15,202 14,103 9,938 3,803
Due From Parent 16,910 16,888 8,167 10,276 37,196
Stockholders' Equity 86,299 72,379 60,699 51,495 44,154
Average Shares Outstanding 13,976 13,975 13,975 13,975 12,056
</TABLE>
<PAGE>
Our Mission -- To be the leader in the delivery of high quality health care
products and services to our customers and the individuals in their care -- To
realize this mission by providing innovative products and services to our
customers which will exceed their expectations --
[STETHOSCOPE APPEARS HERE]
To attract, empower and retain competent employees who will grow with our
organization and provide us with a competitive advantage in our markets --
Through the pursuit of this mission Vitalink will create a partnership with our
customers and employees which will result in the enhancement of shareholder
value.
<PAGE>
[LOGO APPEARS HERE]
Vision
To be the leader in the delivery of
health care services through the integration
of people, science and systems.
3
<PAGE>
Corporate Profile
Vitalink Pharmacy Services, one of the nation's leading institutional pharmacy
companies, provides pharmaceutical dispensing of individual medications,
infusion therapy products and services, medical supplies and pharmacy consulting
to its customers. Vitalink's customers are nursing facilities as well as other
institutions and their patients and home infusion patients. Vitalink currently
operates 23 institutional pharmacies, four regional infusion pharmacies and one
central enteral distribution facility. Through these operations Vitalink
provides services to patients in 29 states.
- ---------------------------------------
Value
Creating shareholder value
through anticipating and responding to
the needs of our provider partners.
- ---------------------------------------
Contents
2
To Our Shareholders
4
Market Trends
6
Vitalink Locations
7
The Vitalink Difference
13
Financial Information
29
Corporate Information
<PAGE>
To Our Shareholders
Fiscal 1996 was another record year for Vitalink. We not only achieved record
financial results but have successfully positioned our company for continued
growth throughout fiscal 1997 and beyond. Net revenues increased 26% for the
year to $141 million from $112 million. Net income rose 19% to $13.9 million and
earnings per share increased to $0.99 from $0.84.
Consistent with our strategic objective to acquire quality providers, Vitalink
completed two acquisitions in fiscal 1996. In July, we acquired Home Intravenous
Care located in Loveland, Colorado and in November, Brentview Pharmacy in Los
Angeles, California. The Home Intravenous Care acquisition fulfilled our goal to
significantly expand our Colorado operations while adding a JCAHO (Joint
Commission on Accreditation of Healthcare Organizations) accredited home
infusion provider. The Brentview acquisition allowed Vitalink to enter the
southern California market. During the year, we also opened a new hub pharmacy
in Oklahoma City and a satellite pharmacy in St. Petersburg, Florida.
Through pharmacy acquisitions, start-ups, sales to new non-affiliate customers
and additional affiliate customers, Vitalink increased its beds served total
from 42,400 beds at the beginning of the year to 49,900 at year end, an 18%
increase.
Our people and systems form the foundation for Vitalink's current and future
success. Vitalink operates from a philosophy of shared values to which all
employees are dedicated. Customer focus is one of these values. We screen for it
in our employee selection system, use it as a standard in our hiring practices,
foster it through our training programs and reward it through our incentive
programs. This year we added a CQI (Continuous Quality Improvement) process to
measure compliance with our standardized operating practices. The results of
this process are reflected in increased customer satisfaction, decreased
customer turnover and consistent results.
In our quest to develop patient care management programs which guide the
physician, nurse and other caregivers in delivering cost effective care to
patients, we are creating a data warehouse which stores patient clinical
information from each of our pharmacies. This concept allows the pharmacy
computer system to function most efficiently and segregates data for our
Clinical Information Services group to evaluate. By aggregating the data from
the 100,000+ patients we serve in a year, we can isolate and identify
improvements in drug therapy which, if enacted, would increase the quality and
decrease the cost of health care.
Our first patient management programs (OPTIMA(SM)) designed to identify and
treat patients at risk for stroke were rolled-out to our pharmacies and patients
this year. The reception from physicians, nurses and patients has been very
positive. Not only have patients received better care, the reputations of their
providers have been elevated as a result. Vitalink benefits when our customers
are successful.
Programs which utilize sound clinical guidelines to focus pharmacist and nurse
intervention in patient care will continue to be rolled-out through fiscal 1997.
Priority will be given to those disease states in which the greatest clinical
and cost impact can be made. To date, programs geared to the management of
congestive heart failure, depression, asthma, wounds, diabetes and osteoporosis
have been designed.
The strength of the programs we develop is predicated on the expertise and
dedication of our clinical professionals. We have created a formal internal
certification process which ensures that our staff has the training necessary to
implement and deliver these clinical programs. While today our OPTIMA(SM)
programs provide competitive advantage to our customers and our pharmacies, in
the future they will be critical to managing patients in an integrated
environment which focuses on outcomes and assumption of risk.
Extraordinary commitment to customer needs coupled with superior systems make
Vitalink an exceptional company. We thank our shareholders, our employees and
our customers for their support and belief in our mission.
Sincerely,
/s/ Donald C. Tomasso /s/ Donna L. DeNardo
Donald C. Tomasso Donna L. DeNardo
Chairman and Chief Executive Officer President and Chief Operating Officer
Bed Growth
(in thousands)
[LINE GRAPH OF BED GROWTH APPEARS HERE]
<TABLE>
<S> <C> <C> <C> <C>
16.3 30.7 38.4 42.4 49.9
92 93 94 95 96
</TABLE>
.non-affiliate beds
.affiliate beds
Our total number of beds
served has more than
tripled since fiscal year 1992.
<PAGE>
- -----------------------------------------
Vitalink's
Revenue Mix
75% Prescription Management
16% Infusion Therapy
[PIE GRAPH
APPEARS HERE]
3% Consultation
6% Medical Supplies and Other
Market Trends
Anticipating and responding to current and future health care trends is
Vitalink's primary strength. At a time when industry change makes some health
care providers uneasy, Vitalink continues to build the resources necessary to
capitalize on this change.
Demographics, economics, the expansion of health care to non-institutional
settings and consolidation are driving change within the health care industry.
The setting for long-term care continues to broaden beyond the traditional
nursing facility. The aging of our population drives more people into the
Medicare and then the Medicaid programs. Cost pressures from payers continue to
make it attractive to treat higher acuity patients in nursing facilities which
focus on complex rehabilitative care. Vitalink's ability to provide intravenous
medications, tube feedings, respiratory care, cancer chemotherapy treatment and
assistance in post-operative care provides growth opportunities for both
Vitalink and its nursing facility partners.
Demographics--As nursing facilities increasingly focus on offering a medical
model of care for the elderly and chronically ill, the nursing facility setting
is becoming a less appropriate place for the frail-but-not-truly-sick elderly.
In addition, as baby boomers age, many doubt that Medicare and Medicaid will be
able to cover the nation's health care expenses. These trends will foster a
large market for private long-term care insurance, increased coverage for health
care delivery in non-traditional settings and the need for payers to manage the
total health care costs of an aging population. Assisted living facilities, home
health agencies and adult day care can fill the gap between increased demand for
health care services and the need to reduce its cost.
People become frail before they become sick and often need assistance with
medication management before a need for more skilled care arises. Vitalink has
positioned itself to capitalize on the future growth in a wide variety of semi-
institutional, community-based or home-like settings with services designed for
less independent individuals. Vitalink has developed systems which allow maximum
resident autonomy while at the same time ensuring the integrity of medication
dispensing. These systems also facilitate the integration of patients into our
preventative patient care management programs.
Economics--The ability to provide service along a continuum of care, and through
a continuum of cost, will be necessary to address the flexibility and
responsiveness demanded by consumers as they move through various levels of
care.
In the future, payers are more likely to scrutinize the cost of care rather than
the particular location in which it is delivered. The health care system
continues to evolve with the emphasis on integration of various levels of
service designed to make access to health care easier.
Our primary business partners are also changing. Consolidation of independent
nursing and assisted living facility operators into companies with regional or
national presence continues. More long-term care providers are expanding their
service offerings into the assisted living facility, home care, and adult day
care settings by leveraging their expertise in post-acute care in order to bring
consolidated, integrated care systems to both consumers and payers.
The proliferation of post-acute care settings has caused providers to redefine
their product offerings and strive for product integrity, often across multiple
markets. Vitalink is not only positioned to address the needs of larger provider
partners who require comprehensive service packages to accomplish their goals
but is also positioned to service smaller partners who rely upon Vitalink to
provide the necessary resources for them to adequately address market changes.
The systems and processes necessary to assist payers and providers to manage
total health care costs and achieve greater program integrity require
integrating patient care across a spectrum of post-acute care settings. It also
requires that they interface with acute inpatient and chronic outpatient care.
To this end, Vitalink is committed to the development of integrated data systems
and care processes essential to affect and measure outcomes and reduce the
incidence of inappropriate drug use and the associated downstream costs of
such drug misadventures.
Vitalink's patients, provider partners and payers routinely look to Vitalink to
provide consistency, accountability, lower cost, market focus and improved
clinical and quality of life outcomes.
Vitalink's
Payer Mix
29% Medicaid
65% Private/*/
[PIE GRAPH APPEARS HERE]
6% Medicare/**/
*Includes private, Medicare Part A, insurance and other third party payers
**Includes Medicare Part B only
<PAGE>
Vitalink Locations
[MAP OF VITALINK LOCATIONS APPEARS HERE]
Map Key
.
States Served
H
Hub Pharmacies
S
Satellite Pharmacies
R
Regional Infusion Pharmacies
E
Enteral Distribution Site
California
Los Angeles
San Bernardino
Santa Rosa
Colorado
Northglenn
Florida
Deerfield Beach
St. Petersburg
Illinois
Elgin
Hickory Hills
Monticello
Indiana
Indianapolis
Iowa
Bettendorf
Maryland
Baltimore
New Jersey
Ocean
Ohio
Copley
Oklahoma
Oklahoma City
Oregon
Eugene
Portland
Pennsylvania
Allentown
Bridgeville
Williamsport
York
Texas
San Antonio
Wisconsin
Appleton
Medisco Healthcare Services
Acquired July, 1996
San Bernardino, California
Brentview Pharmacy
Acquired November, 1995
Los Angeles, California
Home Intravenous Care
Acquired July, 1995
Loveland, Colorado
Parker's Pharmacy
Acquired April, 1995
San Antonio, Texas
Apothecary Services
Acquired January, 1994
Northglenn, Colorado
Propac Pharmacy
Acquired August, 1993
Portland, Oregon
West End Family Pharmacy
Acquired December, 1992
Ocean, New Jersey
Northern Nursing Home Pharmacy
Acquired August, 1992
Baltimore, Maryland
Carrol-Hansen Drugs
Acquired May, 1992
Aurora, Illinois
Regional Infusion Pharmacies
Colorado
Loveland
Illinois
Hickory Hills
Oregon
Portland
Pennsylvania
Allentown
Enteral Distribution Site
Illinois
Calumet City
The Vitalink Difference
Our network of caring people, innovative
systems and improved outcomes
Caring People--Vitalink's employees play a vital role in enabling the company to
meet the challenges of today and tomorrow. Our objective is to hire the
industry's best, foster their continued development and support them in
providing the best patient care and customer service possible.
To reach our customer service and patient care goals, Vitalink must first
attract and recruit individuals that can accomplish our mission. This is
achieved through a series of structured interviews for key pharmacy personnel.
Our commitment is also reflected in the selection of acquisition candidates who
not only have the required financial profile but who also have dedicated
employees and high quality service reputations.
It is Vitalink's responsibility to ensure our employees are properly trained.
Vitalink's technicians, drivers, billing clerks, support personnel, nurses and
pharmacists receive targeted training to enhance their ability to better serve
our customers. Training begins with clearly communicating the company's core
values and setting the expectation that employees will live by these values.
Training programs that promote key principles in providing unparalleled customer
service are then conducted to achieve Vitalink's mission based on these values.
Vitalink provides initial customer service training programs as well as
technical and professional training. Training modules are added based upon
advances in patient care. An anti-coagulation training program for consultant
pharmacists and nurses, for example, was added prior to the national roll-out of
Vitalink's OPTIMA(SM) (Optimizing Patient Therapy in Medication Administration)
program for stroke management. The certification programs validate the
proficiencies required to properly perform key operational and patient care
roles.
Vitalink is committed to the belief that training promotes the ability of our
employees to serve as integral members of the patient care team, working to
anticipate, avoid and solve the problems of our provider partners.
[PICTURE APPEARS HERE]
-------------------------
Products and Services
Prescription management
Infusion therapies and support services
Patient care management protocols
Remote site dispensing
Facility based information systems
Professional consulting
Medical records management
Pre-survey assessment
Managed care contract support
Clinical information services
Medical supplies
Customer education programs
Nutritional support services
<PAGE>
Innovative Systems--Innovative systems are essential to support the patient care
and customer service goals Vitalink has embraced. Vitalink's goals of
consistency, accountability, clinical superiority and efficiency can only be
achieved through sound underlying systems.
In the future, the ability of a pharmacy provider to effectively direct
medication management across a continuum of care will be critical in providing
real value to the health care system. Safe, effective and efficient use of
medications can only be accomplished by applying a coordinated systems approach
to pharmacy services.
The first critical piece in utilizing a coordinated systems approach is
obtaining accurate patient information. How this data is collected,
- --------------------------------
Integrated Information Systems
Our sound operating systems
insure consistency, accountability,
clinical superiority and efficiency.
[SYSTEMS GRAPHIC APPEARS HERE]
Formulary Development
Continuous Quality Improvement
Outcome Measurement
OPTIMASM Patient Care Management
Protocol Development
Clinical Systems
Revenue
Billing Flexibility
Risk Sharing
Performance Tracking
Accounts Receivable Management
Inventory Management
"Vital Data"
Electronic Record
Financial
Systems
Dispensing
Regulatory Compliance
Automated Systems
Formulary Compliance
Logistics
Operations Systems
analyzed and used is the key to Vitalink's patient care and business
philosophies. Vitalink consultants provide training and support to our provider
partners to ensure that timely, accurate and complete information is
communicated to our pharmacies. The data is then entered into our proprietary
information system specifically designed to enhance our ability to promote
appropriate medication utilization.
Vitalink pharmacists use our information systems to go beyond the
dose, allergy and interaction screening commonly employed by institutional
pharmacies. All prescriptions for every patient are evaluated for
appropriateness relative to specific diagnoses, patient's age, physical
condition, laboratory findings and application of disease state management
protocols.
Using this innovative approach, Vitalink pharmacists recommend patient specific
drug regimen changes that eliminate unnecessary or duplicative therapies, select
drugs that have proven clinical superiority in target populations, reduce or
eliminate drug related problems, lower overall drug costs and improve patient
clinical and quality of life outcomes.
Vitalink's MIS department recently developed VitalCONSULT, an integrated
consultant software package, which allows our pharmacists and nurses to record
outcome events, laboratory data, patient status updates and clinical follow-up
notes and to administer patient care management programs and formularies more
efficiently.
VitalCONSULT allows Vitalink to provide sophisticated clinical support on a
continuous, real-time basis. All patient data required to support clinical
decision making is readily available. This facilitates proactive recommendations
(even by pharmacists providing after-hours, on-call services) and enhances our
ability to effectively communicate with physicians and nursing facility staff in
providing superior clinical services.
Vitalink's information systems have also been enhanced to print drug information
text on charting documents and patient drug information sheets ideally suited
for our assisted living, home care and adult day care patients. This integrated
approach allows Vitalink to follow a patient across multiple service settings
(home to assisted living facility to nursing facility) while addressing their
needs in each setting.
In addition, Vitalink's information systems allow us to query the medical
records of our entire patient population, quality check our clinical processes,
help identify diseases where the opportunity exists to improve
VitalCONSULT
Our proprietary information system allows our pharmacist and nurse consultants
to improve patient clinical and quality of life outcomes.
Vitalink 1996 Annual Report
The Vitalink Difference
<PAGE>
treatment, isolate high cost patterns to develop cost reduction initiatives,
aggregate and report utilization and outcome data and support the
company's initiatives in clinical research and product development.
Integrating patient data management and care support across multiple practice
settings also provides Vitalink with unique competitive advantages for future
anticipated fixed payment contracting and inclusion into integrated health care
systems.
Our CARE group is charged with developing company-wide policies and procedures
to ensure consistent operating practices in all our pharmacies. This consistency
is crucial in providing the high quality services and product integrity demanded
by our customers. In addition, it also provides a competitive advantage in
securing regional or national contracts and other new business.
Vitalink's CARE group standards form the foundation for operational consistency
and brand leverage. Vitalink utilizes interdisciplinary audit teams to ensure
compliance with CARE group standards. The audits are designed to identify areas
for improvement and focus efforts in our continuous quality improvement program.
This system reinforces our organizational commitment to the best operating
practices in addition to providing the oversight necessary to avoid regulatory
compliance issues.
Vitalink's Clinical Information Services (CIS) group has the responsibility to
ensure and improve the quality of Vitalink's clinical systems and capacity. CIS
provides comprehensive drug information services, designs modules for our
patient care management system, conducts drug utilization research and provides
clinical sales support for the organization. This year, the CIS team initiated
the national roll-out of the first program in Vitalink's patient care management
system, OPTIMA/(SM)/.
The OPTIMA/(SM)/ system is designed to improve clinical, functional and economic
outcomes in critical, high mortality/morbidity and costly diseases such as
stroke, osteoporosis, obstructive pulmonary disease, heart failure and
depression. This is achieved through the combination of drug and disease
management practice guidelines (derived from AHCPR, NIH and physician specialty
society protocols), interdisciplinary coordination, care management queuing,
professional training, disease specific drug formularies, physician and facility
staff education and support, outcomes monitoring and data capture and analysis.
Improved Outcomes--The OPTIMA/(SM)/ program is designed to achieve dramatic
changes in patient care. Vitalink's OPTIMA/(SM)/ stroke management/anticoagulant
program follows the national guidelines which have been proven to reduce the
incidence of stroke significantly.
The potential positive impact when applied to our entire patient base could
result in 1,500 less strokes, 500 less deaths, 2,000 fewer occurrences of
serious physical and mental disabilities such as paralysis and dementia and
savings of at least $25 million in health care costs annually.
Utilizing OPTIMA/(SM)/ systems in the management of osteoporosis could help
reduce the incidence of hip fractures in the elderly by over 70%. This is
significant since the elderly, particularly women, who experience hip fractures
have shown at least a 20% greater increase in mortality in the year following
the incident. As people age they are more likely to experience osteoporosis.
Appropriate screening and treatment at age 65 has the potential to keep almost
all patients out of the high-risk for fracture range.
The OPTIMA/(SM)/ program is just one tool that Vitalink uses to enhance
outcomes. Our systems and professionals are being redeployed to play a more
prominent and interactive role in patient management through appropriate drug
therapy which avoids drug misadventures and resultant problems.
Inappropriate drug use is a common problem in the elderly. National data
indicates that noncompliance with prescription directions causes over 125,000
deaths per year, accounts for 5% to 10% of hospital admissions and results in
admissions to nursing facilities with an annual cost over $5 billion.
This problem exists across the entire continuum of care: sub-acute care, long-
term care, assisted living and home care. It causes unnecessary
suffering, disease progression, increases the incidence of debilitation, lessens
the quality of life and causes premature death. Our provider partners feel the
impact in the need for increased patient support through greater staffing and
resultant increased operating costs. Payers experience misdirected resources and
unnecessary costs. Vitalink's goal is to utilize its human and technological
resources to change the status quo.
Having a positive effect on our patients' drug therapies creates tremendous
value for Vitalink's services, provides improved clinical and quality of life
outcomes for our patients, improves the efficiency of our provider partners and
reduces the overall cost of health care.
Our OPTIMA/(SM)/
Program
The GAO estimates that 30%
of all drugs prescribed to the elderly
are taken inappropriately.
Vitalink's OPTIMA/(SM)/ program is targeted
toward minimizing this problem.
- --------------------30% inappropriate
drug use
<PAGE>
- ----------------
Continuum
of Care
[FLOW CHART GRAPHIC APPEARS HERE]
Market Needs
Vitalink's Position
minimum care & cost
Provide first point of entry for
comprehensive services
Increase professional staff efficiency
Provide case management assistance
Assist in initial analysis
of medication regimen
Develop systems reducing
medication dispensing time and improving compliance
$2.3 billion
market
300,000
clients served
Adult
Day Care
Viewed as the preferred
choice for clients
Ability to manage chronic care
elderly with multiple treatments
Provide infusion and
nutritional therapy
products and support
$28 billion
market
7 million
clients served
Home Health
$12 billion
market
1 million
residents served
Increase staff efficiency
Regulatory compliance
Extend staff expertise
Develop consulting
and dispensing systems
which maintain resident
dignity and independence
Assisted Living
Regulatory compliance
Economic outcomes measurement
New business development assistance
Cost control
Increase staff efficiency
Assist facility partners to provide increasingly
complex, cost-sensitive and regulated medical care
$100 billion
market
1.7 million
patients served
Skilled Care
Increased accreditation requirements
Economic outcomes measurement
Ability to manage high acuity patients
Highly trained staff
Cooperation in patient management
$4 billion
market
350,000
patients served
Provide services and
products that bridge acute, long-term, ambulatory
and home care needs
Subacute
maximum care & cost
Vitalink 1996 Annual Report
The Vitalink Difference
#
<PAGE>
Report of Independent
Public Accountants
To the Board of Directors and Shareholders of Vitalink Pharmacy Services, Inc.:
We have audited the accompanying consolidated balance sheets of Vitalink
Pharmacy Services, Inc. (a Delaware Corporation) and subsidiaries as of May 31,
1996 and 1995, and the related consolidated statements of income, stockholders'
equity and cash flows for each of the three years in the period ended May 31,
1996. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform an audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Vitalink Pharmacy Services,
Inc. and subsidiaries as of May 31, 1996 and 1995, and the results of their
operations and their cash flows for each of the three years in the period ended
May 31, 1996 in conformity with generally accepted accounting principles.
Arthur Andersen LLP
Washington, D.C.
June 25, 1996
<PAGE>
------------------
Earnings Per Share
(in dollars)
.99 .84 .66
[Graph of Earnings Per Share Appears Here]
94 95 96
Consolidated Statements of Income
(in thousands, except per share data)
<TABLE>
<CAPTION>
Year Ended May 31, 1996 1995 1994
- --------------------------------------------------------------------------
<S> <C> <C> <C>
Net Revenues
- --------------------------------------------------------------------------
Affiliates and their patients $ 67,066 $ 54,734 $45,976
------------------------------------------------------------------------
Non-affiliates and their patients 74,049 57,523 52,593
------------------------------------------------------------------------
Total net revenues 141,115 112,257 98,569
------------------------------------------------------------------------
Cost of Goods Sold 71,122 56,280 51,146
- --------------------------------------------------------------------------
Gross Profit 69,993 55,977 47,423
- --------------------------------------------------------------------------
Operating Expenses
- --------------------------------------------------------------------------
Payroll expenses 29,255 22,153 18,901
------------------------------------------------------------------------
Selling, general and
administrative expenses 11,662 9,573 8,558
------------------------------------------------------------------------
Provision for doubtful accounts 2,412 1,772 1,612
------------------------------------------------------------------------
Depreciation and amortization 4,363 3,753 3,357
------------------------------------------------------------------------
Total operating expenses 47,692 37,251 32,428
------------------------------------------------------------------------
Income from Operations 22,301 18,726 14,995
- --------------------------------------------------------------------------
Interest Income and Other, Net 1,003 893 691
- --------------------------------------------------------------------------
Interest Expense (51) (57) (215)
- --------------------------------------------------------------------------
Income Before Allocation of Income Taxes 23,253 19,562 15,471
- --------------------------------------------------------------------------
Income Tax Allocation 9,383 7,882 6,267
- --------------------------------------------------------------------------
Net Income $ 13,870 $ 11,680 $ 9,204
- --------------------------------------------------------------------------
Weighted Average Shares Outstanding 13,976 13,975 13,975
- --------------------------------------------------------------------------
Earnings Per Share $ .99 $ .84 $ .66
- --------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated statements.
Consolidated Balance Sheets
(in thousands, except share data)
<TABLE>
<CAPTION>
As of May 31, 1996 1995
- --------------------------------------------------------------------------------
<S> <C> <C>
- ------
Assets
- ------
Current Assets
- --------------------------------------------------------------------------------
Cash $ 889 $ $198
-----------------------------------------------------------------------------
Receivables (net of allowances of $2,163 and
$1,378) 20,093 13,844
-----------------------------------------------------------------------------
Inventories 7,426 6,520
-----------------------------------------------------------------------------
Deferred income taxes 1,138 1,012
-----------------------------------------------------------------------------
Other 330 167
-----------------------------------------------------------------------------
Total current assets 29,876 21,741
-----------------------------------------------------------------------------
Due from Parent 16,910 16,888
- --------------------------------------------------------------------------------
Property and Equipment, at cost,
Net of Accumulated Depreciation 8,191 6,227
- --------------------------------------------------------------------------------
Pharmacy Contracts
(net of amortization of $3,044 and $2,116) 6,187 7,015
- --------------------------------------------------------------------------------
Goodwill (net of amortization of $2,146 and $1,360) 31,194 26,028
- --------------------------------------------------------------------------------
Other Assets (net of amortization of $3,292 and $2,365) 3,565 2,814
- --------------------------------------------------------------------------------
Total Assets $ 95,923 $ 80,713
- --------------------------------------------------------------------------------
- ------------------------------------
Liabilities and Stockholders' Equity
- ------------------------------------
Current Liabilities
- --------------------------------------------------------------------------------
Accounts payable $3,918 $2,594
-----------------------------------------------------------------------------
Accrued expenses 2,403 3,037
-----------------------------------------------------------------------------
State income taxes payable 725 908
-----------------------------------------------------------------------------
Total current liabilities 7,046 6,539
-----------------------------------------------------------------------------
Deferred Income Taxes ($1,916 and $1,078)
& Other Long-Term Liabilities 2,578 1,795
- --------------------------------------------------------------------------------
Stockholders' Equity
- --------------------------------------------------------------------------------
Common stock
(30,000,000 shares authorized, 13,979,700 and
13,975,000 shares issued, $.01 par value) 140 140
-----------------------------------------------------------------------------
Contributed capital 38,155 38,105
-----------------------------------------------------------------------------
Retained earnings 48,004 34,134
-----------------------------------------------------------------------------
Total stockholders' equity 86,299 72,379
-----------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity $95,923 $80,713
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated balance
sheets.
------------------------
Return on Average Assets
(as percent)
15.5 15.7
[Graph of Return on Average Assets Appears Here]
95 96
<PAGE>
Vitalink 1996 Annual Report
-------------------
Retained Earnings
(in millions of dollars)
13.3 22.5 34.1 48.0
[Vertrical Bar Graph of Retained Earnings Appears Here]
93 94 95 96
Consolidated Statements of
Stockholders' Equity
(in thousands, except share data)
<TABLE>
<CAPTION>
Common Stock Contributed Retained
Shares Amount Capital Earnings
- ------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Balance, May 31, 1993 13,975,000 $140 $38,105 $13,250
- ------------------------------------------------------------------------
Net income -- -- -- 9,204
- ------------------------------------------------------------------------
Balance, May 31, 1994 13,975,000 140 38,105 22,454
- ------------------------------------------------------------------------
Net income -- -- -- 11,680
- ------------------------------------------------------------------------
Balance, May 31, 1995 13,975,000 140 38,105 34,134
- ------------------------------------------------------------------------
Net income -- -- -- 13,870
- ------------------------------------------------------------------------
Exercise of stock options 4,700 -- 50 --
- ------------------------------------------------------------------------
Balance, May 31, 1996 13,979,700 $140 $38,155 $48,004
- ------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated statements.
Consolidated Statements
of Cash Flows
(in thousands)
<TABLE>
<CAPTION>
Year Ended May 31, 1996 1995 1994
- ----------------------------------------------------------------------------------
<S> <C> <C> <C>
- ------------------------------------
Cash Flows from Operating Activities
- ------------------------------------
Net income $ 13,870 $ 11,680 $ 9,204
- ----------------------------------------------------------------------------------
Reconciliation of net income to net
cash provided by operating activities
- ----------------------------------------------------------------------------------
Depreciation and amortization 4,363 3,753 3,357
--------------------------------------------------------------------------------
Provision for doubtful accounts 2,412 1,772 1,612
--------------------------------------------------------------------------------
Gain on sale of business -- (50) (110)
--------------------------------------------------------------------------------
Decrease (increase) in deferred taxes 712 (114) (77)
--------------------------------------------------------------------------------
Change in assets and liabilities, net of
acquisitions
--------------------------------------------------------------------------------
Change in receivables (8,661) (1,731) (6,217)
------------------------------------------------------------------------------
Change in inventories (450) (1,103) 771
------------------------------------------------------------------------------
Change in other assets (1,163) (21) (21)
------------------------------------------------------------------------------
Change in accounts payable and
accrued expenses 1,559 242 (1,032)
------------------------------------------------------------------------------
Change in state income taxes payable (183) (84) 230
------------------------------------------------------------------------------
Net Cash Provided by Operating Activities 12,459 14,344 7,717
------------------------------------------------------------------------------
- ------------------------------------
Cash Flows from Investing Activities
- ------------------------------------
Investment in property and equipment (3,537) (2,163) (1,567)
- ----------------------------------------------------------------------------------
Proceeds from sale of business -- 144 222
- ----------------------------------------------------------------------------------
(Increase) decrease in due from parent, net (22) (8,721) 2,109
- ----------------------------------------------------------------------------------
Acquisition of pharmacy businesses (5,531) (2,451) (7,217)
- ----------------------------------------------------------------------------------
Deferred payments on previous acquisitions (2,030) (1,400) --
- ----------------------------------------------------------------------------------
Other items, net (644) (107) (312)
- ----------------------------------------------------------------------------------
Net Cash (Used in) Investing Activities (11,764) (14,698) (6,765)
--------------------------------------------------------------------------------
- ------------------------------------
Cash Flows from Financing Activities
- ------------------------------------
Principal payments of debt (54) (56) (764)
- ----------------------------------------------------------------------------------
Exercise of stock options 50 -- --
- ----------------------------------------------------------------------------------
Net Cash (Used in) Financing Activities (4) (56) (764)
-------------------------------------------------------------------------------
Net Increase (Decrease) in Cash 691 (410) 188
- ----------------------------------------------------------------------------------
Cash at Beginning of Period 198 608 420
- ----------------------------------------------------------------------------------
Cash at End of Period $ 889 $ 198 $ 608
- ----------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated statements.
<PAGE>
Vitalink 1996 Annual Report
Notes To Consolidated Financial Statements
- --------------------------------------------------------------------------------
Summary of Significant Accounting Policies
Organization--Vitalink Pharmacy Services, Inc. (the "Company") owns and
operates, directly or through its subsidiaries, institutional pharmacies. As of
May 31, 1996, Manor Care, Inc. ("Manor Care") owned approximately 82.3% of the
Company's common stock. Manor Care, through its wholly-owned subsidiary Manor
HealthCare Corp. ("Manor HealthCare"), operates nursing facilities. Unless the
context otherwise requires, Manor Care shall mean Manor Care and its
subsidiaries other than the Company.
Principles of Consolidation--The consolidated financial statements include the
accounts of Vitalink Pharmacy Services, Inc. and all of its subsidiaries. All
significant intercompany transactions have been eliminated in consolidation.
Revenue Recognition and Concentration of Credit Risk--The Company records
revenues at the time services or supplies are provided. Revenue is reported at
the estimated net realizable amounts expected to be received from individuals,
third party payers or others for services and supplies provided. Net revenues
from Medicaid and Medicare programs were $40,250,000 and $8,151,000,
respectively, for the year ended May 31, 1996 and $32,963,000 and $7,915,000,
respectively, for the year ended May 31, 1995. Accounts receivable outstanding
on the consolidated balance sheets from Medicaid and Medicare programs were 25%
and 9%, respectively, of total accounts receivable at May 31, 1996 and 33% and
13%, respectively, of total accounts receivable at May 31, 1995.
Inventories--Inventories are stated at the lower of cost (first-in, first-out
method) or market and are comprised primarily of products held for resale.
Property and Equipment--The components of property and equipment at May 31,
are as follows:
<TABLE>
<CAPTION>
1996 1995
- ------------------------------------------------------------------------------
(in thousands)
<S> <C> <C>
Leasehold improvements $ 1,125 $ 988
- ------------------------------------------------------------------------------
Furniture, fixtures and equipment 6,907 4,746
- ------------------------------------------------------------------------------
Vehicles 1,553 1,070
- ------------------------------------------------------------------------------
Computer equipment 3,199 2,625
- ------------------------------------------------------------------------------
12,784 9,429
- ------------------------------------------------------------------------------
Less accumulated depreciation (4,593) (3,202)
- ------------------------------------------------------------------------------
$ 8,191 $ 6,227
- ------------------------------------------------------------------------------
</TABLE>
Depreciation and amortization of property and equipment is computed using the
straight-line method over the following estimated useful lives:
<TABLE>
<S> <C>
Leasehold improvements 5-10 years
- --------------------------------------------------
Furniture, fixtures and equipment
including computer equipment 3-8 years
- --------------------------------------------------
Vehicles 2-3 years
- --------------------------------------------------
</TABLE>
Capitalization Policies--Maintenance, repairs and minor replacements are charged
to expense. Major renovations and replacements are capitalized to appropriate
property and equipment accounts. Upon sale or retirement of property, the cost
and related accumulated depreciation are eliminated from the accounts and the
related gain or loss is recorded.
Goodwill and Pharmacy Contracts--Goodwill arising from business acquisitions is
amortized on the straight-line basis over 40 years. Pharmacy contracts,
principally representing the estimated value of acquired contracts to service
customers, are amortized over their estimated useful lives, not to exceed 10
years. The recoverability of these assets is evaluated annually. Amortization
expense charged to operations for goodwill and pharmacy contracts, respectively,
was $786,000 and $928,000 in 1996, $635,000 and $904,000 in 1995 and $536,000
and $830,000 in 1994.
Earnings Per Common Share--Earnings per common share have been computed based
on the weighted average number of shares of common stock outstanding. The effect
of outstanding stock options on the computation is insignificant.
Use of Estimates--The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.
- --------------------------------------------------------------------------------
Related Party Transactions
The Company provides pharmaceutical dispensing, infusion therapy and pharmacy
consulting services to nursing facilities owned and operated by Manor Care and
the patients of these facilities. In prior fiscal years, sales of pharmaceutical
and infusion therapy products and services to Manor Care's nursing facilities
were made at prices charged to other customers less an administrative fee equal
to 3% of the private pay revenues derived from each facility. The administrative
fee was $485,000 and $440,000, respectively, for the two years ended May 31,
1995. Effective June 1, 1995, the Company ceased to pay Manor Care the 3%
administrative fee as the Company assumed the billing and collecting of private
pay revenues derived from Manor Care facilities. Revenues from sales to Manor
Care nursing facilities and patients, which are included in net revenues from
affiliates and their patients in the consolidated statements of income, were
$64,302,000, $52,449,000 and $43,984,000, respectively, for the three years
ended May 31, 1996. Fees from consulting services to Manor Care and Manor Care
facilities, which are included in net revenues from affiliates and their
patients in the consolidated statements of income, are charged based on an
annual fee per bed and totalled $2,764,000, $2,285,000 and $1,992,000,
respectively, for the three years ended May 31, 1996.
The Company and Manor Care have entered into an Administrative Services
Agreement. The agreement has annual renewal terms. Manor Care provides various
services to the Company including, among others, cash management, payroll and
payables processing, employee benefit plans, insurance, legal, accounting, tax,
information systems and certain administrative services, as required.
Substantially all cash received by the Company is immediately deposited in and
combined with Manor Care's corporate funds through its cash management system.
Similarly, operating expenses, capital expenditures and other cash requirements
of the Company are paid by Manor Care and charged to the Company. Administrative
fees of $595,000, $551,000 and $500,000, respectively, for the three years ended
May 31, 1996, were charged based on a time allocation method which Manor Care
utilized to charge administrative services to all of its subsidiaries.
Management believes that the foregoing charges are reasonable allocations of the
costs incurred by Manor Care on the Company's behalf.
Manor Care obtains and provides insurance coverage for group health, auto,
general liability, property casualty and workers' compensation through its self-
insurance and outside insurance programs and charges the Company based on the
relative percentage of insurance costs incurred by Manor Care on the Company's
behalf. Total insurance costs allocated
<PAGE>
were $1,777,000, $1,360,000 and $1,279,000, respectively, for the three years
ended May 31, 1996. Management believes that the foregoing charges are
reasonable allocations of the costs incurred by Manor Care on the Company's
behalf.
The net result of all of these intercompany transactions, plus tax allocations
as discussed in the next footnote regarding income taxes, is included in the due
from parent amount in the accompanying consolidated balance sheets. Due from
parent has no set repayment terms, but it is expected that repayment will occur
as the Company needs cash.
Additionally, Manor Care credited the Company with interest income of $972,000,
$822,000 and $330,000, respectively, for the three years ended May 31, 1996
relating to the average balance due from parent. The interest earned on the
average balance due from parent was calculated based on an average three-month
Treasury Bill rate plus 100 basis points. The average three-month Treasury Bill
rate was 5.13% in 1996, 5.23% in 1995 and 3.26% in 1994.
The Company and Manor Care have entered into an Intercompany Debt and Credit
Agreement whereby Manor Care provides the Company with a line of credit of
$10,000,000. The Intercompany Debt and Credit Agreement, dated June 1, 1991, is
for a five-year term and is automatically renewable unless terminated by either
party. The agreement was renewed on June 1, 1996. Manor Care will pass through
the charges under its own credit facility for the line of credit. These charges
include a 1/4 point fee on the unused funds and a 1/8 point fee on the entire
amount under the line of credit. These fees amounted to $38,000 in each of the
three years ended May 31, 1996. The interest rate charged on borrowed funds is
LIBOR plus 5/8 percentage points. There was no balance outstanding under this
agreement at May 31, 1996 or 1995.
The Company has entered into pharmacy, infusion therapy and consulting services
agreements with Manor Care, whereby the Company has the option to provide
pharmaceutical products and services, infusion therapy products and services and
pharmacy consulting services to Manor Care, Manor Care nursing facilities and
patients. The agreements have a ten-year term commencing June 1, 1991. The
Company will continue to charge Manor Care for consulting services as set forth
above.
During fiscal 1993, the Company entered into an agreement to lease an operating
facility from an employee. Rental expense under the non-cancelable operating
lease was $290,000 in the three years ended May 31, 1996. Future minimum lease
payments for the lease, which expires in 2002, are $1,883,000 at May 31, 1996.
- --------------------------------------------------------------------------------
Income Taxes
An agreement exists whereby the Company joins with Manor Care in the filing of a
consolidated Federal tax return. The consolidated provision of Manor Care is
allocated among its subsidiaries on a separate company basis. Accordingly, the
Company accrues taxes payable to or benefits receivable from Manor Care in the
due from parent account, based on the statutory rate applied to income before
taxes after considering appropriate tax credits. Deferred taxes are recorded for
the tax effect of temporary differences between book and tax income.
The allocation of the consolidated provisions for income taxes follows for the
years ended May 31:
<TABLE>
<CAPTION>
1996 1995 1994
- -------------------------------------
(in thousands)
<S> <C> <C> <C>
Current
- -------------------------------------
Federal $7,459 $6,381 $5,074
-----------------------------------
State 1,722 1,476 1,171
-----------------------------------
Deferred
- -------------------------------------
Federal 164 20 27
-----------------------------------
State 38 5 (5)
-----------------------------------
$9,383 $7,882 $6,267
- -------------------------------------
</TABLE>
Deferred tax assets (liabilities) are comprised of the following at May 31:
<TABLE>
<CAPTION>
1996 1995 1994
- ----------------------------------------------------------------------------
(in thousands)
<S> <C> <C> <C>
Gross deferred tax liabilities
- ----------------------------------------------------------------------------
Depreciation $ (941) $ (784) $(527)
--------------------------------------------------------------------------
Amortization of
intangibles (390) (269) (221)
--------------------------------------------------------------------------
Other (598) (266) (47)
--------------------------------------------------------------------------
Total gross deferred
tax liabilities (1,929) (1,319) (795)
--------------------------------------------------------------------------
Gross deferred tax assets
- ----------------------------------------------------------------------------
Reserve for doubtful
accounts 964 747 548
--------------------------------------------------------------------------
Other 187 506 67
--------------------------------------------------------------------------
Total gross deferred
tax assets 1,151 1,253 615
--------------------------------------------------------------------------
Net deferred tax liabilities $ (778) $ (66) $(180)
- ----------------------------------------------------------------------------
</TABLE>
The Company expects the deferred tax assets to be realized through future
taxable income.
Reconciliation of the Federal statutory income tax rate and the Company's
effective rate is as follows:
<TABLE>
<CAPTION>
1996 1995 1994
- -----------------------------------------------------------------------------
<S> <C> <C> <C>
Federal income tax rate 35.0% 35.0% 35.0%
- -----------------------------------------------------------------------------
State income taxes,
net of Federal tax benefit 4.9% 4.9% 4.9%
- -----------------------------------------------------------------------------
Other 0.4% 0.4% 0.6%
- -----------------------------------------------------------------------------
Effective income tax rate 40.3% 40.3% 40.5%
- -----------------------------------------------------------------------------
</TABLE>
Cash paid for state income taxes was $1,210,000, $1,100,000 and $640,000,
respectively, for the three years ended May 31, 1996.
<PAGE>
Vitalink 1996 Annual Report
- --------------------------------------------------------------------------------
Accrued Expenses
Accrued expenses were as follows:
<TABLE>
<CAPTION>
1996 1995
- -----------------------------------------------------------
(in thousands)
<S> <C> <C>
Payroll and incentive
compensation $2,064 $1,567
- -----------------------------------------------------------
Acquisition related accruals 243 1,333
- -----------------------------------------------------------
Taxes, other than income 20 34
- -----------------------------------------------------------
Other 76 103
- -----------------------------------------------------------
$2,403 $3,037
- -----------------------------------------------------------
</TABLE>
- --------------------------------------------------------------------------------
Leases
The Company operates certain property and equipment under operating leases that
expire at various dates through 2002. Rental expense under noncancelable
operating leases was $1,373,000, $1,086,000, and $1,014,000, respectively, for
the three years ended May 31, 1996. Future minimum lease payments are as
follows:
<TABLE>
<CAPTION>
Operating Leases
- ------------------------------------------------
(in thousands)
<S> <C>
1997 $1,333
- ------------------------------------------------
1998 1,118
- ------------------------------------------------
1999 859
- ------------------------------------------------
2000 690
- ------------------------------------------------
2001 482
- ------------------------------------------------
Thereafter 594
- ------------------------------------------------
Total minimum lease payments $5,076
- ------------------------------------------------
</TABLE>
- --------------------------------------------------------------------------------
Acquisitions and Divestitures
Fiscal Year 1996--On November 3, 1995, the Company acquired the institutional
pharmacy business of Brentview Clinical Pharmacy, located in Los Angeles,
California for $3,206,000 in cash plus the assumption of $45,000 in liabilities
and future contingent payments based on the achievement of future profitability
objectives.
On July 6, 1995, the Company acquired the infusion therapy business of Home
Intravenous Care, Inc., located in Loveland, Colorado, for $2,325,000 in cash
plus the assumption of $105,000 in liabilities and future contingent payments
based on the achievement of certain future profitability objectives.
Fiscal Year 1995--On April 27, 1995, the Company acquired the institutional
pharmacy business of Parker's Pharmacy, Inc., located in San Antonio, Texas, for
$2,451,000 in cash plus the assumption of $107,000 in liabilities.
On June 27, 1994, the Company sold its last retail pharmacy operation located
in Wisconsin for $144,000 in cash.
Fiscal Year 1994--On January 4, 1994, the Company acquired the institutional
pharmacy business of Apothecary Services ("Apothecary"), located in Thornton,
Colorado, for $3,448,000 in cash plus the assumption of $107,000 in liabilities
and a contingent additional purchase price up to a maximum of $1,400,000 based
on the achievement of certain future operating objectives.
On August 24, 1993, the Company acquired White, Mack and Wart, Inc., which
operated Propac Pharmacy ("Propac"), located in Portland, Oregon, for
$3,769,000 in cash plus the assumption of $2,100,000 in liabilities and a
guarantee provision on stock options totalling $656,000, plus future contingent
payments based on the achievement of certain future operating objectives. If
required, the guaranteed value of stock options is payable in fiscal 1999.
In January 1994, the Company sold its retail pharmacy operation in Illinois for
$222,000 in cash.
The above acquisitions are accounted for under the purchase method of accounting
with the assets recorded at their estimated fair market values at the date of
acquisition. The fiscal 1995 and 1996 acquisitions were not material to the
Company's financial position or results of operations on a proforma basis. The
estimated fair market values of pharmacy contracts acquired are amortized over
the expected remaining lives of 10 years including estimated contract renewals.
Goodwill, representing the excess of acquisition costs over the fair market
value of acquired assets, is amortized over 40 years. Other assets include
noncompete covenants totalling $1,681,000 and $2,192,000, respectively, at May
31, 1996 and 1995. Other assets are amortized over their estimated useful lives
ranging from 2 to 10 years. Depreciation and amortization in the consolidated
statements of income include amortization of intangible assets of $2,641,000,
$2,449,000 and $2,256,000, respectively, for the three years ended May 31, 1996.
The guaranteed value of stock options granted to the sellers of acquired
businesses was considered part of the purchase price of the businesses. Included
in deferred income taxes and other long-term liabilities in the consolidated
balance sheets at May 31, 1996 and 1995 is $656,000 representing the guaranteed
value of stock options. An additional $1,000,000 is included in accrued expenses
at May 31, 1995 related to the guaranteed value of stock options granted in a
prior acquisition.
The results of operations of acquired businesses are included in the Company's
consolidated results from the date of acquisition. Had the acquisitions of
Apothecary and Propac occurred on June 1, 1993, management estimates that on an
unaudited pro forma basis, revenues, net earnings and earnings per share would
have been $102,174,000, $9,285,000 and $.66, respectively, for the year ended
May 31, 1994. These pro forma estimates reflect certain adjustments, including
amortization of intangible assets acquired, acquisition employment agreements,
reduced interest income from funds used in connection with the acquisition and
related income tax effects. The pro forma results are not necessarily indicative
of the operating results that would have occurred had the acquisitions been
consummated on June 1, 1993, nor are they indicative of future results.
- --------------------------------------------------------------------------------
Contingencies and Compensating Balances
The Company is subject to legal actions or claims for damages that arise in the
ordinary course of business. In the opinion of management and counsel to the
Company, the ultimate outcome of such litigation will not have a material
adverse effect on the Company's financial position or results of operations.
In connection with acquisitions, contingent purchase price payments exist up to
an aggregate maximum of $4,600,000, plus additional uncapped amounts based on
future performance.
Compensating balances of $75,000 are required under certain debt agreements of
Manor Care.
<PAGE>
Vitalink 1996 Annual Report
- --------------------------------------------------------------------------------
Pension, Profit Sharing and Incentive Plans
The Company participates in the various pension and profit sharing plans of
Manor Care and contributes through Manor Care to certain welfare plans. The
provision for these plans amounted to $433,000, $317,000 and $268,000,
respectively, for the three years ended May 31, 1996. All vested benefits under
retirement plans are funded or accrued. Additionally, included in accrued
expenses at May 31, 1996 and 1995 are $80,000 and $160,000, respectively, of
benefits assumed in the West End acquisition.
The Company also has incentive compensation plans for management personnel and
officers based primarily on new business development and achievement of certain
profitability levels. Incentive compensation expense was $1,003,000, $968,000
and $628,000, respectively, for the three years ended May 31, 1996.
- --------------------------------------------------------------------------------
Capital Stock
In September 1991, the Company's sole shareholder and Board of Directors
authorized 10,000,000 shares of preferred stock at $.01 par value. None of the
preferred stock is issued and outstanding. The Board of Directors is authorized
to determine the rights of the preferred shares.
In September 1991, the Company's Board of Directors adopted the Company's 1991
Key Executive Stock Option and Appreciation Rights Plan (the "Plan"). Under the
Plan, 420,000 shares were reserved for issuance upon exercise of options granted
thereunder. The Plan provides for the granting of options at prices equal to the
market value of the stock at date of grant. In addition, a stock appreciation
right may be granted in tandem with a stock option. At the election of the
Board, the stock appreciation right may be paid in lieu of the option exercise
in cash or shares of common stock or a combination thereof in an amount equal to
the difference between the option exercise price and the then market value of
the shares subject to the option. Options granted are not exercisable during
either the first one or two years after the date of grant and vest over periods
of 48 to 96 months. The options expire from 5 to 10 years after the date of
grant.
In fiscal 1994, the Board adopted and the shareholders approved an increase in
the number of shares reserved for issuance to 1,000,000.
The following summarizes stock option transactions for the three fiscal years
ended May 31:
<TABLE>
<CAPTION>
Number of Shares 1996 1995 1994
- -------------------------------------------------------
<S> <C> <C> <C>
Outstanding at June 1, 497,100 398,600 286,600
- -------------------------------------------------------
Granted
at $10.06-$19.88 109,000 126,000 128,000
- -------------------------------------------------------
Exercised
at $10.06-$12.75 (4,700) -- --
- -------------------------------------------------------
Cancelled
at $11.06-$17.00 (100,000) (27,500) (16,000)
- -------------------------------------------------------
Outstanding at May 31, 501,400 497,100 398,600
- -------------------------------------------------------
Exercisable at May 31, 83,613 75,786 20,126
- -------------------------------------------------------
Available for grant
at May 31, 493,900 503,500 602,000
- -------------------------------------------------------
</TABLE>
In fiscal 1996, the Board of Directors adopted a restricted stock grant plan for
key employees. The plan permits the grant of restricted stock in which vesting
is subject to continued employment for a period of five years from the date of
grant. At May 31, 1996, 15,000 shares of restricted stock grants were
outstanding.
In 1993, options were granted to four of the former shareholders of White, Mack
and Wart, Inc. to purchase 100,000 shares of common stock at $10.88 per share.
Theses options are not exercisable during the first two years after the date of
grant and then vest at the rate of 25% per year commencing at the end of year
two. The options expire six years after the date of grant.
- --------------------------------------------------------------------------------
Quarterly Financial Data
(unaudited)
The following table summarizes the quarterly financial data for the fiscal years
ended May 31, 1996 and 1995:
<TABLE>
<CAPTION>
Income
Quarter Net from Net Per
Ended Revenues Operations Income Share
- ----------------------------------------------------------------------
(in thousands, except per share data)
<S> <C> <C> <C> <C>
Fiscal 1996
- ----------------------------------------------------------------------
August $ 31,822 $ 5,070 $ 3,191 $.23
- ----------------------------------------------------------------------
November 33,998 5,390 3,366 .24
- ----------------------------------------------------------------------
February 36,497 5,646 3,486 .25
- ----------------------------------------------------------------------
May 38,798 6,195 3,827 .27
- ----------------------------------------------------------------------
$141,115 $22,301 $13,870 $.99
- ----------------------------------------------------------------------
Fiscal 1995
- ----------------------------------------------------------------------
August $ 26,911 $ 4,354 $ 2,692 $.19
- ----------------------------------------------------------------------
November 27,450 4,518 2,801 .20
- ----------------------------------------------------------------------
February 28,786 4,876 3,057 .22
- ----------------------------------------------------------------------
May 29,110 4,978 3,130 .22
- ----------------------------------------------------------------------
$112,257 $18,726 $11,680 $.84*
- ----------------------------------------------------------------------
*Does not add due to rounding
</TABLE>
- --------------------------------------------------------------------------------
Market Price Data
Vitalink's common stock trades on The Nasdaq Stock Market under the symbol
"VTLK". The following table sets forth the high and low sales price per share of
Vitalink's common stock for each quarter indicated, as reported in published
financial sources (rounded to the nearest cent):
<TABLE>
<CAPTION>
Market Price Per Share
High Low
- -------------------------------------------------
<S> <C> <C>
Fiscal 1996
- -------------------------------------------------
August $17.50 $14.75
----------------------------------------------
November 19.50 14.75
----------------------------------------------
February 25.38 16.88
----------------------------------------------
May 24.50 19.00
----------------------------------------------
Fiscal 1995
- -------------------------------------------------
August $12.25 $ 8.50
----------------------------------------------
November 15.50 10.75
----------------------------------------------
February 14.25 11.00
----------------------------------------------
May 17.00 12.50
----------------------------------------------
</TABLE>
The Company has not paid, and does not anticipate paying in the foreseeable
future, any dividends to the holders of its common stock.
<PAGE>
Management's Discussion and Analysis
- --------------------------------------------------------------------------------
Results of Operations
Fiscal 1996 Compared to Fiscal 1995--Net revenues for fiscal 1996 were
$141,115,000, an increase of $28,858,000, or 25.7%, over fiscal 1995. The
increase in net revenues was principally attributable to increases in the number
of nursing facility beds serviced by the Company and increased revenues per bed
from higher patient acuity levels. At May 31, 1996, the Company provided
services to approximately 49,900 nursing facility beds, including 19,300 Manor
Care beds and 30,600 non-affiliate beds. At May 31, 1995, the Company provided
services to approximately 42,400 beds, including 16,000 Manor Care beds and
26,400 non-affiliate beds.
Increases in beds serviced were achieved through acquisitions, start-ups in
Oklahoma City and St. Petersburg and marketing efforts to customers in existing
markets. In the first quarter, the Company acquired Home Intravenous Care, Inc.,
located in Loveland, Colorado. Brentview Clinical Pharmacy, located in Los
Angeles, California, was acquired in the second quarter. In fiscal 1996, these
two acquisitions contributed net revenues of $1,821,000 and $3,305,000,
respectively. Included in fiscal 1996 revenues from Manor Care facilities and
patients are $2,764,000 in fees charged for consulting services as compared with
$2,285,000 charged in fiscal 1995.
Gross profit for fiscal 1996 was $69,993,000, an increase of $14,016,000, or
25.0%, over fiscal 1995. The gross profit margin decreased slightly to 49.6%
in fiscal 1996 compared to 49.9% in fiscal 1995.
Operating expenses increased $10,441,000 to $47,692,000, or 33.8% of net
revenues in fiscal 1996 compared to $37,251,000, or 33.2% of net revenues in
fiscal 1995. Both payroll and selling, general and administrative expenses
increased to support the growth in beds serviced. Payroll expenses, as a
percentage of net revenues, increased to 20.7% from 19.7%, primarily resulting
from investments in staff for information systems and selling efforts. The
increase in depreciation and amortization is the result of the amortization of
pharmacy contracts, goodwill and noncompete agreements obtained in connection
with acquired businesses as well as depreciation on capital expenditures for
existing pharmacies.
The increase in interest income and other, net, which consists principally of
interest earned on the balance due from parent, is primarily due to the higher
average monthly balance due from parent resulting from unused operating cash
flows. The interest earned on the loan is equal to the average three-month
Treasury Bill rate plus 100 basis points. Interest income and other, net for
fiscal 1995 also includes a $50,000 gain on the sale of the Company's retail
operation located in Wisconsin.
The Company is required to adopt FASB No. 123 "Accounting for Stock-Based
Compensation" in 1997. The Company plans to adopt the disclosure method
described in this pronouncement and does not believe the implementation will
have a material impact on the Company's financial statements.
Fiscal 1995 Compared to Fiscal 1994--Net revenues for fiscal 1995 were
$112,257,000, an increase of $13,688,000, or 13.9%, over fiscal 1994. Included
in fiscal 1994 net revenues are approximately $801,000 in revenues from a retail
operation which was sold in June 1994. Retail revenues were only $56,000 in
fiscal 1995. The increase in net revenues was principally attributable to
increases in the number of nursing facility beds serviced by the Company and
increased revenues per bed from higher patient acuity levels. At May 31, 1995,
the Company provided services to approximately 42,400 nursing facility beds,
including 16,000 Manor Care beds and 26,400 non-affiliate beds. At May 31, 1994,
the Company provided services to approximately 39,400 beds, including 14,300
Manor Care beds and 25,100 non-affiliate beds.
Increases in beds serviced were achieved through an acquisition and marketing
efforts to customers in existing markets. In the fourth quarter, the Company
completed the acquisition of Parker's Pharmacy, located in San Antonio, Texas.
At the time of acquisition, Parker's serviced approximately 1,300 beds. Included
in fiscal 1995 revenues from Manor Care facilities and patients are $2,285,000
in fees charged for consulting services as compared with $1,992,000 charged in
fiscal 1994. These consulting activities are primarily due to the need to comply
with standards for nursing facilities associated with the implementation of OBRA
in October 1990.
Gross profit for fiscal 1995 was $55,977,000, an increase of $8,554,000, or
18.0%, over fiscal 1994. The gross profit margin was 49.9% for fiscal 1995
compared to 48.1% for fiscal 1994. The increase in gross profit margin was due
to a combination of factors. The elimination of lower margin retail revenues
during fiscal 1995 contributed, in part, to a more favorable product mix. In
addition, the increasing focus of our customers, particularly Manor Care, on the
higher margin subacute market resulted in more sales of higher margin products.
And finally, the Company's greater emphasis on generic and therapeutic
substitution resulted in higher margin product selection.
Operating expenses increased $4,823,000 to $37,251,000, or 33.2% of net revenues
in fiscal 1995 compared to $32,428,000, or 32.9% of net revenues in fiscal 1994.
Both payroll and selling, general and administrative expenses increased to
support the growth in beds serviced. The increase in depreciation and
amortization is the result of the amortization of pharmacy contracts, goodwill
and noncompete agreements obtained in connection with acquired businesses as
well as depreciation on capital expenditures for existing pharmacies.
The increase in interest income and other, net, which consists principally of
interest earned on the balance due from parent, is primarily due to the higher
average monthly balance due from parent resulting from unused operating cash
flows. The interest earned on the loan is equal to the average three-month
Treasury Bill rate plus 100 basis points. Interest income and other, net for
fiscal 1995 also includes a $50,000 gain on the sale of the Company's retail
operation located in Wisconsin.
- --------------------------------------------------------------------------------
Liquidity and Capital Resources
The Company meets its ongoing capital requirements and operating needs from
operating cash flows. Cash flows provided by operating activities were
$12,459,000 in fiscal 1996 compared to $14,344,000 in fiscal 1995. Fiscal 1996
operating cash flows were approximately $2,500,000 lower because of the change
to billing private pay residents in Manor Care facilities directly rather than
being paid by Manor Care. Operating cash flows not used to acquire pharmacies or
invest in new property and equipment is held in the form of a receivable due
from Manor Care. The balance due is classified as due from parent on the
consolidated balance sheets and totalled approximately $17,000,000 at May 31,
1996.
The Company's acquisition program is funded by operating cash flows, a
$10,000,000 line of credit with Manor Care or other conventional sources, if
required. During fiscal 1996, the Company paid cash of $3,206,000 to acquire the
institutional pharmacy business of Brentview Clinical Pharmacy and $2,325,000 to
acquire the infusion therapy business of Home Intravenous Care, Inc. During
fiscal 1995, the Company acquired the institutional pharmacy business of
Parker's Pharmacy for cash of $2,451,000. During fiscal 1994, the Company
acquired the
<PAGE>
institutional pharmacy businesses of Propac and Apothecary for $3,769,000 and
$3,448,000, respectively, in cash. Generally, the purchase contracts for
acquisitions stipulate future payments contingent upon achievement of future
profitability objectives.
On June 1, 1991, the Company entered into an "Intercompany Debt and Credit
Agreement" with Manor Care pursuant to which Manor Care provides the Company
with a line of credit of $10,000,000. Manor Care, through a wholly-owned
subsidiary, owns approximately 82% of the Company. To date, the line of credit
has not been utilized and the entire $10,000,000 balance on the line of credit
remains available to the Company. The line of credit and approximately
$17,800,000 of cash and amounts due from parent are available for general
corporate purposes including potential acquisitions of pharmacies, the internal
development of additional pharmacies, working capital and capital expenditures.
The Company's net working capital has been sufficient to meet capital and other
cash requirements. The Company believes that cash generated from operations, the
$10,000,000 line of credit and the remaining amounts due from parent will be
adequate to meet the Company's foreseeable capital and other cash requirements.
<PAGE>
Vitalink Information
<TABLE>
<CAPTION>
<S> <C>
Officers
Corporate Information
Donald C. Tomasso
Chairman Corporate Headquarters
Chief Executive Officer Vitalink Pharmacy Services, Inc.
1250 East Diehl Road, Suite 208
Stewart Bainum, Jr. Naperville, Illinois 60563
Vice Chairman 630-245-4800
http://www.vtlk.com
Donna L. DeNardo
President Auditors
Chief Operating Officer Arthur Andersen LLP
1666 K Street, N.W.
Vincent C. DiTrapano Washington, DC 20006
Senior Vice President, Operations
Registrar & Transfer Agent
Scott T. Macomber ChaseMellon Shareholder Services
Vice President, Finance New York, New York 10001-2697
Chief Financial Officer
Investment Inquiries
Stephen A. Thompson For more information about Vitalink, please
Vice President, Human Resources and contact the Investor Relations Department at 630-245-4800.
Administration
James A. MacCutcheon For changes of address, information concerning transfer of stock, or
Treasurer miscellaneous requests,
shareholders may contact:
James H. Rempe
Secretary ChaseMellon Shareholder Services
450 West 33rd Street, 15th Floor
Gerald F. Hickey New York, New York 10001-2697
Assistant Treasurer 800-851-9677
K. Peter Kemezys
Assistant Secretary
Directors
Donald C. Tomasso
Chairman
Director, In Home Health, Inc.
Stewart Bainum, Jr.
Vice Chairman
Chairman, Manor Care, Inc.
Donna L. DeNardo
Harold Blumenkrantz
Executive Director, Vitalink
Director, Drug Guild, Inc.
Joseph R. Buckley
Executive Vice President, Manor Care, Inc.
Director, In Home Health, Inc.
Directors--continued
Anil K. Gupta
Professor of Strategy and Organization
College of Business and Management
University of Maryland
James A. MacCutcheon
Senior Vice President and Chief Financial Officer
Manor Care, Inc.
James H. Rempe
Senior Vice President and General Counsel
Manor Care, Inc.
Director, In Home Health, Inc.
Marvin Wilensky
Chairman
Wilmac, Inc.
</TABLE>
20
<PAGE>
- -------------------------------------
Vitalink
Vitalink Pharmacy Services, Inc.
1250 East Diehl Road, Suite 208
Naperville, Illinois 60563
Phone 630-245-4800 Fax 630-505-1319
[LOGO OF VITALINK APPEARS HERE]
21
<PAGE>
EXHIBIT 21
VITALINK PHARMACY SERVICES, INC.
SUBSIDIARIES OF THE REGISTRANT
The following list sets forth the principal subsidiaries of the
registrant and the place of their incorporation. All of these subsidiaries are
wholly-owned by the registrant.
1. Vitalink Infusion Services, Inc., a Delaware corporation.
2. White, Mack and Wart, Inc., an Oregon corporation.
3. Medisco Pharmacies, Inc., a California corporation
<PAGE>
EXHIBIT 23
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the
incorporation of our reports dated June 25, 1996, included in and incorporated
by reference in Vitalink Pharmacy Services, Inc.'s Form 10-K for the year ended
May 31, 1996, into the Company's previously filed Registration Statement File
Nos. 33-75310, and 33-98992.
ARTHUR ANDERSEN LLP
Washington, D.C.,
August 28, 1996
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> MAY-31-1996
<PERIOD-START> JUN-01-1995
<PERIOD-END> MAY-31-1996
<CASH> 889
<SECURITIES> 0
<RECEIVABLES> 20,093
<ALLOWANCES> 2,163
<INVENTORY> 7,426
<CURRENT-ASSETS> 29,876
<PP&E> 12,784
<DEPRECIATION> 4,593
<TOTAL-ASSETS> 95,923
<CURRENT-LIABILITIES> 7,046
<BONDS> 0
0
0
<COMMON> 140
<OTHER-SE> 86,159
<TOTAL-LIABILITY-AND-EQUITY> 95,923
<SALES> 114,115
<TOTAL-REVENUES> 114,115
<CGS> 71,122
<TOTAL-COSTS> 118,814
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 2,412
<INTEREST-EXPENSE> 51
<INCOME-PRETAX> 23,253
<INCOME-TAX> 9,383
<INCOME-CONTINUING> 13,870
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 13,870
<EPS-PRIMARY> .99
<EPS-DILUTED> 0
</TABLE>
<PAGE>
EXHIBIT 99
(Proxy Statement)
<PAGE>
NOTICE OF ANNUAL MEETING
AND PROXY STATEMENT
[LOGO OF VITALINK PHARMACY SERVICES, INC. APPEARS HERE]
ANNUAL MEETING OF STOCKHOLDERS
OCTOBER 2, 1996
<PAGE>
VITALINK PHARMACY SERVICES, INC.
1250 EAST DIEHL ROAD
NAPERVILLE, ILLINOIS 60563
(630) 245-4800
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD OCTOBER 2, 1996
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Vitalink
Pharmacy Services, Inc. (the "Company"), will be held at the Radisson Hotel,
located at 3000 Warrenville Road, Lisle, Illinois, on Wednesday, October 2,
1996, at 9:00 a.m., to consider and vote upon the following matters:
1. To elect a Board of Directors consisting of nine persons to serve until
the next Annual Meeting of Stockholders of the Company and until their
successors are duly elected and qualified.
2. To approve a proposal to adopt the Vitalink Pharmacy Services, Inc. 1996
Long-Term Incentive Plan.
3. To approve a proposal to adopt the Vitalink Pharmacy Services, Inc. 1995
Employee Stock Purchase Plan.
4. To transact such other business as may properly come before such meeting or
any adjournment thereof.
The close of business on August 5, 1996, has been fixed as the record date
for the determination of stockholders entitled to notice of, and to vote at,
the Annual Meeting or any adjournment thereof.
Your management sincerely desires the presence in person of every stockholder
able to attend the meeting; however, in order to be assured of the representa-
tion of the greatest number of stockholders either in person or by proxy, it
is requested that you date and sign the accompanying proxy and return it as
promptly as possible in the enclosed self-addressed envelope. No postage is
required if mailed in the United States.
If you attend the meeting in person, you may revoke your proxy at such meet-
ing and cast your vote in person. If you receive more than one proxy because
your shares are held in various names or accounts, each proxy should be com-
pleted and returned.
By Order of the Board of Directors:
/s/ James H. Rempe
James H. Rempe
Secretary
Silver Spring, Maryland
August 28, 1996
<PAGE>
VITALINK PHARMACY SERVICES, INC.
1250 EAST DIEHL ROAD
NAPERVILLE, ILLINOIS 60563
(630) 245-4800
PROXY STATEMENT
ANNUAL MEETING OF STOCKHOLDERS
OCTOBER 2, 1996
INTRODUCTION
The enclosed proxy is solicited by and on behalf of the Board of Directors of
Vitalink Pharmacy Services, Inc. (the "Company"), a Delaware corporation, to
be used at the 1996 Annual Meeting of Stockholders of the Company (the "Annual
Meeting") to be held on Wednesday, October 2, 1996, at 9:00 a.m., at the
Radisson Hotel, located at 3000 Warrenville Road, Lisle, Illinois, and at any
and all adjournments thereof. All shares represented by proxies will be voted
at the Meeting in accordance with the specifications marked thereon, or if no
specifications are made, proxies will be voted FOR all matters set forth in
the attached Notice of Meeting and in the discretion of the proxy holder as to
any other business which comes before the Meeting. Any stockholder giving a
proxy may revoke the same at any time prior to the voting of such proxy by
giving written notice of revocation to the Secretary, by submitting a later
dated proxy or by attending the Meeting and voting in person. The Proxy State-
ment is first being mailed to stockholders on or about August 28, 1996.
The Company's Annual Report (including audited financial statements) for the
fiscal year ended May 31, 1996, accompanies this Proxy Statement. The Annual
Report is not a part of the proxy soliciting material.
Except where the context requires otherwise, the term "Company" includes
Vitalink Pharmacy Services, Inc. and its subsidiaries.
VOTING AT THE ANNUAL MEETING
The Board of Directors has fixed August 5, 1996, as the record date for de-
termination of stockholders entitled to notice of and to vote at the Meeting
(the "Record Date"). On that date, there were outstanding 13,979,700 shares of
common stock, par value $0.01 per share ("Common Stock"). Each such share of
Common Stock is entitled to one vote. The presence in person or by proxy of
the holders of a majority of the Company's outstanding shares of Common Stock
will constitute a quorum.
A plurality of the shares present and voting at the Annual Meeting, in person
or by proxy, will be necessary for the election of directors. The affirmative
vote of a majority of shares present and voting at the Annual Meeting, in per-
son or by proxy, will be necessary for approval of the proposed Vitalink Phar-
macy Services, Inc. 1996 Long-Term Incentive Plan, for approval of the
Vitalink Pharmacy Services, Inc. 1995 Employee Stock Purchase Plan and for the
taking of all other action at the Annual Meeting.
A stockholder who is present in person or by proxy at the Annual Meeting and
who abstains from voting on any or all proposals will be included in the num-
ber of stockholders present at the Annual Meeting for the purpose of determin-
ing the presence of a quorum. An abstention with respect to any matter, howev-
er, will not be counted either in favor of or against such matter.
Brokers who hold shares for the account of their clients may vote such shares
either as directed by their clients or in their own discretion if permitted by
the exchange or other organization of which they are members. Members of the
NASDAQ Stock Market are permitted to vote their clients' proxies in their own
discretion as to the election of directors. Proxies which are voted by brokers
on some but not all of the proposals are referred to as "broker non-votes."
Broker non-votes will be included in determining the presence of a quorum. A
broker non-vote, however, is not treated as being in favor of or against the
particular proposal under consideration.
If any nominee for election to the Board of Directors named in this Proxy
Statement shall become unavailable for election for any reason, the proxy will
be voted for a substitute nominee selected by the Board of Directors, or the
Board of Directors may elect not to fill the vacancy and reduce the number of
directors.
1
<PAGE>
SOLICITATION OF PROXIES
The cost of the proxy solicitations will be borne by the Company. In addition
to the use of the mails, proxies may be solicited by the directors, officers
and employees of the Company, without additional compensation, by personal in-
terview, telephone, telegram or otherwise. Arrangements may also be made with
brokerage firms or other custodians, nominees or fiduciaries for the forward-
ing of soliciting material to the beneficial owners of Common Stock of the
Company held of record by such persons, and the Company will reimburse such
respective brokers, custodians, nominees and fiduciaries for the reasonable
out-of-pocket expenses incurred by them in connection therewith.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
the Company's reporting officers and directors, and persons who own more than
ten percent of the Company's Common Stock, to file reports of ownership and
changes in ownership on Forms 3, 4, and 5 with the Securities and Exchange
Commission (the "Commission"), the NASDAQ Stock Market and the Company. Based
solely on the Company's review of the forms filed with the Commission and
written representations from reporting persons that they were not required to
file Form 5 for certain specified years, the Company believes that all of its
reporting officers, directors and greater than ten percent beneficial owners
complied with all filing requirements applicable to them during fiscal year
ended May 31, 1996.
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT
As of the Record Date, the only greater than 5% beneficial owner of Common
Stock of the Company is Manor Healthcare Corp., a wholly-owned subsidiary of
Manor Care, Inc. (Hereinafter, as and when the context requires, Manor Care,
Inc. and its subsidiaries are collectively referred to as "Manor Care, Inc." )
As of that date, Manor Care, Inc. owned beneficially 11,500,000 shares of Com-
mon Stock of the Company, comprising 82.3% of the Company's Common Stock. The
address of Manor Care, Inc. is 11555 Darnestown Road, Gaithersburg, Maryland
20878.
The following table sets forth, as of the Record Date, the amount of the
Company's Common Stock beneficially owned by (1) each director and nominee,
(2) the chief executive officer and the four other most highly compensated ex-
ecutive officers, and (3) all officers and directors as a group.
<TABLE>
<CAPTION>
NUMBER OF COMPANY
SHARES BENEFICIALLY PERCENT
NAME OF BENEFICIAL OWNER OWNED OF CLASS(1)
------------------------ ------------------- -----------
<S> <C> <C>
Stewart Bainum, Jr. 0 0
Harold Blumenkrantz 1,000 *
Joseph R. Buckley 0 0
Donna L. DeNardo 40,833(2) *
Anil K. Gupta 3,000 *
James A. MacCutcheon 0 0
James H. Rempe 0 0
Donald C. Tomasso 0 0
Marvin Wilensky 100 *
Vincent C. DiTrapano 2,100(3) *
Scott T. Macomber 26,700(4) *
Stephen A. Thompson 1,000(5) *
All directors and officers as a group
(12 persons) 74,733(6) *
</TABLE>
- ----------------
*Less than 1% of Class.
(See footnotes on page 3)
2
<PAGE>
(1) Percentages are based on 13,979,700 shares outstanding on the Record Date,
plus shares which would be issued assuming that the person exercises all
options which are exercisable within 60 days thereafter.
(2) Represents 40,833 shares which Ms. DeNardo has the right to acquire
pursuant to stock options which are presently exercisable or which become
exercisable within 60 days after the Record Date.
(3) Includes 2,000 shares which Mr. DiTrapano has the right to acquire
pursuant to stock options which are presently exercisable or which become
exercisable within 60 days after the Record Date.
(4) Includes 1,200 shares owned by minor children of Mr. Macomber, for which
he is custodian. Beneficial ownership of such shares is disclaimed. Also
includes 25,500 shares which Mr. Macomber has the right to acquire
pursuant to stock options which are presently exercisable or which become
exercisable within 60 days after the Record Date.
(5) Includes 1,000 shares which Mr. Thompson has the right to acquire pursuant
stock options which are presently exercisable or which become exercisable
within 60 days after the Record Date.
(6) Includes a total of 69,333 shares which the officers, nominees and
directors included in the group have the right to acquire pursuant to
stock options which are presently exercisable or which become exercisable
within 60 days after the Record Date.
The following table also sets forth, as of August 1, 1996, the amount of
Manor Care, Inc. Common Stock beneficially owned by (1) each director and nom-
inee, (2) the chief executive officer, and the four other most highly compen-
sated executive officers and (3) all officers and directors as a group.
<TABLE>
<CAPTION>
NUMBER OF SHARES
OF MANOR CARE, INC.
COMMON STOCK
SHARES BENEFICIALLY PERCENT
NAME OF BENEFICIAL OWNER OWNED OF CLASS(1)
------------------------ ------------------- -----------
<S> <C> <C>
Stewart Bainum, Jr. 12,255,602(2) 19.29%
Harold Blumenkrantz 0 0
Joseph R. Buckley 99,605(3) 0
Donna L. DeNardo 11,788(4) *
Anil K. Gupta 0 0
James A. MacCutcheon 89,484(5) *
James H. Rempe 132,153(6) *
Donald C. Tomasso 71,218(7) *
Marvin Wilensky 337 *
Vincent C. DiTrapano 0 0
Scott T. Macomber 4,215(8) *
Stephen A. Thompson 0 0
All directors, nominees and
officers as a group
12 persons) 12,564,460(9) 19.77%
</TABLE>
- ----------------
*Less than 1% of Class.
(1) Percentages are based on a total of 62,867,418 shares outstanding on
August 1, 1996, plus shares which would be issued assuming that the person
exercises all options which are exercisable within 60 days.
(2) Includes 91,752 shares owned directly by Mr. Bainum, Jr. Also includes
5,417,761 shares owned by Bainum Associates Limited Partnership ("Bainum
Associates") and 4,415,250 shares owned by MC Investments Limited
Partnership ("MC Investments"), in both of which Mr. Bainum, Jr. is
managing general partner with the sole right to dispose of the shares.
Authority to vote such shares is held by the voting general partner, Mr.
B. Houston McCeney. Also includes 1,679,628 shares owned by Mid Pines
Associates Limited Partnership ("Mid Pines"), in which Mr. Bainum, Jr. is
managing general partner and has shared voting authority, and 1,500 shares
owned by the Foundation for Maryland's Future, in which Mr. Bainum, Jr. is
the sole director. Mr. Bainum, Jr. has a direct or indirect pecuniary
interest in 1,168,068 shares, 810,546 shares and 348,777 shares owned
respectively by Bainum Associates, MC Investments and Mid Pines. Also
includes 647,500 shares which Mr. Bainum, Jr. has the right to acquire
pursuant to stock options which are presently exercisable or which become
exercisable within 60 days after the August 1, 1996, and 1,504 shares and
707 shares, respectively, which Mr. Bainum, Jr. has the right to receive
upon termination of his employment with Manor Care, Inc. pursuant to the
terms of the Manor Care, Inc. Retirement Savings and Investment Plan (the
"401(k) Plan") and the Manor Care, Inc. Nonqualified Retirement Savings
and
3
<PAGE>
Investment Plan (the "Nonqualified Savings Plan"). Does not include shares
owned by Realty Investment Co. Inc. and its subsidiaries, a real estate
investment and management company in which Mr. Bainum, Jr. owns, directly or
indirectly, 25.0% of the outstanding common stock which represents a
pecuniary interest in 843,868 shares owned by Realty.
(3) Includes 99,000 shares Mr. Buckley has the right to acquire pursuant to
stock options which are presently exercisable or which became exercisable
within 60 days after the August 1, 1996, and 467 and 138 shares,
respectively, which Mr. Buckley has the right to receive upon termination
of his employment with Manor Care, Inc. pursuant to the terms of the
401(k) Plan and the Nonqualified Savings Plan.
(4) Includes 7,167 shares Ms. DeNardo has the right to acquire pursuant to
stock options which are presently exercisable or which become exercisable
within 60 days after the August 1, 1996, and 274 and 90 shares,
respectively, shares which Ms. DeNardo has the right to receive upon
termination of her employment with the Company pursuant to the terms of
the 401(k) Plan and the Nonqualified Savings Plan.
(5) Includes 89,250 shares Mr. MacCutcheon has the right to acquire pursuant
to stock options which are presently exercisable or which become
exercisable within 60 days after the August 1, 1996, and 234 shares which
Mr. MacCutcheon has the right to receive upon termination of his
employment with Manor Care, Inc. pursuant to the terms of the 401(k) Plan.
(6) Includes 63,124 shares Mr. Rempe has the right to acquire pursuant to
stock options which are presently exercisable or which become exercisable
within 60 days after the August 1, 1996, and 551 shares which Mr. Rempe
has the right to receive upon termination of his employment with Manor
Care, Inc. pursuant to the terms of the 401(k) Plan.
(7) Includes 40 shares held as custodian for children of Mr. Tomasso.
Beneficial ownership of such shares is disclaimed. Also includes 64,500
shares which Mr. Tomasso has the right to acquire pursuant to stock
options which are presently exercisable or which become exercisable within
60 days after the August 1, 1996, and 82 shares and 96 shares,
respectively, which Mr. Tomasso has the right to receive upon termination
of his employment with Manor Care, Inc. pursuant to the terms of the
401(k) Plan and the Nonqualified Savings Plan.
(8) Includes 3,000 shares Mr. Macomber has the right to acquire pursuant to
stock options which are presently exercisable or which become exercisable
within 60 days after the August 1, 1996, and 328 shares and 187 shares,
respectively, which Mr. Macomber has the right to receive upon termination
of his employment with the Company pursuant to the terms of the 401(k)
Plan and the Nonqualified Savings Plan.
(9) Includes a total of 970,541 shares which the officers, nominees and
directors included in the group have the right to acquire pursuant to
stock options which are presently exercisable or which become exercisable
within 60 days after the August 1, 1996, and a total of 3,112 shares and
1,031 shares, respectively, which such directors and officers have the
right to receive upon the termination of their employment pursuant to the
terms of the 401(k) Plan and the Nonqualified Savings Plan.
4
<PAGE>
THE NOMINATION AND ELECTION OF DIRECTORS
The Company's By-laws permit the Board of Directors to determine from time to
time the aggregate number of directors constituting the entire Board, which
may not be less than three nor more than nine. Accordingly, at the Annual
Meeting, nine directors will be elected to serve until the next Annual Meeting
of Stockholders of the Company and until their successors are duly elected and
qualified.
If any nominee is unable to serve for any reason, the proxy will be voted for
a substitute nominee selected by the Board of Directors, or the Board of Di-
rectors may elect not to fill the vacancy and reduce the number of directors.
The following table sets forth information with respect to each nominee for
election as a director of the Company. All of the nominees, except for Joseph
R. Buckley, have previously been elected by the stockholders of the Company.
The Board of Directors appointed Mr. Buckley effective July 10, 1996.
<TABLE>
<CAPTION>
SERVED AS
DIRECTOR POSITIONS WITH THE COMPANY;
NAME AGE SINCE BUSINESS EXPERIENCE; OTHER DIRECTORSHIPS
- ---- --- --------- ----------------------------------------------------------------
<S> <C> <C> <C>
Stewart Bainum, Jr. 50 1991 Vice Chairman of the Board since December 1994; Chairman of the
Board from September 1991 to December 1994; Chief Executive
Officer from March 1987 to December 1994; President from March
1987 to September 1991; also Chairman and Chief Executive
Officer of Manor Care, Inc. since March 1987; President of Manor
Care, Inc. since June 1989; Director of Manor Care, Inc. since
1976.
Harold Blumenkrantz 58 1994 Executive Director (Management position) since November 1995;
Secretary, West End Family Pharmacy, Inc. since January 1988;
Secretary, Homestead Pharmacy, Inc. since 1968; Director of Drug
Guild, Inc. since 1986.
Joseph R. Buckley 48 1996 Executive Vice President, Manor Care, Inc. since March 1996;
President, Assisting Living Division of Manor Healthcare Corp.
from June 1995 to March 1996; Senior Vice President, Manor Care,
Inc. from June 1990 to March 1996. Director of In Home Health,
Inc. since October 1995.
Donna L. DeNardo 44 1991 Director, President and Chief Operating Officer since September
1991; Vice President and General Manager from December 1989 to
September 1991; Vice President of Manor Healthcare Corp. (a
wholly owned subsidiary of Manor Care, Inc.) from December 1989
to September 1991; various management positions with Manor
Healthcare Corp. from 1977 through December 1989, including
Senior Regional Director of Nursing Facility Operations and
Nursing Facility Administrator.
Anil K. Gupta 46 1992 Professor of Strategy and Organization, University of Maryland,
College of Business and Management, since 1986.
James A. MacCutcheon 44 1994 Treasurer since 1992; Senior Vice President (Finance), Chief
Financial Officer and Treasurer of Manor Care, Inc. since
October 1987.
James H. Rempe 66 1994 Secretary since 1991; Senior Vice President, General Counsel and
Secretary of Manor Care, Inc. since December 1980. Director of
In Home Health, Inc. since October 1995.
Donald C. Tomasso 51 1991 Chairman of the Board and Chief Executive Officer since December
1994; Vice Chairman of the Board from September 1991 to December
1994; Director of Manor Healthcare Corp. since May 1991 and In
Home Health, Inc. since October 1995; President of Manor
Healthcare Corp. since February 1995; President and Chief
Operating Officer of Manor Healthcare Corp. from May 1991
through January 1995; formerly employed by Marriott Corporation
for more than five years, last serving as Executive Vice
President/General Manager, Roy Rogers Division.
</TABLE>
5
<PAGE>
<TABLE>
<CAPTION>
SERVED AS
DIRECTOR POSITIONS WITH THE COMPANY;
NAME AGE SINCE BUSINESS EXPERIENCE; OTHER DIRECTORSHIPS
- ---- --- --------- ----------------------------------------------------------------
<S> <C> <C> <C>
Marvin Wilensky 68 1992 Founder and Chairman of the Board of Wilmac, Inc. (a private
corporation engaged in arranging financing of nursing homes)
since March 1991; President and Chief Operating Officer of
Hillhaven Corporation from June 1986 to May 1988; Special
Advisor to Hillhaven Corporation from May 1988 to October 1990.
</TABLE>
STRUCTURE AND FUNCTIONING OF THE BOARD OF DIRECTORS
The Board of Directors held four meetings during the fiscal year ended May
31, 1996. During such fiscal year, each incumbent serving attended 75% or more
of the aggregate of (1) the total number of meetings of the Board of Directors
and (2) the total number of meetings of all Committees on which such director
served. The standing committees of the Board include the Audit Committee, the
Compensation/Key Executive Stock Option and Appreciation Rights Plan Committee
and the Nominating Committee, the current members of which are as follows:
<TABLE>
<CAPTION>
COMPENSATION/KEY
EXECUTIVE STOCK OPTION
AND APPRECIATION RIGHTS
PLAN COMMITTEE
-----------------------
<S> <C>
Marvin Wilensky, Chairman
Stewart Bainum, Jr.
Anil K. Gupta
James A. MacCutcheon
James H. Rempe
Donald C. Tomasso
<CAPTION>
AUDIT COMMITTEE NOMINATING COMMITTEE
--------------- ---------------------------
<S> <C>
Anil K. Gupta, Chairman Donald C. Tomasso, Chairman
Marvin Wilensky Stewart Bainum, Jr.
</TABLE>
The Compensation/Key Executive Stock Option and Appreciation Rights Plan Com-
mittee, which held two meetings during the 1996 fiscal year, administers the
Key Executive Stock Option and Appreciation Rights Plan and grants stock op-
tions and appreciation rights thereunder.
The Audit Committee, which held three meetings during the 1996 fiscal year,
reviews the scope and results of the annual audit, reviews and approves the
services and related fees of the Company's independent public accountants, and
reviews the Company's internal accounting controls.
The Nominating Committee, which held two meetings during the 1996 fiscal
year, recommends to the Board of Directors the members to serve on the Board
of Directors during the ensuing year. The Committee does not consider nominees
recommended by stockholders.
Directors who are full-time employees of the Company or of Manor Care, Inc.
(including its subsidiaries) receive no separate remuneration for their serv-
ices as directors. The remuneration of all non-employee directors is currently
$8,000 per annum, payable monthly, $1,500 per diem for Board meetings attended
and $1,000 per diem for Committee meetings attended, except where the Commit-
tee meeting is on the same day as a Board meeting. If more than one Committee
meeting is attended in any one day, the Committee meeting fee is paid for each
meeting. In addition, directors are reimbursed for travel expenses and other
out-of-pocket costs incurred in attending meetings.
6
<PAGE>
COMPENSATION OF EXECUTIVE OFFICERS
The following table sets forth certain information concerning the annual and
long-term compensation for services in all capacities to the Company for the
fiscal years ended May 31, 1996, 1995, and 1994, of Ms. DeNardo, Mr.
DiTrapano, Mr. Macomber and Mr. Thompson (the "Named Officers"), the only ex-
ecutive officers of the Company who received compensation from the Company
during the fiscal year ended May 31, 1996. All other executive officers of the
Company also serve as officers of Manor Care, Inc. and are compensated by
Manor Care, Inc.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
--------------------------- ------------
STOCK
NAME AND OPTIONS ALL OTHER
PRINCIPAL POSITION YEAR SALARY BONUS OTHER SHARES(#) COMPENSATION(1)
------------------ ---- -------- ------- ----- --------- ---------------
<S> <C> <C> <C> <C> <C> <C>
Donna L. DeNardo 1996 $186,101 $82,815 (2) 20,000 $10,924
President and Chief 1995 169,762 83,523 (2) 30,000 9,000
Operating Officer 1994 151,919 85,483 (2) 25,000 9,838
Vincent C. DiTrapano 1996 $147,245 $68,174 (2) 12,500 $50,461(3)
Senior Vice President, 1995 134,826 57,235 (2) 17,000 775
Operations 1994 103,461 46,557 (2) 10,000 -
Scott T. Macomber 1996 $127,067 $46,634 (2) 10,000 $ 7,409
Vice President, 1995 118,885 47,435 (2) 15,000 7,197
Finance 1994 112,538 52,633 (2) 10,000 6,672
Stephen A. Thompson (4) 1996 $105,447 $36,906 (2) 10,500 $ 4,024
Vice President, Human 1995 - - - - -
Resources and Adminis-
tration 1994 - - - - -
</TABLE>
- ----------------
(1) Represents amounts contributed by the Company for fiscal 1996, 1995, and
1994 for the Named Officers under the Manor Care, Inc. Retirement Savings
and Investment Plan (the "401(k) Plan") and the Manor Care, Inc.
Nonqualified Retirement Savings and Investment Plan (the "Nonqualified
Savings Plan"), which provide retirement and other benefits to eligible
employees, including the above Named Officers. During fiscal 1996, the
Company contributed $3,645 for Ms. DeNardo, $713 for Mr. DiTrapano, $2,487
for Mr. Macomber and $2,012 for Mr. Thompson under the 401(k) Plan; and,
$7,279 for Ms. DeNardo, $1,070 for Mr. DiTrapano, $4,923 for Mr. Macomber
and $2,012 for Mr. Thompson under the Nonqualified Savings Plan.
(2) The value of perquisites and other compensation does not exceed the lesser
of $50,000 or 10% of the amount of annual salary and bonus paid to the
Named Officers.
(3) Includes $48,678 related to expenses incurred by the Company with respect
to Mr. DiTrapano's prior residence (see "Certain Transactions"), including
the difference between the guaranteed and actual sale price of the
residence and a gross-up in Mr. DiTrapano's income to account for income
tax liability to Mr. DiTrapano for such amount.
(4) Mr. Thompson became employed by the Company in February, 1992 and was
designated an executive officer upon his election to Vice President, Human
Resources and Administration, in August, 1995.
Donald C. Tomasso is Chairman and Chief Executive Officer of the Company. Mr.
Tomasso also serves as President of Manor Healthcare Corp., a subsidiary of
Manor Care, Inc. Manor Healthcare Corp. owns 11,500,000 shares of the
Company's Common Stock. (See "Security Ownership of Principal Stockholders and
Management" above). Mr. Tomasso receives no compensation from the Company.
The Company's Board of Directors and stockholder adopted the Company's Key
Executive Stock Option and Appreciation Rights Plan (the "Stock Option Plan")
in September 1991. Under the Stock Option Plan, 1,000,000 shares of Common
Stock have been reserved for issuance upon exercise of options granted there-
under. Under the Plan, the Company may treat an exercise of a stock option as
a stock appreciation right.
The following tables set forth certain information at May 31, 1996, and for
the fiscal year then ended, concerning stock options granted to the Named Of-
ficers. None of the Named Officers exercised stock options pertaining to the
Common Stock of the Company during the 1996 fiscal year. All Common Stock fig-
ures and exercise prices have been adjusted to reflect stock dividends and
stock splits effective in prior fiscal years.
7
<PAGE>
STOCK OPTION GRANTS IN FISCAL 1996
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE
VALUE AT ASSUMED
ANNUAL RATE OF STOCK
PRICE APPRECIATION
INDIVIDUAL GRANTS FOR OPTION TERM (1)
------------------------------------------------- ---------------------
PERCENTAGE OF
TOTAL OPTIONS
GRANTED TO ALL
NUMBER OF EMPLOYEES EXERCISE
OPTIONS IN FISCAL BASE PRICE EXPIRATION
NAME GRANTED 1996 PER SHARE DATE 5%(2) 10%(3)
---- --------- -------------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Donna L. DeNardo 20,000"C"(4) 18.35% $19.88 12/15/05 $ 250,000 $ 633,600
Vincent C. DiTrapano 12,500"C"(4) 11.47% $19.88 12/15/05 $ 156,250 $ 396,000
Scott T. Macomber 10,000"C"(4) 9.17% $19.88 12/15/05 $ 125,000 $ 316,800
Stephen A. Thompson 3,750"A"(4) 3.44% $16.56 06/29/00 $ 17,175 $ 37,913
3,750"B"(4) 3.44% $16.56 06/29/05 $ 39,038 $ 98,963
3,000"C"(4) 2.75% $19.88 12/15/05 $ 37,500 $ 95,040
</TABLE>
- ----------------
(1) The dollar amounts under these columns are the result of calculations at
the 5% and 10% rates set by the Securities and Exchange Commission and
therefore are not intended to forecast future possible appreciation, if
any, of the Company's stock price. Since options are granted at market
price, a zero percent gain in the stock price will result in no realizable
value to the option holders.
(2) A 5% per year appreciation in stock price from $16.56 share yields $21.14
on the expiration date of "A" options, and $26.97 on the expiration date
of "B" options. A 5% per year appreciation in the stock price from $19.88
per share yields $32.38 on the expiration date of the "C" options.
(3) A 10% per year appreciation in stock price from $16.56 per share yields
$26.67 on the expiration date of "A" options and $42.95 on the expiration
date of "B" options. A 10% per year appreciation in the stock price from
$19. 88 per share yields $51.56 on the expiration date of the "C" options.
(4) The "A" options vest at the rate of 33 1/3% per year commencing on the
second through the fourth anniversaries of the date of the stock option
grant. The "B" options vest at the rate of 10% per year commencing on the
second through fifth anniversaries of the date of the stock option grant
and 20% per year on the sixth through eighth anniversaries. The "C"
options vest at a rate of 20% per year commencing on the first through the
fifth anniversaries of the date of the stock option grant.
FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
VALUE OF UNEXERCISED
NUMBER OF UNEXERCISED IN-THE-MONEY OPTIONS
OPTIONS AT MAY 31, 1996 AT MAY 31, 1996(1)
------------------------- -------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Donna L. DeNardo 40,833 114,167 $290,731 $957,861
Vincent C. DiTrapano 1,000 38,500 $ 12,250 $332,000
Scott T. Macomber 25,500 59,500 $167,440 $486,910
Stephen A. Thompson 1,000 14,500 $ 10,250 $ 98,600
</TABLE>
- ----------------
(1) The closing price of the Company's Common Stock, as reported by the
National Association of Securities Dealers Automated Quotation System-
National Market System (NASDAQ-NMS) on May 31, 1996 was $23.00. The value
is calculated on the basis of the difference between the option exercise
price and $23.00, multiplied by the number of shares of Common Stock
underlying the option.
EMPLOYMENT AGREEMENTS
Under the terms of an agreement between Donna L. DeNardo and the Company, her
annual salary is presently $215,000. The agreement currently extends through
December 1, 1999. Ms. DeNardo is entitled to an annual bonus of up to 80% of
her base compensation based on the performance of the Company, of which Ms.
DeNardo serves as President and Chief Operating Officer.
8
<PAGE>
Under the terms of an agreement between Vincent C. DiTrapano and the Company,
his annual salary is presently $158,900. The agreement currently extends
through December 1, 1997. Mr. DiTrapano is entitled to an annual bonus of up
to 70% of his base compensation based on the performance of the Company, of
which Mr. DiTrapano is Senior Vice President, Operations.
RETIREMENT PLANS
Effective January 1, 1992, the Company adopted the Manor Care, Inc. Retire-
ment Savings and Investment Plan (the "401(k) Plan"), a defined contribution
retirement, saving and investment plan maintained by Manor Care, Inc. for its
employees and the employees of its participating affiliated companies. The
401(k) Plan is qualified under Section 401(a) of the Internal Revenue Code of
1986, as amended (the "Code"), and includes a cash or deferred arrangement un-
der Section 401(k) of the Code. All employees age 21 or over with at least one
year of service, and who have worked at least 1,000 hours during the year, are
eligible to participate. Subject to certain non-discrimination requirements,
each employee may contribute an amount to the 401(k) Plan on a pre-tax basis
up to 15% of the employee's salary, but not more than the current federal
limit of $9,500. The Company will match contributions made by its employees
subject to certain limitations described in greater detail below. The amount
of the match will be equal to a percentage of the amount of salary reduction
contribution made on behalf of a participant during the plan year based upon a
formula that involves the profits of Manor Care, Inc. for the year and the
number of years of service of the participant. In no event will the Company
make a matching contribution which exceeds 6% of a participant's salary.
Amounts contributed by the Company pursuant to the 401(k) Plan for the fiscal
years ended May 31, 1996, 1995 and 1994 for the Named Officers are included in
the Summary Compensation Table under the column headed "All Other Compensa-
tion."
Effective January 1, 1992, the Company adopted the Manor Care, Inc. Nonquali-
fied Retirement Savings and Investment Plan (the "Nonqualified Savings Plan")
maintained by Manor Care, Inc. for its employees and the employees of its par-
ticipating affiliated companies. Certain select highly compensated members of
the management of the Company are eligible to participate in the Nonqualified
Savings Plan. The Nonqualified Savings Plan mirrors the provisions of the
401(k) Plan, to the extent feasible, and is intended to provide the partici-
pants with a pre-tax savings vehicle to the extent that pre-tax savings are
not permissible under the 401(k) Plan as a result of various governmental reg-
ulations, such as non-discrimination testing. All of the Named Officers have
elected to participate in the Nonqualified Savings Plan. Amounts contributed
by the Company pursuant to the Nonqualified Savings Plan for the fiscal years
ended May 31, 1996, 1995, and 1994 for the Named Officers are included in the
Summary Compensation Table under the column headed "All Other Compensation."
The Company match under the 401(k) Plan and the Nonqualified Savings Plan is
limited to a maximum aggregate of 6% of the annual salary of a participant.
Effective December 1993, participants were given the right to elect to receive
the Company matching contribution either in Manor Care, Inc. stock or cash or
a combination. Likewise, participant contributions under the two plans may not
exceed the aggregate of 15% of the annual salary of a participant.
Effective January 1, 1992, the Company adopted a non-contributory Cash Accu-
mulation Retirement Plan (the "CARP") maintained by Manor Care, Inc. for its
employees and the employees of its participating affiliated companies. The
CARP is qualified under Section 401(a) of the Code. All employees age 21 or
over and who have worked for the Company for a twelve month period during
which such employee completed at least 1,000 hours are automatically members
of the CARP. Each year the account of each employee is adjusted to reflect in-
terest at a rate calculated in accordance with the CARP. Amounts accrued under
the CARP become fully vested after five years of service. On July 2, 1996, the
Board of Directors of Manor Care, Inc. voted to not allow any new participants
in the CARP after August 15, 1996, and to discontinue the annual benefit ac-
crual by Manor Care, Inc. after December 15, 1996. However, the interest will
continue on the balance of a participating employee's account. These changes
by Manor Inc., will be applicable to the employees of the Company participat-
ing in the CARP. Until December 31, 1996, the annual benefit accrual made by
the Company will be based on salary as follows:
<TABLE>
<CAPTION>
BASE PERCENTAGE BASE PERCENTAGE BASE PERCENTAGE
IF AGE PLUS IF AGE PLUS IF AGE PLUS
SERVICE IS SERVICE IS SERVICE IS
LESS THAN 45 45 TO 54 55 OR MORE
--------------- --------------- ---------------
<S> <C> <C> <C>
First $12,000 3% 3.5% 4%
Next $6,000 2% 2.5% 3%
Additional Compensation up to
$100,000 1% 1.5% 2%
</TABLE>
9
<PAGE>
COMPENSATION/KEY EXECUTIVE STOCK OPTION
AND STOCK APPRECIATION RIGHTS PLAN
COMMITTEE REPORT ON EXECUTIVE COMPENSATION
The compensation philosophy of Vitalink Pharmacy Services, Inc. ("the Compa-
ny") is to be competitive with the leading service companies and selected di-
rect competitors in the marketplace, to attract, retain and motivate a highly
qualified workforce, and to provide career opportunities. The Company uses
various compensation surveys, primarily conducted and evaluated by independent
consultants, to provide data to support the development of competitive compen-
sation plans which reinforce this philosophy. Summary data on service compa-
nies of similar size participating in each survey are utilized as the basis
for the evaluations. This philosophy is applied by the Compensation/Key Execu-
tive Stock Option and Appreciation Rights Plan Committee of the Board of Di-
rectors (the "Committee") in determining compensation for the Chief Operating
Officer ("COO") and executive officers. In evaluating the COO's performance,
the Committee, in addition to financial performance, considers factors impor-
tant to the Company such as ethical business conduct, progress against the
Company's strategic plan objectives, management succession planning, customer
service satisfaction and the general overall perception of the Company by fi-
nancial leaders and customers. Donald C. Tomasso is Chief Executive Officer
("CEO") of the Company and is also President of Manor Healthcare Corp., a sub-
sidiary of Manor Care, Inc. Mr. Tomasso does not receive any compensation from
the Company for his services as CEO. Donna L. DeNardo is COO of the Company.
Ms. DeNardo's base salary paid in fiscal 1996 is shown under the heading "Sal-
ary" in the Summary Compensation Table.
The Committee is responsible for setting and administering the policies which
govern executive compensation and the stock-based programs of the Company. The
members of the Committee are Messrs. Wilensky (Chairman), Bainum, Jr., Gupta,
MacCutcheon, Rempe and Tomasso.
Compensation of the Company's officers is reviewed annually by the Committee.
Changes proposed for these employees are evaluated and approved by the Commit-
tee on an individual basis.
There are three components in the Company's executive compensation program:
1. Base salary
2. Cash bonus
3. Long-term incentive compensation (stock options and stock appreciation
rights)
The Committee continues to believe that compensation for the COO and other
executive officers should be weighted in favor of more "pay at risk" or "vari-
able pay."
BASE SALARY
Base salary is the only component that is not variable. Scope and complexity
of the position as well as external market factors are used to determine base
salary levels. Salary changes are based on guidelines established for all em-
ployees using individual performance to determine the change.
CASH BONUS
A cash bonus based on growth in revenues and profit is used to focus manage-
ment attention on these areas.
LONG-TERM INCENTIVE COMPENSATION (STOCK OPTIONS AND STOCK APPRECIATION RIGHTS)
Long-term compensation comprised of stock options and stock appreciation
rights (SARs) have been established to focus attention on the Company's and
stockholders' long-term goals and to increase ownership and retention in the
Company's stock.
The Committee has granted stock options and SARs with a vesting schedule of
up to eight years in order to retain management and focus option holders on
the long-term goals of the Company to be more closely aligned with the inter-
ests of stockholders. If the proposed Vitalink Pharmacy Services, Inc. 1996
Long-Term Incentive Plan is approved by the stockholders at the Annual Meet-
ing, the Committee will have the discretion to grant restricted shares, incen-
tive stock options, nonqualified stock options, stock appreciation rights or
performance shares as it may determine to be desirable in order to recruit and
retain management, to focus the optionees on the long-term goals of the Com-
pany and to more closely align their interests with the interests of the
stockholders.
The Committee believes the Company has an overall compensation plan which
fulfills current Company philosophy and, in addition, promotes increased
shareholder value through performance-based compensation.
10
<PAGE>
IMPACT OF INTERNAL REVENUE CODE SECTION 162(M)
The Omnibus Budget Reconciliation Act of 1993 disallows, effective January 1,
1994, a federal income tax deduction for compensation, other than certain per-
formance-based compensation, in excess of $1 million annually paid by the Com-
pany to any currently-serving Named Officer identified in the Summary Compen-
sation Table. Stock option awards under the Stock Option Plan qualify as per-
formance-based compensation and are exempt from consideration for purposes of
calculating the $1 million limit. If the stockholders approve the Vitalink
Pharmacy Services, Inc. 1996 Long-Term Incentive Compensation Plan at the An-
nual Meeting, appropriate steps will be taken to qualify awards made thereaf-
ter as performance-based compensation and thus be exempt from consideration
for purposes of calculating the $1 million limit and the Stock Option Plan
will be terminated, except as to possible reissuance of forfeited shares. No
individual named in the Summary Compensation Table is likely to receive com-
pensation in fiscal 1997 which would exceed such amount. The Committee intends
to monitor the Company's compensation programs with respect to such laws.
COMPENSATION/KEY EXECUTIVE STOCK OPTION AND STOCK APPRECIATION
RIGHTS PLAN COMMITTEE
Marvin Wilensky, Chairman
Stewart Bainum, Jr.
Anil K. Gupta
James A. MacCutcheon
James H. Rempe
Donald C. Tomasso
11
<PAGE>
PERFORMANCE GRAPH-SHAREHOLDER RETURN
The following Performance Graph compares the yearly percentage change in the
cumulative total stockholder return on the Company's Common Stock against the
cumulative total return on the S&P 500 Stock Index and the S&P Health Care
Composite Index for the fiscal years ended May 31, 1996, 1995, 1994, 1993 and
1992, the only full or partial fiscal years since the Company's initial public
offering on March 3, 1992. The Performance Graph assumes reinvestment of divi-
dends, where applicable.
COMPARISON OF FIVE YEAR CUMULATIVE RETURN AMONG
VITALINK PHARMACY SERVICES, INC., S&P 500 AND S&P HEALTH CARE COMPOSITE
[PERFORMANCE CHART APPEARS HERE]
Assumes $100 invested on March 3, 1992, in the Common Stock of Vitalink Phar-
macy Services, Inc., the S&P 500 Index and the S&P Health Care Composite. To-
tal return assumes reinvestment of dividends, where applicable.
<TABLE>
<CAPTION>
03/03/92 05/31/92 05/31/93 05/31/94 05/31/95 05/31/96
-------- -------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Vitalink Pharmacy
Services, Inc. $100 $ 83 $ 64 $ 57 $ 96 $131
S&P 500 $100 $104 $116 $121 $146 $187
S&P Health Care
Composite $100 $ 96 $ 84 $ 83 $113 $161
</TABLE>
- ----------------
Prior to fiscal year 1995, the Company selected a peer group for comparison
purposes which consisted of Omnicare, Inc., Choice Drug Systems, Inc.,
Medisys, Inc. and Synetic, Inc. Due to the acquisition of Medisys and Synetic
by others during fiscal year 1995, the Company has elected to use a published
industry index, the S&P Health Care Composite, in place of a peer group.
PROPOSED APPROVAL OF VITALINK PHARMACY SERVICES, INC.
1996 LONG-TERM INCENTIVE PLAN
GENERAL
The Stock Option Plan, which became effective in 1991, provides for the issu-
ance of up to 1,000,000 shares of Common Stock pursuant to non-qualified stock
options and stock appreciation rights ("SARs"). As of July 10, 1996, there re-
mained for issuance a total of 493,900 shares pursuant to the Stock Option
Plan. On July 10, 1996, the Board adopted the Vitalink Pharmacy Services, Inc.
1996 Long-Term Incentive Plan (the "Incentive Plan") for key employees (in-
cluding officers) of the Company and its subsidiaries subject to approval of
the Incentive Plan by the affirmative vote of the holders of a majority of the
number of shares of Common Stock present in person, or by proxy at the Annual
Meeting. Upon stockholder approval of the Incentive Plan, the Stock Option
Plan will terminate, except as to possible reissuance of forfeited shares. The
Incentive Plan authorizes the awarding of a maximum of 493,900 shares
12
<PAGE>
(subject to adjustment for stock splits and similar capital changes) of Common
Stock to eligible employees as described in greater detail below. Thus, if the
Incentive Plan is approved by the stockholders at the Annual Meeting, there
will be no increase in shares available for issuance pursuant to the Incentive
Plan over shares remaining available for issuance pursuant to the Stock Option
Plan.
The continuing growth and development and financial success of the Company
and its subsidiaries are dependent upon ensuring the best possible management.
The Board believes the Incentive Plan will be an important aid to the Company
in attracting and retaining individuals of outstanding abilities and in re-
warding them for the continued profitable performance of the Company and its
subsidiaries.
The types of awards that may be granted under the Incentive Plan are re-
stricted shares, incentive stock options, nonqualified stock options, stock
appreciation rights and performance shares. The Incentive Plan provides that
over the next ten years restricted shares, incentive stock options, nonquali-
fied stock options, stock appreciation rights, and/or performance shares in-
volving up to 493,900 shares (subject to adjustment for stock splits, and sim-
ilar capital changes) of Common Stock may be granted. Common Stock issued un-
der the Incentive Plan may be authorized and unissued stock, treasury stock or
stock purchased on the open market (including private transactions). To the
extent that an award lapses or the rights of a participant to whom it was
granted terminate, any shares of Common Stock subject to the award will again
be available for awards under the Incentive Plan. The following description of
the Incentive Plan is qualified in its entirety by reference to the Vitalink
Pharmacy Services, Inc. 1996 Long-Term Incentive Plan, a copy of which is at-
tached as Exhibit A to this Proxy Statement. The amount of compensation that
will accrue to the participants pursuant to the Incentive Plan, if approved by
the stockholders at the Annual Meeting, is not currently determinable.
The Incentive Plan was drafted to obtain the benefits of the exemption from
Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act") pro-
vided by Rule 16b-3. Section 16(b) of the Exchange Act provides, among other
things, that an officer who purchases and sells the stock of the corporation
which employs him within a six month period is liable to the corporation for
the difference between the purchase price and sale price. Rule 16b-3 promul-
gated under the Exchange Act provides that the acquisition of stock by an of-
ficer of the corporation under an incentive plan, pursuant to certain require-
ments, does not constitute a "transaction" subject to Section 16(b) of the Ex-
change Act.
ADMINISTRATION
The Incentive Plan provides that it will be administered by a Key Executive
Stock Option Plan Committee of the Board (the "Committee"), which establishes
the conditions of each grant made under the Incentive Plan and determines
which key employees will receive awards as well as the type and amount of each
award. Members of the Committee shall be non-employee directors as defined in
Rule 16b-3 and are not eligible to receive awards under the Incentive Plan.
ELIGIBILITY
Key employees of the Company and its subsidiaries (including employees who
are members of the Board, but excluding directors who are not employees) who,
in the opinion of the Committee, are mainly responsible for the continued
growth and development and financial success of the business of the Company or
one of its subsidiaries are eligible to be granted awards under the Incentive
Plan. Subject to the provisions of the Incentive Plan, the Committee shall
from time to time select from such eligible persons those to whom awards shall
be granted and determine the number of shares to be granted. Because eligibil-
ity is determined by these subjective criteria, it is not possible at this
time to determine (except as to awards described in the following paragraph)
either the number of employees eligible to participate in the Incentive Plan
or the amount of awards which will be made.
At its July 10, 1996 meeting, the Committee granted to Donna DeNardo options
to purchase 18,300 shares, including 4,575 shares pursuant to Incentive Stock
Options, to Vincent C. DiTrapano options to purchase 10,200 shares, including
2,550 shares pursuant to Incentive Stock Options, to Scott Macomber options to
purchase 8,700 shares, including 2,175 shares pursuant to Incentive Stock Op-
tions, to Stephen A. Thompson options to purchase 5,900 shares, including
1,475 shares pursuant to Incentive Stock Options and to two other key employ-
ees options to purchase a total of 5,900 shares, including 1,475 shares pursu-
ant to Incentive Stock Options, all under the Incentive Plan. All of such
awards will vest at the rate of twenty percent per year for the first five
years, expire ten years after the date of the award and are exercisable at
$23.75 per share with respect to both nonqualified stock options and Incentive
Stock Options. Exercisability of such awards is subject to stockholder ap-
proval of the Incentive Plan at the Annual Meeting.
13
<PAGE>
RESTRICTED SHARES
Restricted share awards are shares of Common Stock bearing restrictive leg-
ends prohibiting their sale, transfer, pledge or hypothecation until the expi-
ration of a restriction period of not more than ten years set at the time of
grant. In addition or in lieu of a restriction period, the Committee may es-
tablish a performance goal which must be achieved as a condition to retention
of the award. The recipient of an award is entitled to receive dividends and
vote the restricted shares, unless forfeited.
STOCK OPTIONS
Options granted under the Incentive Plan may be either Incentive Stock Op-
tions, as defined in the Internal Revenue Code, as amended, or options which
do not so qualify ("nonqualified options"). At the time an option is granted,
the Committee determines the number of shares of Common Stock subject to each
stock option, the manner and time of exercise, and the vesting schedule. No
options granted under the Incentive Plan may be exercised more than 10 years
after date of grant; however, Incentive Stock Options granted to a Ten Percent
Shareholder (as defined) may not be exercised more than 5 years after the date
of grant. The option price per share for stock options will be set in the
grant, but will be equal to or greater than the fair market value of a share
of Common Stock on the date of grant, except with respect to an Incentive
Stock Option granted to a Ten Percent Shareholder (as defined) shall be at
least 110% of the fair market value on the date of grant. The option exercise
price may be paid with cash and/or shares of Common Stock. Options will be ev-
idenced by stock option agreements in a form approved by the Committee and are
not transferable except by will or descent. Under the Plan, no Covered Em-
ployee (as defined in Section 162(m)(3) of the Internal Revenue Code) may be
granted more than 100,000 shares of Stock Options during any calendar year.
With respect to Incentive Stock Options granted to any employee, the aggregate
fair market value determined on the date of grant with respect to which any
Incentive Stock Option is first exercisable shall not exceed $100,000.
The granting of an option does not entitle the participant to any dividends,
voting or other rights of a stockholder, unless and until the participant re-
ceives stock upon exercise of the option. The Committee may limit an option by
restricting its exercise in whole or in part for specified periods.
Incentive Stock Options are not transferrable except by will or the laws of
descent and distribution. With respect to nonqualified options, the Committee
may impose such restrictions on transferability as it may determine.
STOCK APPRECIATION RIGHTS
An SAR is the right to receive payment for the appreciation in value of one
share of Common Stock over a specified price. An SAR may be granted either in
tandem with a stock option award or independently. If the SAR is granted in
tandem with a stock option award, the payment is measured by the excess of the
fair market value of the Common Stock at the time of exercise over the option
price (which can not be less than the fair market value of the stock at the
time of grant). If the SAR is granted independent of a stock option, the Com-
mittee will specify whether the award is a "regular" SAR or whether the award
is a "book value" SAR. If the award is a "regular" SAR, the payment is mea-
sured by the excess of the fair market value of the stock at the time of exer-
cise over the fair market value at the time of grant. If the award is a "book
value" SAR, the payment is measured by the excess of the book value of the
Common Stock at the time of exercise over the book value of the Common Stock
at the time of grant.
Stock appreciation payments, at the election of the participant, may be made
in cash or Common Stock or a combination of both. The Committee must approve
any election to receive cash.
An SAR issued pursuant to an option cannot be exercised less than six months
after the grant; an SAR issued independently is subject to the terms and con-
ditions established on grant. SARs are deemed to be exercised on the last day
of the Exercise Period, if not previously exercised, which may not extend more
than ten years beyond the date of grant. The Committee may impose such re-
strictions on transferability of SARs as it may determine.
The granting of an SAR does not entitle the participant to any dividend, vot-
ing or other rights of a stockholder, unless and until the participant re-
ceives stock upon the exercise of an SAR. SARs which are not exercisable imme-
diately upon being granted may be made immediately exercisable upon the occur-
rence of retirement or disability, as determined by the Committee in its sole
discretion. Under the Plan, no Covered Employee (as defined in Section
162(m)(3) of the Internal Revenue Code) may be granted more than 100,000 SARs
during any calendar year.
PERFORMANCE SHARES
A performance share award involves the grant of a right to receive a speci-
fied number of shares of the Common Stock upon satisfaction of certain perfor-
mance-related objectives specified in the granting instrument. The perfor-
14
<PAGE>
mance-related objectives may relate to the individual, the Company, a depart-
ment or a division of the Company and/or a group or class of participants. The
measuring period used to establish the performance criteria will be specified
by the Committee at the time of grant and may be subsequently waived or re-
duced, or the performance criteria may be adjusted, upon the occurrence of
events determined by the Committee in its sole discretion to justify such
waiver, reduction or adjustment. Under the Plan, no Covered Employee (as de-
fined in Section 162(m)(3) of the Internal Revenue Code) may be granted more
than 100,000 shares of Performance Shares during any calendar year.
RETIREMENT OR DISABILITY
The Committee may, in its discretion, waive the forfeiture, termination or
lapse of an award in the event of retirement or disability of the participant.
INCOME TAX CONSEQUENCES
The Federal income tax consequences of an award under the Incentive Plan de-
pend on the type of award, as discussed below. The grant of a restricted share
award or a performance share award does not immediately produce taxable income
to a recipient or a tax deduction to the Company. However, at the time the re-
strictions expire or the performance objectives have been achieved, as the
case may be, a recipient will recognize taxable ordinary income in an amount
equal to the fair market value of the stock on the date the restrictions ex-
pire or the performance criteria are achieved and the Company will be entitled
to a corresponding income tax deduction. In the case of a restricted share
award, during the restriction period, a recipient will be taxed on the divi-
dends received from the restricted shares as additional compensation, and the
Company will be entitled to a corresponding compensation deduction.
Generally, a recipient of an incentive stock option will not recognize tax-
able income at the time of grant or exercise and the Company will not be enti-
tled to an income tax deduction. Provided the minimum holding periods are sat-
isfied, any gain on a disposition of stock acquired through an incentive stock
option will be taxable to a recipient as long-term capital gain. If the mini-
mum holding periods are not satisfied, a recipient will recognize ordinary in-
come in the amount of the excess of the fair market value of the stock on the
date the option is exercised over the option price, and the Company will be
entitled to a corresponding income tax deduction.
The grant of a nonqualified stock option does not result in taxable income to
a recipient or a tax deduction for the Company. Upon exercise, a recipient
will recognize taxable ordinary income in an amount equal to the excess of the
fair market value of the stock on the date of exercise over the option price,
and the Company will be entitled to a corresponding income tax deduction.
A recipient of a stock appreciation right will not recognize taxable income
at the time the right is granted, and the Company will not be entitled to a
tax deduction. However, ordinary taxable income will be recognized by a recip-
ient and a corresponding deduction will be taken by the Company, at the time
of exercise, in an amount equal to the cash and the fair market value of the
stock received.
AMENDMENT AND TERMINATION
The Board of Directors may at any time and from time to time alter, amend,
suspend or terminate the Incentive Plan in whole or in part, except (i) any
such action affecting options granted or to be granted under the Incentive
Plan which are intended to qualify as Incentive Stock Options shall be subject
to stockholder approval to the extent such stockholder approval is required
pursuant to Section 422 of the Internal Revenue Code and (ii) no such action
may be taken without the consent of the participant to whom any award has been
granted, which adversely affects the rights of such participant concerning
such award, except as such termination or amendment of the Incentive Plan is
required by statute, or rules and regulations promulgated thereunder.
The Incentive Plan terminates on July 10, 2006. Awards may be granted under
the Incentive Plan at any time and from time to time prior to the termination
of the Incentive Plan. Any award outstanding at the time the Incentive Plan is
terminated shall remain in effect until said award is exercised or expires.
VOTE REQUIRED
Approval of the Incentive Plan requires approval by the holders of a majority
of the shares of Common Stock present in person or by proxy at the Annual
Meeting.
The Board of Directors recommends a vote FOR the proposal to adopt the
Vitalink Pharmacy Services, Inc. 1996 Long-Term Incentive Plan. Proxies re-
ceived by the Board of Directors will be so voted unless stockholders specify
a contrary choice.
15
<PAGE>
PROPOSED APPROVAL OF VITALINK PHARMACY SERVICES, INC.
1995 EMPLOYEE STOCK PURCHASE PLAN
GENERAL
On October 12, 1995, the Board of Directors unanimously approved the Vitalink
Pharmacy Services, Inc. 1995 Employee Stock Purchase Plan (the "Stock Purchase
Plan") subject to approval of the Stock Purchase Plan by a majority of the
shares of Common Stock present in person or by proxy at the Annual Meeting.
The purposes of the Stock Purchase Plan are to build a proprietary interest
among employees of the Company and to assist the Company in its goal of re-
cruiting and retaining highly qualified employees at all levels of the organi-
zation.
The following description of the Stock Purchase Plan is qualified in its en-
tirety by reference to the Vitalink Pharmacy Services, Inc. 1995 Employee
Stock Purchase Plan, a copy of which is attached as Exhibit B to this Proxy
Statement. The amount of compensation that will accrue to the employees pursu-
ant to the Stock Purchase Plan, if approved by the stockholders, is not cur-
rently determinable.
The Stock Purchase Plan authorizes the purchase of a maximum of 100,000
shares (subject to adjustment for stock splits and similar capital changes) of
Common Stock to eligible employees.
The Stock Purchase Plan was drafted to obtain the benefits of the exemption
from Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act")
provided by Rule 16b-3. Section 16(b) of the Exchange Act requires (1) direc-
tors, officers and holders of more than ten percent of an issuer's securities
file statements with the Securities and Exchange Commission, reporting the
purchase or sale of such securities and (2) provides for the recovery by the
issuer of any profits realized by such persons resulting from the purchase and
sale or sale and purchase of such securities within a period of six months.
Section 16 potentially applies to directors and officers of the Company and
stockholders who own 10% or more of the outstanding Common Stock (the "Section
16 Persons"). Generally, each quarterly purchase of Common Stock pursuant to
the Stock Purchase Plan on behalf of a participant who is also a Section 16
Person would be deemed to be a new purchase for purposes of Section 16. Thus,
a participant who is also a Section 16 Person would be required to file a
statement on Form 4 each quarter a purchase was made on his behalf. Further-
more, to sell any shares without exposure to Section 16 liability could re-
quire a participant who is also a Section 16 Person to terminate his partici-
pation in the Plan and wait six months thereafter before selling any shares of
Common Stock. Under Rule 16b-3, however, if the Plan is approved by the stock-
holders, such a participant would not be required to file a Form 4 each quar-
ter if a purchase under the Stock Purchase Plan was made on his behalf, nor
would such purchases be subject to the six month trading limitations.
ELIGIBILITY
Each employee of the Company and its subsidiaries having at least one year of
continuous service on the first day of each January, April, July and October
(an "Offering Date"), beginning January 1, 1996, is eligible to participate in
the Stock Purchase Plan. All employees will be eligible to participate after
completing one year of employment. Any employee who immediately after the
grant of a right owns 5% or more of the Common Stock or the stock of Manor
Care, Inc., however, would not be eligible to participate. The Company pres-
ently employs approximately 945 persons, of whom 624 meet the eligibility re-
quirements set forth above.
ADMINISTRATION
The Stock Purchase Plan will be administered by the Board of Directors.
Rights will be granted quarterly on each Offering Date, and are exercisable
effective on the succeeding last trading day of March, June, September and De-
cember, respectively. Eligible employees may purchase shares of Common Stock
through accumulation of payroll deductions (of not less than 2% nor more than
10% of compensation, as defined in the Stock Purchase Plan). No Participant
shall have the right to purchase shares of Common Stock under the Plan at a
rate of more than $25,000 in value in any calendar year, such value to be
based on the fair market value of the Common Stock as of the Offering Date on
which the Participant becomes eligible to purchase Common Stock in such year
under the terms of the Plan. At the end of each three month Offering Period,
the Company will contribute cash equal to one-ninth of the employee payroll
deductions to the Stock Purchase Plan, and the aggregate employee payroll de-
ductions and the Company contribution will be used either by the Company to
sell Common Stock to the participants or by the Company's designated agent to
purchase Common Stock in the open market. The agent will allocate the pur-
chased Common Stock among the employee accounts in proportion to their payroll
deductions. The Company will pay the administrative expenses for the purchase
of the Common Stock, including broker's commissions, transfer fees and similar
costs. On August 5, 1996, the closing price of the Common Stock as reported by
the NASDAQ National Market System was $24.25.
16
<PAGE>
AMENDMENT AND TERMINATION
The Board of Directors may at any time amend or terminate the Stock Purchase
Plan except that no action may be made without the approval of stockholders to
the extent such approval is required pursuant to Section 423 of the Internal
Revenue Service.
INCOME TAX CONSEQUENCES
Generally, a recipient of stock acquired through the Stock Purchase Plan will
not recognize taxable income (and the Company will not be entitled to an in-
come tax deduction) until such recipient disposes of the stock. Provided the
minimum holding periods are satisfied, upon disposition of stock acquired
through the Stock Purchase Plan, the lesser of (1) the excess of the fair mar-
ket value of the stock on the date of purchase over the price paid, or (2) the
excess of the fair market value of the stock at the time of disposition over
the price paid, will be taxable to a recipient as ordinary income (compensa-
tion), and the Company will not be entitled to a corresponding income tax de-
duction. Any additional gain will be taxable to such recipient as long-term
capital gain. If the minimum holding periods are not satisfied, a recipient
will recognize ordinary income (compensation) in the amount of the excess of
the fair market value of the stock on the date of purchase over the price
paid, and the Company will be entitled to a corresponding income tax deduc-
tion. Any additional gain will be taxable to such recipient as long-term capi-
tal gain.
VOTE REQUIRED
Approval of the Stock Purchase Plan requires approval by the holders of a ma-
jority of the shares of Common Stock present in person or by proxy at the An-
nual Meeting.
The management of the Company recommends a vote FOR the proposal to adopt the
Vitalink Pharmacy Services, Inc. 1995 Employee Stock Purchase Plan. Proxies
received by the Board of Directors will be so voted unless stockholders spec-
ify a contrary choice.
CERTAIN TRANSACTIONS
Pursuant to agreements with Manor Care, Inc., each having a ten-year term
commencing June 1, 1991, the Company provides pharmaceutical dispensing, infu-
sion therapy and pharmacy consulting services to nursing facilities owned and
operated by Manor Care, Inc. and the residents of these facilities. Sales of
pharmaceutical and infusion therapy products and services to Manor Care Inc.'s
nursing facilities are made at prices charged to other customers. Revenues
from sales to Manor Care, Inc. nursing facilities and patients were
$64,302,000 in fiscal year 1996. Fees from consulting services to Manor Care,
Inc. and Manor Care, Inc. facilities were charged in fiscal year 1996 based on
an annual fee per bed and amounted to $2,764,000.
The Company and Manor Care, Inc. have entered into an Administrative Services
Agreement. The agreement has annual renewal terms. Manor Care, Inc. provides
various services to the Company, including among others, cash management, pay-
roll and payables processing, employee benefit plans, insurance, legal, ac-
counting, tax, information systems, and administrative services as required.
Substantially all cash received by the Company is immediately deposited in and
combined with Manor Care, Inc.'s corporate funds through its cash management
system. Similarly, operating expenses, capital expenditures and other cash re-
quirements of the Company are paid by Manor Care, Inc. and charged to the Com-
pany. For the year ended May 31, 1996, administrative fees of $595,000 were
charged based on a time allocation method which Manor Care, Inc. utilized to
charge administrative services to all of its subsidiaries.
Manor Care, Inc. provides insurance coverages for group health, auto, general
liability, property, casualty and workers compensation. Manor Care, Inc.,
through its self-insurance and outside insurance programs, charges the Company
based on the relative percentage of insurance costs incurred by Manor Care,
Inc. on the Company's behalf. Total insurance costs allocated were $1,777,000
in fiscal year 1996. Management believes that the foregoing charge is a rea-
sonable allocation of the costs incurred by Manor Care, Inc. on the Company's
behalf.
The Company leases a portion of its Monticello, Illinois, pharmacy from Manor
Care, Inc. under an annual lease which currently expires on March 31, 1997.
The annual rental payable under the lease is currently $8,000.
The Company and Manor Care, Inc. have entered into an Intercompany Debt and
Credit Agreement whereby Manor Care, Inc. provides the Company with a Line of
Credit of $10,000,000. The Intercompany Debt and Credit Agreement, dated June
1, 1991, is for a five-year term and is automatically renewable unless termi-
nated by either party. Manor Care, Inc. will pass through the charges under
its own credit facility for the Line of Credit. These charges include a
1/4 percentage point fee on the unused funds and a 1/8 percentage point fee on
the entire amount under the Line of Credit. These fees amounted to $38,000 in
fiscal year 1996. The interest rate charged on borrowed funds is LIBOR
17
<PAGE>
plus 5/8 percentage points. There was no balance outstanding under this agree-
ment at May 31, 1996. Pursuant to the agreement, the Company is required to
loan to Manor Care, Inc. all of its excess cash. Manor Care, Inc. credited the
Company with interest income of $1,001,000 in fiscal year 1996 relating to the
average balance "Due from Parent". Interest earned was based on an average
three month Treasury bill rate of 5.13% plus 100 basis points in fiscal year
1996. At May 31, 1996, the balance "Due from Parent" was $16,910,000.
An agreement exists whereby the Company joins with Manor Care, Inc. in the
filing of a consolidated federal income tax return. The consolidated provision
of Manor Care, Inc., which is computed in accordance with the provisions of
SFAS No. 109, is allocated among its subsidiaries on a separate company basis.
Accordingly, the Company accrues taxes payable to or benefits receivable from
its Parent in the "Due from Parent" account, based on the statutory rate ap-
plied to income before taxes after considering appropriate tax credits. De-
ferred taxes are recorded for the tax effect of temporary differences between
book and tax income.
In December 1992, the Company entered into an agreement to lease an operating
facility from Harold Blumenkrantz, a director and employee of the Company, and
Mark Blumenkrantz, his son and also an employee of the Company. Rental ex-
penses under the non-cancelable operating lease were $290,000 in the three
years ended May 31, 1996. Future minimum lease payments for the lease, which
expires in 2002, are $1,883,000 at May 31, 1996.
In the opinion of management, the foregoing transactions were on terms at
least as advantageous to the Company as could have been obtained from non-af-
filiated persons.
In December 1993, the Company loaned $30,000 to Vincent C. DiTrapano, Senior
Vice President (Operations) of the Company. In September 1994, the Company
loaned an additional $72,000 to Mr. DiTrapano. Both loans were made in connec-
tion with Mr. DiTrapano's construction of a residence necessitated by his em-
ployment with the Company and relocation to Naperville, Illinois. The $72,000
loan was made as an advance on the equity Mr. DiTrapano had in his prior resi-
dence in Reading, Pennsylvania, as indicated by an independent appraisal of
the value of the house. Based on the appraisal, the Company guaranteed a sale
price of $275,000. Due to adverse market conditions, however, the house was
eventually sold for $240,000, $35,000 less than the guaranteed sales price. As
a result, the Company forgave $35,000 with respect to Mr. DiTrapano's $72,000
loan. As of August 15, 1996, both loans were paid in full. The interest rate
on both loans was 7% per annum.
In December 1995, the Company paid $500,000 to each Mr. Blumenkrantz in con-
sideration of the termination by each Mr. Blumenkrantz of (i) options to pur-
chase 50,000 shares of Common Stock and tandem SARs which may, under certain
circumstances, be exercised in lieu of the options, and (ii) Guarantee Agree-
ments dated December 1, 1992, which guaranteed that such options would have a
value of $10 per share in excess of the exercise price. On December 15, 1995,
the Company granted to each Mr. Blumenkrantz options to purchase 15,000 shares
of Common Stock and tandem SARs which may, under certain circumstances, be ex-
ercised in lieu of the options, exercisable from December 1, 1998, through No-
vember 30, 1999, at an exercise price of $19.88 per share, and entered into
Guarantee Agreements whereby the Company guarantees that such options will
have a value of $5 in excess of the exercise price. The Company's guarantee
obligations are effective only if the respective Mr. Blumenkrantz has been em-
ployed by the Company through November 30, 1998.
RELATIONSHIP WITH INDEPENDENT PUBLIC ACCOUNTANTS
Arthur Andersen LLP has been the Company's independent public accountants
since 1981. In the Spring of 1997, the Board of Directors will select the
Company's independent public accountants to audit the accounts of the Company
for the current fiscal year. Representatives of Arthur Andersen LLP are ex-
pected to be present at the Meeting, and will have an opportunity, if they so
desire, to make a statement and will be available to respond to appropriate
questions.
STOCKHOLDER PROPOSALS
The Company's 1997 Annual Meeting is presently proposed to be held on October
9, 1997. Stockholder proposals must be submitted to the Secretary no later
than May 9, 1997, in order to be eligible for inclusion in the Company's proxy
materials for such meetings.
18
<PAGE>
OTHER BUSINESS
As of the date of the Proxy Statement, management does not know of any busi-
ness other than that mentioned above which will be presented for considera-
tion. However, if any other matters should properly come before the meeting,
it is the intention of the persons named in the accompanying form of proxy to
vote the proxies in accordance with their judgment on such matters.
After the business session and a report to the stockholders on the progress
of the Company, a discussion period will take place during which stockholders
will have an opportunity to discuss matters of interest concerning the Compa-
ny.
- ----------------
A COPY OF THE COMPANY'S 1996 FORM 10-K (EXCLUDING EXHIBITS) FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION WILL BE MADE AVAILABLE TO STOCKHOLDERS,
WITHOUT CHARGE, UPON WRITTEN REQUEST TO THE VICE PRESIDENT, FINANCE OF
VITALINK PHARMACY SERVICES, INC., 1250 EAST DIEHL ROAD, SUITE 208, NAPERVILLE,
ILLINOIS 60563. THE REPRODUCTION COST OF UP TO 25c PER PAGE WILL BE CHARGED IF
EXHIBITS ARE REQUESTED.
19
<PAGE>
EXHIBIT A
VITALINK PHARMACY SERVICES, INC.
1996 LONG-TERM INCENTIVE PLAN
SECTION ONE
DESIGNATION AND PURPOSE OF PLAN
The purpose of the Vitalink Pharmacy Services, Inc. 1996 Long-Term Incentive
Plan (the "Plan") is to increase the ownership of Company Stock by those offi-
cers, professional staff and other key employees who are mainly responsible
for the continued growth and development and financial success of the Company
and its subsidiaries. Such stock ownership gives such employees a proprietary
interest in the Company which induces them to continue in its employ. The Plan
also enables the Company to attract and retain such employees and reward them
for the continued profitable performance of Vitalink Pharmacy Services, Inc.
SECTION TWO
DEFINITIONS
The following definitions are applicable herein:
A. "Award"--Individually or collectively, Options, Stock Appreciation Rights,
Performance Shares or Restricted Stock granted hereunder.
B. "Award Period"--the period of time during which a Stock Appreciation Right
which has not been granted pursuant to an Option may be exercised. The Award
Period shall be set forth in the document issuing the Stock Appreciation Right
to the selected Eligible Employee.
C. "Board"--the Board of Directors of the Company.
D. "Book Value"--the book value of a share of Stock determined in accordance
with the Company's regular accounting practices as of the last business day of
the month immediately preceding the month in which a Stock Appreciation Right
is exercised as provided in Section Nine D.
E. "Code"--the Internal Revenue Code of 1986, as amended. Reference in the
Plan to any section of the Code shall be deemed to include any amendments or
successor provisions to such section and any regulations promulgated thereun-
der.
F. "Committee"--the Key Executive Stock Option Plan Committee appointed to
administer the Plan pursuant to Section Four.
G. "Company"--Vitalink Pharmacy Services, Inc., including any present or fu-
ture "subsidiary corporation" as such term is defined in Section 424(f) of the
1986 Internal Revenue Code, as amended.
H. "Covered Employee"--an individual described in Section 162(m)(3) of the
Code.
I. "Date of Grant"--the date on which the granting of an Award is authorized
by the Committee or such later date as may be specified by the Committee in
such authorization.
J. "Eligible Employee"--any person employed by the Company or a Subsidiary on
a regularly scheduled basis who satisfies all of the requirements of Section
Six.
K. "Exercise Period"--the period or periods during which a Stock Appreciation
Right is exercisable as described in Section Nine B.
L. "Fair Market Value"--the fair market value of the Stock as determined in
accordance with Section Eight D.
M. "Incentive Stock Option"--an incentive stock option within the meaning of
Section 422 of the Code.
N. "Option" or "Stock Option"--either a nonqualified stock option or an In-
centive Stock Option granted under Section Eight. It also means any Option
which remains after a Participant has exercised his Option with respect to
part of the shares covered by a Stock Option Agreement as described in Section
Eight B.
O. "Option Period" or "Option Periods"--the period or periods during which an
Option is exercisable as described in Section Eight E.
P. "Option Price"--the price, expressed on a per share basis, for which the
Company Stock can be acquired by the holder of an Option pursuant to the exer-
cise of such Option.
Q. "Participant"--an Eligible Employee of the Company or a Subsidiary who has
been granted an Option, a Stock Appreciation Right, a Performance Share Award
or a Restricted Stock Award under this Plan.
R. "Performance Share"--an Award granted under Section Ten.
S. "Restricted Stock"--an Award granted under Section Seven.
A-1
<PAGE>
T. "Stock" and "Company Stock"--the common stock of the Company.
U. "Stock Appreciation Right"--an Award granted under Section Nine.
V. "Subsidiary"--any corporation of which fifty percent (50%) or more of its
outstanding voting stock or voting power is beneficially owned, directly or
indirectly, by the Company.
W. "Ten Percent Shareholder"--a Participant who, at the Date of Grant, owns
directly or indirectly (within the meaning of Section 424(d) of the Internal
Revenue Code) stock possessing more then ten percent (10%) of the total com-
bined voting power of all classes of stock of the Company or a subsidiary
thereof.
X. Wherever appropriate, words used in this Plan in the singular may mean the
plural, the plural may mean the singular and the masculine may mean the femi-
nine.
SECTION THREE
EFFECTIVE DATE, DURATION AND STOCKHOLDER APPROVAL
A. Effective Date and Stockholder Approval. Subject to the approval of the
Plan by a majority of the outstanding shares of Stock voted at the 1996 Annual
Meeting of Stockholders, the Plan shall be effective as of July 10, 1996.
B. Period for Grant of Awards. Awards may be made as provided herein for a
period of ten (10) years after July 10, 1996.
SECTION FOUR
ADMINISTRATION
A. Appointment of Committee. The Board of Directors shall appoint one or more
Key Executive Stock Option Plan Committees which shall consist of not less
than two (2) members of such Board of Directors and which members shall be
Non-Employee Directors as defined in Rule 16b-3 under the Securities Exchange
Act of 1934, as amended (or such greater number of members which may be re-
quired by said Rule 16b-3). In addition, such Board of Directors shall desig-
nate a member of the Committee to act as Chairman of the Committee, and such
Board of Directors may remove any member of the Committee at any time and ap-
point any director to fill any vacancy on the Committee.
B. Committee Meetings. The Committee shall hold its meetings at such times
and places as specified by the Committee Chairman. A majority of the Committee
shall constitute a quorum. All actions of the Committee shall be taken by all
of the members of the meeting duly called by its Chairman; provided, however,
any action taken by a written document signed by a majority of the members of
the Committee shall be as effective as action taken by the Committee at a
meeting duly called and held.
C. Committee Powers. Subject to the provisions of this Plan, the Committee
shall have full authority in its discretion to (i) designate the Participants
to whom Awards shall be granted, (ii) determine the number of shares to be
made available under each such Award, (iii) determine the period or periods in
which the Participant may exercise such Award (iv) determine the date when
such Award expires, (v) determine the price for Stock under such Award, and
(vi) determine the grounds of forfeiture of an Award. The Committee shall have
all powers necessary to administer the Plan in accordance with its terms, in-
cluding the power to interpret this Plan and resolve all questions arising
thereunder. The Committee may prescribe such rules and regulations for admin-
istering this Plan as the Committee deems appropriate.
SECTION FIVE
GRANT OF AWARDS AND
LIMITATION OF NUMBER OF SHARES SUBJECT TO AWARD
The Committee may, from time to time, grant Awards to one or more Eligible
Employees, provided that (i) subject to any adjustment pursuant to Section
Eleven, the aggregate number of shares of Stock subject to Stock Options,
Stock Appreciation Rights, Performance Share Awards or Restricted Stock Awards
under this Plan may not exceed 493,900 shares; (ii) to the extent that a Stock
Option, Stock Appreciation Right, Performance Share Award or Restricted Stock
Award lapses or the rights of the Participant to whom it was granted termi-
nate, expire or are cancelled for any other reason, in whole or in part,
shares of Stock (or remaining shares) subject to such Award shall again be
available for the grant of an Award under the Plan; and (iii) Shares delivered
by the Company under the Plan may be authorized and unissued Stock, Stock held
in the treasury of the Company or Stock purchased on the open market (includ-
ing private purchases) in accordance with applicable securities laws. In de-
termining the size of Awards, the Committee shall take into account the re-
sponsibility level, performance, potential, and cash compensation level of a
Participant, and the Fair Market Value of the Stock at the time of Awards, as
well as such other considerations it deems appropriate.
A-2
<PAGE>
SECTION SIX
ELIGIBILITY
Key employees of the Company and its Subsidiaries (including employees who
are members of the Board, but excluding directors who are not employees) who,
in the opinion of the Committee, are mainly responsible for the continued
growth and development and financial success of the business of the Company or
one or more of its Subsidiaries shall be eligible to be granted Awards under
the Plan. Subject to the provisions of the Plan, the Committee may from time
to time select from such eligible persons those to whom Awards shall be
granted and determine the nature and amount of each Award. No employee of the
Company or its Subsidiaries shall have any right to be granted an Award under
this Plan. A member of the Committee shall not be eligible for any Award here-
under.
SECTION SEVEN
RESTRICTED STOCK AWARDS
A. Grants of Shares of Restricted Stock. An Award made pursuant to this Sec-
tion Seven shall be granted in the form of shares of Stock, restricted as pro-
vided in this Section Seven. Shares of the Restricted Stock shall be issued to
the Participant without the payment of consideration by the Participant. The
shares of Restricted Stock shall be issued in the name of the Participant and
shall bear a restrictive legend prohibiting sale, transfer, pledge or hypothe-
cation of the shares of Restricted Stock until the expiration of the restric-
tion period.
The Committee may also impose such other restrictions and conditions on the
shares of Restricted Stock as it deems appropriate.
B. Restriction Period. At the time a Restricted Stock Award is made, the Com-
mittee may establish a restriction period applicable to such Award which shall
not be more than ten (10) years. Each Restricted Stock Award may have a dif-
ferent restriction period, at the discretion of the Committee. In addition to
or in lieu of a restriction period, the Committee may establish a performance
goal which must be achieved as a condition to the retention of the Restricted
Stock. The performance goal may be based on the attainment of specified types
of performance measurement criteria, which may differ as to various Partici-
pants or classes or categories of Participants. Such criteria may include,
without limitation, the attainment of certain performance levels by the indi-
vidual Participant, the Company, a department or division of the Company
and/or a group or class of participants. Any such performance goals, together
with the ranges of Restricted Stock Awards for which the Participants may be
eligible shall be set from time to time by the Committee and shall be timely
communicated to the Eligible Employees in advance of the commencement of the
performance of services to which such performance goals relate. The total num-
ber of shares of Restricted Stock which may be granted to any single Covered
Employee under this Plan during any calendar year shall be limited to 100,000.
C. Forfeiture or Payout of Award. In the event a Participant ceases employ-
ment during a restriction period, or in the event performance goals attribut-
able to a Restricted Stock Award are not achieved, subject to the terms of
each particular Restricted Stock Award, and subject to discretionary action by
the Committee as set forth below in Section Thirteen, a Restricted Stock Award
is subject to forfeiture of the shares of stock which had not previously been
removed from restriction under the terms of the Award.
Any shares of Restricted Stock which are forfeited will be transferred to the
Company.
Upon completion of the restriction period and satisfaction of any perfor-
mance-goal criteria, all restrictions upon the Award will expire and new cer-
tificates representing the Award will be issued without the restrictive legend
described in Section Seven A. As a condition precedent to receipt of the new
certificates, the Participant (or the designated beneficiary or personal rep-
resentative of the Participant) will agree to make payment to the Company in
the amount of any taxes, payable by the Participant, which are required to be
withheld with respect to such shares of Stock.
SECTION EIGHT
STOCK OPTIONS
A. Grant of Option. One or more Options may be granted to any Eligible Em-
ployee. Upon the grant of an Option to an Employee, the Committee shall spec-
ify whether the Option is intended to constitute a non-qualified stock option
or an Incentive Stock Option. The total number of shares of Stock subject to
Options which may be granted to any single Covered Employee under this Plan
during any calendar year shall be limited to 100,000.
B. Stock Option Agreement. Each Option granted under the Plan shall be evi-
denced by a written "Stock Option Agreement" between the Company and the Par-
ticipant containing such terms and conditions as the Committee determines, in-
cluding, without limitation, provisions to qualify Incentive Stock Options as
such under Section 422 of the
A-3
<PAGE>
Code. Such agreements shall incorporate the provisions of this Plan by refer-
ence. The date of granting an Option is the date specified in the written
Stock Option Agreement which is signed by the Participant and the Company.
C. Determination of Option Price. The Option price for Stock shall be not
less than 100% of the fair market value of the Stock on the date of grant.
Notwithstanding the foregoing, in the case of an Option which is designed to
qualify as an Incentive Stock Option (as defined in Section 422 of the Code)
which is granted to a Ten Percent Shareholder, the Option Price shall not be
less than 110% of such fair market value.
D. Determination of Fair Market Value. The fair market value of the Stock on
the date of granting an Option shall be the mean of the high and low prices at
which the Stock was sold on the market on such date. In the event no such
sales of Stock occurred on such date, the fair market value of the Stock shall
be determined by the Committee in accordance with applicable Regulations of
the Internal Revenue Service.
E. Term of Option. The term of an Option may vary within the Committee's dis-
cretion; provided, however, that the term of an Option shall not exceed ten
(10) years from the date of granting the Option to the Participant, and, to
this end, all Options granted pursuant to this Plan must provide that each
such Option cannot be exercised after the expiration of ten (10) years from
the date each such Option is granted. Notwithstanding the foregoing, in the
case of any Option which is designed to qualify as an Incentive Stock Option
(as defined in Section 422 of the Code) which is granted to a Ten Percent
Shareholder, the term of such Option may not exceed five (5) years from the
date of grant of such Option.
F. Limitation on Exercise of Option. The Committee may limit an Option by re-
stricting its exercise in whole or in part for specified periods.
G. Method of Exercising an Option. Subject to the terms of a particular Op-
tion, a Participant may exercise it in whole or in part by written notice to
the Secretary of the Company stating in such written notice the number of
shares of Stock such Participant elects to purchase under his Option.
H. No Obligation to Exercise Option. A Participant is under no obligation to
exercise an Option or any part thereof.
I. Payment for Option Stock. Stock purchased pursuant to an Option shall be
paid in full at the time of purchase. Payment may be made (a) in cash, (b)
with the approval of the Committee, by delivery to the Company of shares of
Stock having an aggregate fair market value equal to the exercise price, or
(c) a combination of (a) and (b). Payment may also be made, in the discretion
of the Committee, by delivery (including by facsimile transmission) to the
Company or its designated agent of an executed irrevocable Option exercise
form together with irrevocable instructions to a broker-dealer to sell (or
margin) a sufficient portion of the shares and deliver the sale (or margin
loan) proceeds directly to the Company to pay for the exercise price. Upon re-
ceipt of payment and subject to paragraph J of this Section Eight, the Company
shall, without transfer or issue tax to the Participant or other person enti-
tled to exercise the Option, deliver to the Participant (or other person enti-
tled to exercise the Option) a certificate or certificates for such shares.
J. Delivery of Stock to Participant. The Company shall undertake and follow
all necessary procedures to make prompt delivery of the number of shares of
Stock which the Participant elects to purchase upon exercise of an Option
granted under this Plan. Such delivery, however, may be postponed, at the sole
discretion of the Company, to enable the Company to comply with any applicable
procedures, regulations or listing requirements of any government agency,
stock exchange or regulatory authority.
K. Failure to Accept Delivery of Stock. If a Participant refuses to pay for
Stock which he has elected to purchase under his Option, in accordance with
the terms of payment, which had previously been agreed upon, his Option shall
thereupon, at the sole discretion of the Committee, terminate, and such funds
previously paid for unissued Stock shall be refunded. Stock which has been
previously issued to the Participant and been fully paid for shall remain the
property of the Participant and shall be unaffected by such termination.
L. Non-Transferability of Options. During the lifetime of a Participant, an
Incentive Stock Option granted to him may be exercised only by him. It may not
be sold, assigned, pledged or otherwise transferred except by will or by the
laws of descent and distribution. In the case of Options which are not Incen-
tive Stock Options, the Committee may impose such restrictions on transfera-
bility, if any, as it may in its sole discretion determine.
M. Purchase for Investment
(a) Written Agreement by Participants. Unless a registration statement under
the Securities Act of 1933 is then in effect with respect to the Stock a
Participant receives upon exercise of his Option, a Participant shall acquire
the Stock he receives upon exercise of his Option for investment and not for
resale or distribution and he shall furnish the Company with a written
statement to that effect when he exercises his Option and a reference to such
investment warranty shall be inscribed on the Stock certificate(s).
A-4
<PAGE>
(b) Registration Requirement. Each Option shall be subject to the
requirement that, if at any time the Board determines that the listing,
registration or qualification of the shares subject to the Option upon any
securities exchange or under any state or Federal law is necessary or
desirable as a condition of, or in connection with, the issuance of shares
thereunder, the Option may not be exercised in whole or in part unless such
listing, registration or qualification shall have been effected or obtained
(and the same shall have been free of any conditions not acceptable to the
Board).
N. Special Limitations on Exercise of Incentive Stock Options. The aggregate
fair market value (determined at the time the Incentive Stock Option is grant-
ed) of the Stock with respect to which any Incentive Stock Option is first ex-
ercisable during any calendar year shall not exceed $100,000.
SECTION NINE
STOCK APPRECIATION RIGHTS
A. Grant of Stock Appreciation Rights. Stock Appreciation Rights may be
granted under the Plan in conjunction with an Option either at the time of
grant or by amendment or may be separately awarded. Stock Appreciation Rights
shall be subject to such terms and conditions not inconsistent with the Plan
as the Committee shall impose. However, the total number of Stock Appreciation
Rights which may be granted to a single Covered Employee under this Plan dur-
ing any calendar year shall be limited to 100,000.
B. Right to Exercise; Exercise Period. A Stock Appreciation Right issued pur-
suant to an Option shall be exercisable to the extent the Option is exercis-
able. A Stock Appreciation Right issued independent of an Option shall be ex-
ercisable pursuant to such terms and conditions established in the grant.
C. Automatic Redemption of Unexercised Stock Appreciation Rights. If on the
last day of the Option Period, in the case of a Stock Appreciation Right
granted pursuant to an Option, or the specified Award Period, in the case of a
Stock Appreciation Right issued independent of an Option, the Participant has
not exercised such Stock Appreciation Right, then such Stock Appreciation
Right shall be automatically redeemed by the Company for an amount equal to
the payment that would otherwise have been made to the Participant if the Par-
ticipant had chosen to exercise the Stock Appreciation Right on the last day
of the Option Period or the specified Award Period, as the case may be.
D. Rights Upon Exercise. An exercisable Stock Appreciation Right granted pur-
suant to an Option shall entitle the Participant to surrender unexercised the
Option or any portion thereof to which the Stock Appreciation Right is at-
tached, and to receive in exchange for the Stock Appreciation Right a payment
(in cash or Stock or a combination thereof as described below) equal to the
Fair Market Value of one share of Stock at the date of exercise minus the Op-
tion Price times the number of shares called for by the Stock Appreciation
Right (or portion thereof) which is so exercised. With respect to the issuance
of Stock Appreciation Rights which are not granted pursuant to an Option, the
Committee shall specify upon the Date of the Grant of the Stock Appreciation
Right whether the Stock Appreciation Right is a "regular" Stock Appreciation
Right or a "book value" Stock Appreciation Right. Upon the exercise of a regu-
lar Stock Appreciation Right, the Participant will receive a payment equal to
the Fair Market Value of one share of Stock at the date of exercise minus the
Fair Market Value of one share of Stock as of the Date of Grant of the Stock
Appreciation Right times the number of shares called for by the Stock Appreci-
ation Right (or portion thereof) which is so exercised. Upon the exercise of a
book value Stock Appreciation Right, the Participant will receive a payment
equal to the Book Value of one share of Stock at the date of exercise minus
the Book Value of one share of Stock as of the Date of the Grant of the Stock
Appreciation Right times the number of shares called for by the Stock Appreci-
ation Right (or portion thereof) which is so exercised.
The value of any Stock to be received upon exercise of a Stock Appreciation
Right shall be the Fair Market Value of the Stock on such date of exercise. To
the extent that a Stock Appreciation Right issued pursuant to an Option is ex-
ercised, such Option shall be deemed to have been exercised, and shall not be
deemed to have lapsed.
E. Transferability. The Committee may impose such restrictions on transfera-
bility of Stock Appreciation Rights, if any, as it may in its sole discretion
determine.
SECTION TEN
PERFORMANCE SHARES
A. Grant of Performance Share Units. Awards made pursuant to this Section Ten
shall be granted in the form of Performance Shares, subject to such terms and
conditions not inconsistent with the Plan as the Committee shall impose. Per-
formance Shares shall be issued to the Participant without the payment of con-
sideration by the Participant.
A-5
<PAGE>
Awards shall be based on the attainment of specified types and combination of
performance measurement criteria, which may differ as to various Participants
or classes or categories of Participants. Such criteria may include, without
limitation, the attainment of certain performance levels by the individual
Participant, the Company, a department or division of the Company and/or a
group or class of Participants. Such criteria, together with the ranges of
Performance Shares from which employees may be eligible shall be set from time
to time by the Committee and shall be communicated to the Eligible Employees.
The total number of Performance Shares which may be granted to any single Cov-
ered Employee under this Plan during any calendar year shall be limited to
100,000.
B. Performance Period. The measuring period to establish the performance cri-
teria set forth in a Performance Share Award shall be determined by the Com-
mittee. A Performance Share Award may initially provide, or the Committee may
at any time thereafter, but no more frequently than once in any six (6) month
period, amend it to provide, for waiver or reduction of the measuring period
and, if appropriate, for adjustment of the performance criteria set forth in
the Performance Share Award, upon the occurrence of events determined by the
Committee in its sole discretion to justify such waiver, reduction or adjust-
ment.
C. Form of Payment. Upon the completion of the applicable measuring period, a
determination shall be made by the Committee in accordance with the Award as
to the number of shares of Stock to be awarded to the Participant. The appro-
priate number of shares of Stock shall thereupon be issued to the Participant
in accordance with the Award in satisfaction of such Performance Share Award.
SECTION ELEVEN
CHANGES IN CAPITAL STRUCTURE OR SHARES
In the event any reorganization, merger, consolidation, recapitalization,
liquidation, reclassification, stock dividend, stock split, combination of
shares, rights offering, or extraordinary dividend or divestiture (including a
spin-off), or any other change in the capital structure or shares of the Com-
pany, the Committee, shall make adjustments, determined by the Committee in
its discretion to be appropriate, as to the number and kind of securities sub-
ject to this Plan and specified in Section Five of this Plan and as to the
number and kind of securities covered by each outstanding Award and, where ap-
plicable, the price per share thereunder; provided, however, that with respect
to Incentive Stock Options, such adjustments shall be made in accordance with
Section 424(h) of the Code unless the Committee determines otherwise.
SECTION TWELVE
CORPORATE REORGANIZATION OR DISSOLUTION
A. Discontinuation of the Plan. The Plan shall be discontinued in the event
of the dissolution or liquidation of the Company or in the event of a Reorga-
nization (as hereinafter defined) in which the Company is not the surviving or
acquiring company, or in which the Company is or becomes a wholly-owned sub-
sidiary of another company after the effective date of the Reorganization and
no plan or agreement respecting the Reorganization is established which spe-
cifically provides for the continuation of the Plan and the change, conver-
sion, or exchange of the stock relating to existing Awards under this Plan for
securities of another corporation. Upon the dissolution of the Plan in connec-
tion with an event described in this Paragraph A, all Awards shall become
fully vested and all outstanding Options and Stock Appreciation Rights shall
become immediately exercisable by the holder thereof. Any Options or Stock Ap-
preciation Rights granted under the Plan may be terminated as of a date fixed
by the Committee, provided that no less than fifteen (15) days written notice
of the date so fixed shall be given to each Participant and each such Partici-
pant shall have the right during such period to exercise all or any portion of
such Options or Stock Appreciation Rights. Any Stock Appreciation Rights not
so exercised shall be redeemed.
B. Continuation of the Plan Upon a Reorganization. In the event of a Reorga-
nization (as hereinafter defined) (i) in which the Company is not the surviv-
ing or acquiring company, or in which the Company is or becomes a wholly-owned
subsidiary of another company after the effective date of the Reorganization,
and (ii) with respect to which there is a reorganization agreement which un-
dertakes to continue the Plan and to provide for the change, conversion or ex-
change of the Stock attributable to outstanding Awards for securities of an-
other corporation, then the Plan shall continue and the Committee shall adjust
the shares under such outstanding Awards (and shall adjust the shares remain-
ing under the Plan which are then to be available for the grant of additional
Awards under the Plan, if the reorganization agreement makes specific provi-
sions therefor), in a manner not inconsistent with the provisions of the reor-
ganization agreement and this Plan for the adjustment, change, conversion or
exchange of such Awards.
A-6
<PAGE>
The term "Reorganization" as used in this Section Twelve shall mean any stat-
utory merger, statutory consolidation, sale of all or substantially all of the
assets of the Company, or sale, pursuant to an agreement with the Company, of
securities of the Company pursuant to which the Company is or becomes a whol-
ly-owned subsidiary of another company after the effective date of the Reorga-
nization.
C. Adjustments and Determinations. Adjustments and determinations under this
Section Twelve shall be made by the Committee, whose decisions as to what ad-
justments or determinations shall be made, and the extent thereof, shall be
final, binding, and conclusive.
SECTION THIRTEEN
RETIREMENT AND DISABILITY
The Committee may, in its discretion, waive the forfeiture, termination, or
lapse of an Award in the event of retirement or disability of a Participant
(each as determined by the Committee, in its discretion). Exercise of such
discretion by the Committee in any individual case, however, shall not be
deemed to require, or to establish a precedent suggesting such exercise in any
other case.
SECTION FOURTEEN
MISCELLANEOUS PROVISIONS
A. Nontransferability. The Committee may impose such restrictions on the
transferability of an Award, if any, as it may in its sole discretion deter-
mine.
B. No Employment Right. Neither this Plan nor any action taken hereunder
shall be construed as giving any right to be retained as an officer or em-
ployee of the Company or any of its Subsidiaries.
C. Tax Withholding. Either the Company or a Subsidiary, as appropriate, shall
have the right to deduct from all Awards paid in cash any federal, state or
local taxes as it deems to be required by law to be withheld with respect to
such cash payments. In the case of Awards paid in Stock, the employee or other
person receiving such Stock may be required to pay to the Company or a Subsid-
iary, as appropriate, the amount of any such taxes which the Company or Sub-
sidiary is required to withhold with respect to such Stock. At the request of
a Participant, or as required by law, such sums as may be required for the
payment of any estimated or accrued income tax liability may be withheld and
paid over to the governmental entity entitled to receive the same. The Commit-
tee may from time to time establish procedures for withholding of Stock.
D. Fractional Shares. Any fractional shares concerning Awards shall be elimi-
nated at the time of payment by rounding down for fractions of less than one-
half and rounding up for fractions of equal to or more than one-half. No cash
settlements shall be made with respect to fractional shares eliminated by
rounding.
E. Government and Other Regulations. The obligation of the Company to make
payment of Awards in Stock or otherwise shall be subject to all applicable
laws, rules, and regulations, and to such approvals by any government agencies
as may be required. The Company shall be under no obligation to register under
the Securities Act of 1933, as amended ("Act"), any of the shares of Stock is-
sued, delivered or paid in settlement under the Plan. If Stock awarded under
the Plan may in certain circumstances be exempt from registration under the
Act, the Company may restrict its transfer in such manner as it deems advis-
able to ensure such exempt status.
F. Severance. Subject to the provision of Paragraph B of this Section Four-
teen, in the event a Participant's employment with the Company terminates, his
rights under any Award which constitutes an Option or a Stock Appreciation
Right terminate one (1) month from the date of such termination of employment.
Such rights shall be exercisable only to the extent the Participant was enti-
tled to exercise such rights under the Award on the date of such termination
of employment.
G. Death. If a Participant dies prior to the full exercise of his Option
and/or Stock Appreciation Right, his Option to purchase Stock under such Op-
tion and/or Stock Appreciation Right may be exercised to the extent, if any,
that Participant would be entitled to exercise it at the date of the death of
the Participant by the person to whom the Option and/or Stock Appreciation
Right shall pass by will or by the laws of descent and distribution within
twelve (12) months of the death of the Participant or the expiration of the
term of the Option and/or Stock Appreciation Right whichever date is sooner.
H. Limitation. In no event may an Option be exercised by anyone after the ex-
piration date provided for in Section Eight of the Plan.
A-7
<PAGE>
I. Limits on Discretion. Anything in this Plan to the contrary notwithstand-
ing, if the Award so provides, the Committee shall not have any discretion to
increase the amount of compensation payable under the Award to the extent such
discretion would cause the Award to lose its qualification as performance-
based compensation for purposes of Section 162(m)(4)(c) of the Code and the
regulations thereunder.
J. Governing Law. All matters relating to the Plan or to Awards granted here-
under shall be governed by the laws of the State of Maryland, without regard
to its principles of conflict of laws.
K. Titles and Headings. The titles and headings of the sections in the Plan
are for convenience of reference only, and in the event of any conflict, the
text of the Plan, rather than such titles and headings, shall control.
SECTION FIFTEEN
AMENDMENT OF PLAN
A. Discretion of the Board. The Board may at any time and from time to time
alter, amend, suspend or terminate the Plan in whole or in part, except (i)
any such action affecting Options granted or to be granted under this Plan
which are intended to qualify as Incentive Stock Options shall be subject to
stockholder approval to the extent such stockholder approval is required pur-
suant to Section 422 of the Internal Revenue Code and (ii) no such action may
be taken without the consent of the Participant to whom any Award shall there-
tofore have been granted, which adversely affects the rights of such Partici-
pant concerning such Award, except as such termination or amendment of the
Plan is required by statute, or rules and regulations promulgated thereunder.
B. Automatic Termination. This Plan shall terminate on July 10, 2006. Awards
may be granted under this Plan at any time and from time to time prior to the
termination of the Plan. Any Award outstanding at the time the Plan is termi-
nated shall remain in effect until said Award is exercised or expires.
A-8
<PAGE>
EXHIBIT B
VITALINK PHARMACY SERVICES, INC.
1995 EMPLOYEE STOCK PURCHASE PLAN
SECTION ONE
PURPOSES
The 1995 Vitalink Pharmacy Services, Inc. Employee Stock Purchase Plan (the
"Plan") is intended to provide a method whereby employees of Vitalink Pharmacy
Services, Inc. and its Subsidiaries (hereinafter referred to, unless the con-
text otherwise requires, as the "Company") will have an opportunity to acquire
a proprietary interest in the Company through the purchase of shares of Common
Stock. Such stock ownership induces such employees to continue in the employ
of the Company. The Plan also enables the Company to attract and retain such
employees. It is the intention of the Company to have the Plan qualify as an
"employee stock purchase plan" under Section 423 of the Code. The provisions
of the Plan shall, accordingly, be construed as to extend and limit participa-
tion in a manner consistent with the requirements of that section of the Code.
SECTION TWO
DEFINITIONS
A. Agent. The term "Agent" shall have the meaning set forth in Section Thir-
teen hereof.
B. Board of Directors. The term "Board of Directors" shall mean the Board of
Directors of the Company or any individual or committee to which the Board of
Directors has delegated authority to act with respect to a specific activity.
C. Code. The term "Code" shall mean the Internal Revenue Code of 1986, as
amended.
D. Common Stock. The term "Common Stock" shall mean the $0.01 par value Com-
mon Stock of the Company.
E. Company. The term "Company" shall mean Vitalink Pharmacy Services, Inc., a
Delaware corporation.
F. Compensation. The term "Compensation" shall mean basic cash compensation,
before any payroll deductions for taxes or any other purposes, including regu-
lar commissions paid by the Company or a Subsidiary to a Participant in re-
spect of the service of such Participant to the Company or a Subsidiary during
an Offering Period increased by any amounts with respect to which the Partici-
pant has elected to defer or reduce remuneration for federal income tax pur-
poses (i) under the Manor Care, Inc. Retirement Savings and Investment Plan or
similar plan maintained by the Company or a Subsidiary, (ii) under the Manor
Care, Inc. Nonqualified Retirement Savings and Investment Plan or similar plan
maintained by the Company or a Subsidiary, or (iii) under any "cafeteria plan"
(as described in Section 125 of the Code) maintained by Manor Care, Inc., the
Company or a Subsidiary. Compensation shall not include any amounts paid to
the Participant as (i) bonuses, (ii) overtime pay, (iii) any amounts paid dur-
ing that Offering Period on account of the Participant under any other em-
ployee pension benefit plan (as defined in Section 3(2) of ERISA), and (iv)
except as otherwise provided in the preceding sentence, any amounts which are
not includible in the income of the Participant for federal income tax purpos-
es.
G. Continuous Service. The term "Continuous Service" as of any date shall
mean the period determined by the Company, on a uniform basis for employees
similarly situated, to represent the then unbroken period of service of an em-
ployee as an employee of the Company or of a Subsidiary designated by the
Board of Directors to participate in the Plan or of Manor Care, Inc. or a sub-
sidiary thereof; provided, however, that in the case of such a Subsidiary,
Continuous Service shall not include service prior to the date of its affilia-
tion with the Company, unless the Board of Directors otherwise provides for
recognition of such service. A break in Continuous Service shall be deemed to
have occurred whenever an employee voluntarily or involuntarily ceases to be
an employee. The transfer by an employee from (i) one corporation to another
corporation participating in the Plan or (ii) Manor Care, Inc. or a subsidiary
thereof to the Company or a Subsidiary shall not affect the Continuous Service
of the employee.
H. Designated Subsidiary. The term "Designated Subsidiary" shall mean a Sub-
sidiary designated by the Board of Directors to participate in the Plan.
I. ERISA. The term "ERISA" shall mean the Employee Retirement Income Security
Act of 1974, as amended.
J. Nominee. The term "Nominee" shall have the meaning as set forth in Section
Seven hereof.
K. Offering Date. The term "Offering Date" shall mean the first day of each
January, April, July and October, commencing January 1, 1996.
B-1
<PAGE>
L. Offering Period. The term "Offering Period" shall mean a three-month pe-
riod commencing with an Offering Date and ending with the following Purchase
Date.
M. Option. The term "Option" shall mean the right of a Participant to acquire
Common Stock pursuant to the provisions of the Plan.
N. Participant. The term "Participant" shall mean an eligible employee who
has authorized payroll deductions for the purchase of Common Stock under the
Plan in accordance with Section Four hereof.
O. Purchase Date. The term "Purchase Date" shall mean the last trading day of
each March, June, September, and December, commencing March, 1996 or if a pay
period ends on the last day of a calendar quarter, the next trading day.
P. Retirement. The term "Retirement" shall mean termination of employment of
a Participant on or after the sixty-fifth (65th) birthday of the Participant.
Q. Subsidiary. The term "Subsidiary" shall mean a Subsidiary corporation of
the Company as defined by Section 424(f) of the Code.
R. Wherever appropriate, words used in this Plan in the singular may mean the
plural, the plural may mean the singular and the masculine may mean the femi-
nine.
SECTION THREE
ELIGIBILITY
All employees of the Company, or Designated Subsidiaries of the Company, who
shall have completed one (1) year of Continuous Service as of any Offering
Date, shall be eligible to participate in the Plan, provided that (i) no em-
ployee shall be eligible who, immediately after any Option is granted, owns
stock possessing five percent (5%) or more of the total combined voting power
or value of all classes of stock of the Company or of any Subsidiary of the
Company (applying the rules of Section 424(d) of the Code in determining stock
ownership), (ii) no Director of the Company or of any Subsidiary, who is not
an officer or other employee of any thereof, shall participate in the Plan and
(iii) no employee shall be eligible whose customary employment is twenty (20)
hours or less per week or whose customary employment is for not more than five
(5) months in any calendar year.
SECTION FOUR
METHOD OF PURCHASE
A. On each Offering Date, each Participant shall be deemed to have been
granted the right to purchase such number of shares of Common Stock as pro-
vided herein.
An eligible employee shall become a Participant in the Plan by authorizing
payroll deductions for the purchase of Common Stock under the Plan prior to an
Offering Date with instructions for the purchase of Common Stock under the
Plan. At the time a Participant files his or her authorization, the Partici-
pant shall elect to have deductions made from his or her pay on each payday
during the time he or she is a Participant at a rate not less than two percent
(2%) and not in excess of ten percent (10%) in whole percentages of his or her
Compensation. All payroll deductions made for a Participant shall be credited
to his or her account under the Plan. A Participant may not make any separate
cash payment into such account. No interest will be paid on funds in the ac-
count of a Participant.
A Participant shall be deemed to have continued his or her most recent elec-
tion to participate in the Plan for the next Offering Period unless he or she
notifies the Company on or before the twentieth (20th) day of the month pre-
ceding the beginning of the next Offering Period that he or she elects not to
participate in the Plan for the next Offering Period. Such notice may not be
revoked. Similarly, a Participant may elect to increase or decrease the amount
of his or her payroll deduction on or before the twentieth (20th) day of the
month preceding the beginning of the next Offering Period, such increase or
decrease to be effective at the beginning of the next Offering Period.
Prior to each Purchase Date, the Company shall elect whether, and in what
proportion, the Agent on the Purchase Date shall purchase Common Stock on be-
half of the Participants in the open market and/or the Company shall sell the
Common Stock to the Participants.
(i) If the Company shall elect that such purchases be made in whole or in
part in the open market, on or before such Purchase Date, the Company shall
contribute to the Agent an amount equal to ten percent (10%) of the purchase
price of the Common Stock purchased in the open market. The Agent shall cause
the portion of the proceeds received from contributions of the Participants
designated by the Company for open market purchases and such contribution of
the Company to be applied to the open market purchases of Common Stock. The
account of each Participant shall be credited with the number of shares of
Common Stock equal to the sum of the contributions
B-2
<PAGE>
of the Participant and the share of the Participant of the contribution of
the Company applied by the Agent to the purchase of Common Stock divided by
the average price per share of Common Stock purchased by the Agent.
(ii) If the Company shall elect that such purchases be made in whole or in
part from the Company, on the Purchase Date the Company shall sell to the
Participants, and the Agent shall cause the portion of the proceeds received
from contributions of the Participants designated by the Company for
purchases from the Company to be applied to the purchase of, Common Stock at
90% of the market price of a share of Common Stock on the applicable Purchase
Date. Such Common Stock may be either Treasury shares or newly-issued shares.
The market price per share of Common Stock purchased from the Company with
payroll deductions made during each Offering shall be the mean of the high
and low prices at which the Common Stock was sold in the over-the-counter
market as reported by NASDAQ (or, if the Common Stock is then traded on a
national securities exchange, the mean of the high and low prices at which
the Common Stock was sold), as published in The Wall Street Journal, on the
Purchase Date.
Unless the Company otherwise directs, the Agent may, but shall not be obli-
gated to, allocate fractional shares of Common Stock for any Participant or
purchase shares of Common Stock in odd lots. Upon termination of an account,
any fractional shares in the Participant's account will be sold, and the pro-
ceeds therefrom shall be delivered to such Participant. In the event frac-
tional shares are not allocated to the accounts of the Participants under the
Plan, any accumulated payroll deductions which would have been used to pur-
chase fractional shares shall remain in the accounts of the Participants. No
interest will be paid on such funds in accounts of Participants and shall be
deemed to be a payroll deduction of the next Offering Period.
B. No Participant shall have the right to purchase Common Stock under the
Plan at a rate of more than $25,000 in value thereof in any calendar year,
such value to be based on the fair market value per share of the Common Stock
as of the Offering Date on which a Participant becomes eligible to purchase
Common Stock in such year under the terms of the Plan.
C. A Participant may not increase or reduce the amount of his or her payroll
deduction during an Offering Period, provided, however, that a Participant may
reduce the amount of his or her payroll deduction to zero at any time during
the Offering Period in which case the employee may not participate again in
the Plan until the following Offering Period. A Participant shall be deemed to
have elected to purchase all of the shares which his or her authorized payroll
deductions and share of the contribution of the Company would purchase on a
Purchase Date.
D. If at any time the number of shares as to which Options have been granted
shall exceed the remaining number of shares authorized for purchase under the
Plan, the number of shares which may be purchased by each Participant shall be
reduced proportionately.
E. At any time prior to a Purchase Date the Board of Directors may terminate
the Plan without any obligation whatsoever to the Participants, other than to
refund to each Participant, without interest, any sum accumulated for him or
her by payroll deductions.
SECTION FIVE
WITHDRAWALS
A Participant may withdraw funds in his or her account under the Plan only by
withdrawal from the Plan; in the event of the withdrawal of the Participant,
he or she shall not be eligible to participate in the Plan until the next Of-
fering Date.
SECTION SIX
TERMINATION OF EMPLOYMENT
A. Upon termination of the employment of a Participant for any reason, ex-
cluding death while in the employ of the Company or a Designated Subsidiary or
Retirement, the Common Stock and/or cash credited to his or her account and
not used to purchase shares will be returned to the Participant within sixty
(60) days after the end of the then current Offering Period or as soon as ad-
ministratively practicable thereafter. As an alternative to a distribution of
Common Stock, a Participant may request that the Agent sell the Common Stock
in the account of a Participant and forward the net proceeds to such person or
persons.
B. Upon termination of the employment of a Participant because of (i) death,
or (ii) Retirement, his or her beneficiary (as defined in Section Nine), or
the Participant, as the case may be, shall have the right to elect, by written
notice
B-3
<PAGE>
given to the Secretary of the Company prior to the expiration of the period of
thirty (30) days commencing with the date of the death of the Participant, or
Retirement of the Participant, as the case may be, either
(i) to withdraw all of the payroll deductions credited to the account of the
Participant under the Plan or
(ii) to exercise the Option of the Participant on the Purchase Date next
following the date of the death of the Participant or Retirement of the
Participant, as the case may be, for the purchase of the number of full
shares of Common Stock which the Participant was entitled to purchase
pursuant to the Option, and any excess funds in the Participant's account
will be returned to said beneficiary or Participant, as the case may be.
In the event that no such written notice of election shall be duly received
by the office of the Secretary of the Company, the beneficiary or Participant,
as the case may be, shall automatically be deemed to have elected to withdraw
the payroll deductions credited to the account of the Participant at the date
of the death or Retirement of the Participant, as the case may be, and the
same will be paid to the said beneficiary or Participant within sixty (60)
days after the end of the current Offering Period or as soon as administra-
tively practicable thereafter.
In addition, upon termination of the employment of a Participant because of
(i) death, or (ii) Retirement, the Common Stock and/or cash (except as other-
wise provided in this Section Six B) shall be distributed to the Participant
or to the person or persons entitled thereto under Section Nine within sixty
(60) days after the end of the current Offering Period or as soon as adminis-
tratively practicable thereafter. As an alternative to a distribution of Com-
mon Stock, a Participant or such person or persons entitled to receive the ac-
count of a Participant under Section Nine may request that the Agent sell the
Common Stock in the account of a Participant and forward the net proceeds to
the Participant or such person or persons.
SECTION SEVEN
STOCK
Subject to adjustment upon changes in capitalization of the Company as pro-
vided in Section Ten, the maximum number of shares of Common Stock which shall
be made available for purchase under the Plan is 100,000 shares.
Shares purchased pursuant to an Option will initially be registered in the
name of a Nominee designated by the Company, as custodian for the account of
the Participant entitled thereto. Stock certificates will not be issued to
Participants for shares held in the name of the Nominee, but all rights accru-
ing to an owner of record of such shares (including voting rights) will belong
to the Participant for whose account such shares are held. Notwithstanding the
foregoing, each Participant may elect to have some or all of the full shares
of Common Stock previously purchased and registered in the name of the Nominee
on his or her behalf registered in the name of such Participant. Written no-
tice of such an election must be given by the Participant to the Nominee,
specifying the number of full shares of Common Stock to be registered in the
name of such Participant. The specified number of shares of Common Stock will
be transferred to and registered in the name of the notifying Participant as
soon as administratively practicable.
The Board of Directors may, in its discretion, require as a condition to the
grant of the right to purchase hereunder that the shares of Common Stock re-
served for issuance upon the exercise of the Option shall have been duly au-
thorized for trading on the NASDAQ National Market and that either
(i) a Registration Statement under the Securities Act of 1933, as amended,
with respect to said shares shall be effective; or
(ii) the Participant shall have represented in form and substance
satisfactory to the Company that it is the intention of the Participant to
purchase such shares for investment.
SECTION EIGHT
NONASSIGNABILITY
Neither payroll deductions credited to the account of a Participant nor any
rights with regard to the exercise of an Option or to receive Common Stock un-
der the Plan may be assigned, transferred, pledged or otherwise disposed of in
any way by the Participant other than by will or the laws of descent and dis-
tribution. Any such attempted assignment, transfer, pledge, or other disposi-
tion shall be without effect, except that the Company may treat such act as an
election to withdraw funds in accordance with Section Five.
B-4
<PAGE>
SECTION NINE
DESIGNATION OF BENEFICIARY
A Participant may file a written designation of a beneficiary who is to re-
ceive any shares of Common Stock and/or cash in the event of the death of the
Participant prior to the delivery of such shares or cash to Participant. Such
designation of beneficiary may be changed by the Participant at any time by
written notice to the Secretary of the Company. Within thirty (30) days after
the death of the Participant, the beneficiary may, as provided in Section Six,
elect to exercise the Option of the Participant when it becomes exercisable on
the Purchase Date next following the date of the death of the Participant.
Upon the death of a Participant and upon receipt by the Company of proof of
the identity and survivorship of a beneficiary validly designated by the Par-
ticipant under the Plan, and notice of election of the beneficiary to exercise
the Option, the Company shall deliver such Common Stock and/or cash to such
beneficiary. In the event of the death of a Participant and in the absence of
a beneficiary validly designated under the Plan who is living at the time of
such death of a Participant, the Company shall deliver such Common Stock
and/or cash to the executor or administrator of the estate of the Participant
within sixty (60) days after the end of the current Offering Period or as soon
as administratively practicable thereafter, or if no such executor or adminis-
trator has been appointed (to the knowledge of the Company), the Company, in
its discretion, may deliver such Common Stock and/or cash to the spouse or to
any one or more dependents of the Participant as the Company may designate. No
beneficiary shall, prior to the death of the Participant by whom he or she has
been designated, acquire any interest in the Common Stock or cash credited to
the Participant under the Plan.
SECTION TEN
RECAPITALIZATION
In the event any reorganization, merger, consolidation, recapitalization,
liquidation, reclassification, stock dividend, stock split, combination of
shares, rights offering, or extraordinary dividend or divestiture (including a
spin-off), or any other change in the capital structure or shares of the Com-
pany, the Board of Directors, shall make adjustments, determined by the Board
of Directors in its discretion to be appropriate, as to the number and kind of
securities subject to this Plan and specified in Section Five of this Plan and
as to the number and kind of securities covered by each outstanding Option
and, where applicable, the price per share thereunder.
SECTION ELEVEN
RIGHTS AS A STOCKHOLDER
An employee shall have no rights as a stockholder with respect to any shares
offered hereunder until completion of payment therefor. Participants will not
be issued stock certificates unless requested. All Common Stock purchased un-
der the Plan during an Offering Period will be held by the Nominee for at
least two (2) years from the Offering Date of the Offering Period. Common
Stock may be sold during this two-year period, but may not be transferred to
another agent or nominee. Notwithstanding the foregoing, a Participant must
sell a minimum of fifty (50) shares of Common Stock each time he or she elects
to sell Common Stock or such fewer whole shares of Common Stock in the account
of the Participant upon termination of employment.
SECTION TWELVE
STATUS OF PLAN FUNDS
All amounts held by the Company under the Plan shall be added to the general
funds of the Company and shall be used for such purposes as the Company shall
from time to time determine. The Company shall not be obligated to segregate
such payroll deductions.
SECTION THIRTEEN
ADMINISTRATION
The Plan shall be administered by the Board of Directors. The interpretation
and construction of any provision of the Plan and the adoption of rules and
regulations for administering the Plan shall be made by the Board of
Directors. Determinations made by the Board of Directors with respect to any
matter or provision contained in the Plan shall be final, conclusive and bind-
ing upon the Company and upon all Participants, their heirs or legal repre-
sentatives. Any rule or regulation adopted by the Board of Directors shall re-
main in full force and effect unless and until altered, amended, or repealed
by the Board of Directors. The Board of Directors may delegate to a committee
any authority of the Board of Directors under this Plan.
B-5
<PAGE>
An Agent may be appointed by the Board of Directors to perform the functions
and have the responsibilities assigned to the Agent in this Section Thirteen
with respect to the purchase of Common Stock. The Board of Directors shall
have the right to change the Agent at any time.
Notwithstanding any other provision to the contrary contained herein, the
Agent shall have all authority to determine the time of open market purchases,
the prices at which such open market purchases are made, the manner of such
open market purchases and the selection of brokers or dealers (which may in-
clude the Agent) to make such purchases. If Common Stock is purchased at vary-
ing Market Prices, an average price will be allocated to the account of each
Participant.
All costs and expenses incurred in administering the Plan shall be paid by
the Company, excluding (i) costs associated with requests for the issuing of
stock certificates to Participants or to the person or persons entitled to re-
ceive the same under Section Nine hereof, (ii) the costs of the sale of Common
Stock, and (iii) the costs associated with a Participant terminating or with-
drawing from the Plan.
SECTION FOURTEEN
AMENDMENT OR TERMINATION
Subject to Section Four(E), the Board of Directors may at any time terminate
or amend the Plan, except any such action shall be subject to stockholder ap-
proval to the extent such stockholder approval is required pursuant to Section
423 of the Internal Revenue Code.
SECTION FIFTEEN
NOTICES
All notices or other communications by a Participant to the Company under or
in connection with the Plan shall be deemed to have been given when received
by the Secretary of the Company.
SECTION SIXTEEN
APPROVAL OF STOCKHOLDERS
The effectiveness of this Plan is subject to its approval by the stockholders
of the Company within twelve (12) months after the date it is adopted by the
Board of Directors.
SECTION SEVENTEEN
REGISTRATION AND QUALIFICATION OF THE PLAN UNDER APPLICABLE SECURITIES LAWS
No Option shall be granted under the Plan until such time as the Company has
qualified or registered the shares which are subject to the Option under the
applicable state and federal securities laws to the extent required by such
laws.
B-6
<PAGE>
- -------------------------------------------------------------------------------
VITALINK PHARMACY SERVICES, INC.
1250 East Diehl Road, Naperville, Illinois 60563
This Proxy is Solicited on Behalf of the Board of Directors
PROXY FOR ANNUAL MEETING OCTOBER 2, 1996
The undersigned hereby appoints MARVIN C. WILENSKY and DONALD C. TOMASSO,
and each of them, the true and lawful attorneys and proxies, with full power of
substitution, to attend the Annual Meeting of Stockholders of VITALINK PHARMACY
SERVICES, INC. to be held in the Radisson Hotel, 3000 Warrenville Road, Lisle,
Illinois, on Wednesday, October 2, 1996 at 9:00 a.m. and at any adjournment
thereof, and to vote all shares of common stock held of record which the
undersigned could vote, with all the powers the undersigned would possess if
personally present at such meeting, as designated on the reverse side.
(Continued and to be signed on the reverse side)
- --------------------------------------------------------------------------------
*FOLD AND DETACH HERE*
<PAGE>
- -------------------------------------------------------------------------------
The Board of Directors recommends a vote FOR Items (1), (2) and (3).
1 ELECTION OF DIRECTORS
FOR all nominees WITHHOLD AUTHORITY
listed below to vote FOR all nominees listed below
[_] [_]
S. BAINUM, JR., H. BLUMENKPANTZ, J.R. BUCKLEY, D.L. DENARDO, A.K. GUPTA, J.A.
MACCUTCHEON, J.H. REMPE D.C. TOMASEC, M.C. WILENSKY
(Instructions: to withhold authority to vote for any individual nominee, write
that nominee's name in the space provided below.)
- --------------------------------------------------------------------------------
Please mark
your votes as
indicated in [X]
this example
FOR AGAINST ABSTAIN
(2) Approval of the Vitalink Pharmacy Services, [_] [_] [_]
Inc. 1996 Long-Term Incentive Plan.
(3) Approval of the Vitalink Pharmacy Services, [_] [_] [_]
Inc. 1996 Employee Stock Purchase Plan.
(4) In their discretion, upon such other business [_] [_] [_]
as may properly come before the meeting.
If you plan to attend the Annual Meeting of Stockholders, please mark the
following box and promptly return this Proxy Card. [_]
+ This proxy, when properly executed, will be voted
in the manner directed herein by the undersigned
stockholder. If not otherwise specified, the shares
represented by this Proxy will be voted FOR Items
(1), (2) and (3), and for and in accordance with
the discretion of the persons named as proxies as
to such other matters as may properly come before
the meeting, or at any adjournment thereof.
Dated:_______________________________________, 1996
---------------------------------------------------
Signature
---------------------------------------------------
Signature
(Signature should agree exactly with the name or
names appearing above. Joint owners should both
sign in signing as attorney, administrator,
executor, guardian or trustee, please set forth
your full title. If the signer is a corporation,
please sign the full corporate name by a duly
authorized officer.)
- --------------------------------------------------------------------------------
*FOLD AND DETACH HERE*
